PBC TODAYPBC TODAY<div class="ExternalClassDCE7E0A2106F46F183BF6A47961697E0"><html> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text">​<div class="text-container galileo-ap-content-editor"><div align="left"><span style="font-size:11px;color:rgb(83, 102, 127);font-style:italic;font-weight:bold;">An Update on the People, Places, and Possibilities of the Phoenix Biomedical Campus in Downtown Phoenix • Oversight provided by Arizona State University (Michael Crow, President), Northern Arizona University (Rita Cheng, President), University of Arizona (Robert Robbins, President), Arizona Board of Regents (John Arnold, Executive Director), and City of Phoenix led by Mayor Kate Gallego</span></div><div align="left"><br>​<br></div><div align="left"><span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">850 N. 5th Street building now available for tours</span></div><div align="left"><span style="font-size:11px;color:rgb(0, 0, 0);">After years of visioning, planning, and construction, 850 N. 5th Street is available for tours. The building is a collaborative effort between the City of Phoenix, Arizona State University, and Wexford Science & Technology, LLC. Totaling 227,000 SF with 100,000 SF of commercial lab or office space on the top three floors above Arizona State University research and innovation and GateWay Community College's Center for Entrepreneurial Innovation. 850 N. 5th Street will be a gathering hub for life science and biomedical innovation. The building is part of ongoing expansion on the Phoenix Biomedical Campus, connecting the downtown biomedical campus to the Evans Churchill Neighborhood and Roosevelt Row Arts District. Designed to integrate research, entrepreneurial activity, and corporate engagement, 850 N. 5th Street serves as a bridge between the surrounding neighborhoods, the academic community, and the professional community. The building's design purposefully invites the neighborhood to participate in its success through the first-floor program elements that are visually porous and accessible. A portion of the building will include turn-key lab space for private research, growing companies, or a soft-landing option for larger companies locating in Phoenix. To schedule a tour or receive information about available lease space, contact Kyle Jardine at 480-779-7181 or </span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:Kyle.Jardine@wexfordscitech.com">email</a><span style="font-size:15px;color:rgb(0, 0, 0);font-family:calibri, helvetica, arial, sans-serif;">.</span></div><div align="left"><br></div><div align="left"><span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Connect2STEM 2021 reimagined for 2021</span></div><div align="left"><span style="font-size:11px;color:rgb(0, 0, 0);">Register to attend the (free) 7th Annual Connect2STEM event on Saturday, January 30, 2021 starting at 10 a.m. There will be two ways for families to experience Connect2STEM 2021 – via the drive-through experience or Connect2STEM TV. Load up the car with your favorite STEM fans for a drive-through STEM experience. The entire family can enjoy fun activities while maintaining safe social distance. See live performances, visit discovery zones, and solve mysteries of science – and medicine throughout your drive. Due to space restrictions, limited tickets and time slots will be offered. Can't attend? Connect2STEM TV will be live throughout the day, showcasing some truly amazing STEM experiences for the whole family. For more information and to register, </span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://phoenixmed.arizona.edu/c2s">click here</a><span style="font-size:11px;color:rgb(0, 0, 0);">.</span></div><div align="left"><br></div><div align="left"><span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Take part in Friday’s ASU Biomedical Innovation Speaker Series</span></div><div align="left"><span style="font-size:11px;color:rgb(0, 0, 0);">Join Arizona State University and the Arizona Biomedical Research Center to hear top experts in the biomedical field. On tap for this Friday, November 20, 2020 from 11 a.m. to Noon is Thomas Osha, Senior Vice President of Innovation and Economic Development at Wexford Science and Technology, who will discuss how universities can leverage their research and technologies and collaborate across institutions and sectors to create knowledge-led economic development locally and globally. A big thank you to Dr. Susan Pepin for putting this series together. Here’s the </span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://asu.zoom.us/j/82073044607">Zoom link</a><span style="font-size:11px;color:rgb(0, 0, 0);"> for Friday’s talk (no pre-registration required).</span></div><div align="left"><br></div><div align="left"><span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Participate in UArizona’s Wellness Wednesdays</span></div><div align="left"><span style="font-size:11px;color:rgb(0, 0, 0);">The University of Arizona Health Sciences is holding “</span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://mailchi.mp/uahs.arizona.edu/wellness-wednesdays-celebrating-health-holiday">Wellness Wednesdays: A Community Connection</a><span style="font-size:11px;color:rgb(0, 0, 0);">,” a series of free virtual lunchtime events launched earlier this year to promote nutritious foods, healthy minds, and strong bodies. There are two more live Wellness Wednesday sessions this year: “Tai Chi for Health and Well-Being” on Nov. 18, and “Awareness Through Movement: Improving Your Health and Life Using the Feldenkrais Method” on Dec. 2. To register for these sessions, </span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://mailchi.mp/ahsc.arizona.edu/wellness-wednesdays">click here</a><span style="font-size:11px;color:rgb(0, 0, 0);">.</span></div><div align="left"><br></div><div align="left"><span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">City publishes new Phoenix Biomedical Campus brochure</span></div><div align="left"><span style="font-size:11px;color:rgb(0, 0, 0);">Take a peek at the new brochure for the Phoenix Biomedical Campus. Produced by the City of Phoenix, the brochure is available for download on the </span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="/Documents/Phoenix%20Biomedical%20Campus%202020.pdf">PBC website</a><span style="font-size:11px;color:rgb(0, 0, 0);"> and hard copies will be shared upon delivery. For more information, contact Claudia Whitehead via </span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">email</a><span style="font-size:11px;color:rgb(0, 0, 0);">.</span></div><div align="left"><br></div><div align="left"><span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">NAU OT Virtual Open House set for Dec. 3.</span><span style="font-size:12px;color:rgb(83, 102, 127);"></span></div><div align="left"><span style="font-size:11px;color:rgb(0, 0, 0);">The next virtual open house for interested applicants to the Northern Arizona University Occupational Therapy (OT) program is Thursday, December 3, 2020. To register to attend, </span><a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://nau.edu/occupational-therapy/">click here</a><span style="font-size:11px;color:rgb(0, 0, 0);">.</span></div></div><br></td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PEOPLE </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Noteworthy individuals making a difference</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="/news-events/110">OncoMyx Therapeutics appoints Dr. Charles Baum as board chair</a> (OncoMyx Therapeutics, 11-06-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://chs.asu.edu/news/feeling-down-grab-boost-some-water">ASU Hydration Science Lab Director Stavros Kavouras finds link between dehydration, mood in latest study</a> (ASU College of Health Solutions, 11-05-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="/news-events/107">Dr. Ziad Obermeyer discusses opportunities and challenges of algorithms in healthcare at annual Buffmire Lecture</a> (Flinn Foundation, 10-27-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="/news-events/104">TGen appoints Dr. Sunil Sharma as physician-in-chief</a> (TGen, 10-27-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PLACES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Properties and new developments where good things happen</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://associationsnow.com/2020/11/the-future-of-meetings-find-out-how-specialized-cities-lend-themselves-to-specialized-meetings/">The future of meetings: how specialized cities lend themselves to specialized meetings</a> (Associations Now, 11-03-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://flinn.org/bioscience/resources/arizonas-bioscience-ecosystem/">Flinn Foundation publishes “new and improved” directory and map of bioscience businesses and organizations statewide</a> (Flinn Foundation, 11-01-20) </li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">POSSIBILITIES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Significant research & educational opportunities going on</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.paysonroundup.com/news/health/university-of-arizona-health-sciences-has-e-newsletter-program/article_619a271b-9ac3-5daf-81c4-f09f39534e1d.html">University of Arizona Health Sciences launches “Wellness Wednesdays: Celebrating Health & Holiday”</a> (Payson Roundup, 11-17-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://chs.asu.edu/news/defining-health-care-spending-waste-us">ASU College of Health Solutions researchers publish papers exploring health care spending waste</a> (ASU College of Health Solutions, 11-16-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer">Arming the rabbit pox virus to fight cancer</a> (OncoMyx Therapeutics, 11-12-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://nau.edu/cher/adrd-apha-award-2020/">SHERC researchers win APHA Rural and Environmental Research Award for work with family caregivers of individuals with Alzheimer’s disease and related dementias</a> (NAU, 10-22-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="/news-events/105">OncoMyx Therapeutics presents preclinical data for novel oncolytic virotherapy at AACR Tumor Immunology & Immunotherapy Virtual Conference</a> (OncoMyx Therapeutics, 10-19-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://asunow.asu.edu/20201015-new-edson-college-partnership-opens-doors-qualitative-research-around-recovery-and-exercise">New Edson College partnership opens doors for qualitative research around recovery and exercise</a> (ASU Edson College of Nursing and Health Innovation, 10-15-20)</li> </ul> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);"></span> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://asunow.asu.edu/20200714-arizona-impact-asu-acts-fast-help-nurses-transition-icu">ASU acts fast to help nurses transition to ICU</a> (ASU Edson College of Nursing and Health Innovation, 07-14-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PARTICULARS</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text editor-text "> <div></div> <div class="text-container galileo-ap-content-editor"> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Contact:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(0, 0, 0);">David Krietor, Executive Director, 602-741-5580, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:david.krietor@asu.edu">david.krietor@asu.edu</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Website:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=">biomedicalphoenix.com</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">Claudia Whitehead</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">claudia.whitehead@phoenix.gov</a> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Events Calendar:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://asuevents.asu.edu/">ASU</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.pxu.org/Page/38">Bioscience H.S.</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://events.nau.edu/?view=grid&search=y">NAU</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://puhsaa.com/">PUHS Alumni Assoc.</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/giving/events/">TGen</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://uahs.arizona.edu/events">UArizona</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Jobs:</span> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://careers.insidehighered.com/jobs/?Keywords=%22phoenix+biomedical+campus%22#browsing">Inside Higher Ed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.indeed.com/jobs?q=%22phoenix%20Biomedical%20Campus%22&l=Phoenix%2c%20AZ&radius=0&vjk=9d8bff47682c0b93">Indeed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://jobs.azbio.org/">AZBio Job Center</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Getting Around:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://phoenixmed.arizona.edu/campus">Campus Map</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.valleymetro.org/maps-schedules">Public Transit</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="http://gridbikes.com/">Bike Share</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://parking.arizona.edu/parking/biomedical-campus/index.php?referral=compurchase">Parking</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;"> <a style="text-decoration-line:underline;color:rgb(83, 102, 127);" href="https://campaign.r20.constantcontact.com/render?ca=efcc81f0-d6a0-4cbe-a5bc-b0ae379077a0&preview=true&m=1102821891921&id=preview" target="_blank">View as Webpage</a> </span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="left" width="100%" class="divider-container editor-col OneColumnMobile"> <div class="gl-contains-divider"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%" class="editor-divider"> <tbody> <tr> <td valign="top" align="center" class="divider-container"> <table style="border-collapse:collapse;table-layout:fixed;cursor:default;min-width:100%;" class="galileo-ap-content-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="padding:9px 0px;" valign="top" align="center" width="100%" class="divider-base divider-solid"> <table style="border-collapse:collapse;table-layout:fixed;width:680px;min-width:100%;height:1px;" align="center" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="background-color:rgb(214, 214, 214);border-bottom-style:none;height:1px;line-height:1px;padding-bottom:0px;" bgcolor="D6D6D6" align="center" height="1"> <img class="" style="display:block;width:5px;margin:5px;" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" vspace="0" hspace="0" border="0" alt="" /> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text editor-text "> <div></div> <div class="text-container galileo-ap-content-editor"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Feel free to share this e-newsletter with people you think would find it of interest. To subscribe or share news, send us an email.</span> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="left" width="100%" class="content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">PBC </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">| </span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">David Krietor, Executive Director</span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> 602</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">-741-5880 </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">|</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> </span> <a style="text-decoration-line:underline;font-size:10px;color:rgb(83, 102, 127);font-weight:bold;" target="_blank" rel="noopener noreferrer" href="mailto:david.krietor@asu.edu">david.krietor@asu.edu</a> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> biomedicalphoenix.com</span> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/115/Project-Hero-Image-PBC-1.jpg2020-11-19T07:00:00ZPhoenix Bio News
Arming the rabbit pox virus to fight cancerArming the rabbit pox virus to fight cancer<div class="ExternalClass2D5A152ABD844A598AAEEF1473D7917F"><html> <span style="font-size:17.3333px;">​Oncolytic viruses hold promise as cancer treatments due to their cancer-killing prowess and ability to be combined with other therapies. But few drugs derived from oncolytic viruses have made it to the market.</span><br style="font-size:17.3333px;"><br style="font-size:17.3333px;"><span style="font-size:17.3333px;">Arizona State University spinout OncoMyx Therapeutics is designing anti-cancer therapies from a type of rabbit pox virus called myxoma. The company has early data showing that the virus, when armed with relevant transgenes, can suppress different types of cancer in mice both as an injection directly into tumors and through systemic administration by intravenous infusion.</span><br style="font-size:17.3333px;"><br style="font-size:17.3333px;"><span style="font-size:17.3333px;">In mouse models of melanoma and bone cancer, the drug significantly slowed tumor growth, and it was even better at shrinking tumors and prolonging the animal’s lives when paired with a PD-1 or PD-L1 inhibitor, according to data presented at the Society for Immunotherapy of Cancer (SITC) virtual meeting.</span>​<br><span style="font-size:17.3333px;"> </span><span style="font-size:17.3333px;"></span><span style="font-size:17.3333px;"> </span><span style="font-size:17.3333px;" id="ms-rterangepaste-start"></span><span style="font-size:17.3333px;"> </span><p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;"><br></span></p><p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">“These data support the further development of our multi-armed myxoma virotherapies in combination with checkpoint inhibitors and other immuno-oncology approaches to increase the number of cancer patients who could benefit from immunotherapies,” Steve Potts, Ph.D., co-founder and CEO of OncoMyx, </span><a target="_blank" href="https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/" rel="nofollow" style="box-sizing:inherit;color:rgb(237, 28, 38);font-weight:bold;"><span style="font-size:17.3333px;">said</span></a><span style="font-size:17.3333px;"> in a statement.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Myxoma virus, like many other oncolytic viruses, works by directly infecting cancer cells, causing them to die. This process also releases tumor antigens that can stimulate an immune response to the cancer. But myxoma virus can offer several advantages.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">First, the natural host of myxoma virus are rabbits, and it doesn’t cause disease in any other animals or in humans. This means that the virus can be systemically injected into people safely, and that it doesn’t have to overcome pre-existing immunity, which might otherwise kill it off before it could provide any therapeutic benefit.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">What’s more, as a large DNA virus, myxoma virus can serve as a vector to carry additional genes to target different facets of cancer immunity.</span></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">OncoMyx researchers showed that myxoma virus can replicate with up to six genes transferred to it, and that the virus can effectively express transgenes. These multi-armed myxoma viruses inhibited cancer growth across a wide range of human tumor types in lab dishes as well as in mice bearing human tumor xenografts.<br style=""></span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">The team further tested myxoma viruses bearing up to three genes, or arms, in immunocompetent mice. One arm was a cytokine that modulates T cell and natural-killer cell activity and recruitment to the tumor, Leslie Sharp, chief scientific officer of OncoMyx, explained in an email to FierceBiotechResearch. A second arm remodels the tumor microenvironment and removes cancer cells' suppression of T-cell immunity. And the third arm is a proinflammatory agent.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Unedited viruses were able to slow the growth of some tumors, but the effects were clearly better when the genes were edited in. “As is typical for preclinical models, response varies by model, but generally gives dose-dependent changes in tumor growth inhibition in the range of 70% to 99% including tumor regression and complete responses,” Sharp said. Tumor suppression was observed following both intratumoral and intravenous delivery of the viruses, and it led to increased survival of the animals.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Moreover, myxoma virus generally did better when being paired with either a PD-1 or PD-L1 inhibiting drug. That was even the case in a melanoma model that’s known to be resistant to immune checkpoint inhibition, suggesting it could be used in combination therapy to further boost the anti-tumor response.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Further analysis showed that multi-armed myxoma increased the population of tumor-infiltrating immune cells; the ratio of CD8+ T cells and immune-suppressing regulatory T cells was higher, and so was the ratio between pro-inflammatory M1 macrophages and healing-supportive M2 macrophages.​<br style=""></span></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Very few virus-based cancer treatments have made it to market, and the ones that did have their limitations.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Amgen’s FDA-approved melanoma therapy Imlygic, for example, uses a cancer-killing herpes virus, which is genetically edited to reduce its harm on noncancerous tissue. But it can’t completely prevent it from infecting healthy cells. Plus, it needs to be injected directly into melanoma tumors to achieve the best results and avoid toxicity. Oncorine, the world’s first commercial oncolytic virus product, approved in China in 2005 for the treatment of head and neck cancer, is based on an adenovirus that also goes through an attenuation step to limit its damage of healthy cells. Because both types of viruses can infect humans, therapies based on them must overcome pre-existing immunity.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Nevertheless, oncolytic viruses remain hot targets of cancer research. A team at City of Hope recently </span><a target="_blank" href="https://www.fiercebiotech.com/research/virus-combo-makes-solid-tumors-vulnerable-to-car-t-attack-mice" style="box-sizing:inherit;color:rgb(237, 28, 38);font-weight:bold;"><span style="font-size:17.3333px;">engineered</span></a><span style="font-size:17.3333px;"> an oncolytic virus to express the CD19 protein on solid tumor cells, thereby allowing them to be targetable by CD19-directed CAR-T cell therapies, which so far have only worked in some blood cancers.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Researchers led by Astellas’ drug discovery unit </span><a target="_blank" href="https://www.fiercebiotech.com/research/cancer-killing-virus-boosts-immuno-oncology-responses-mice-astellas-led-study" style="box-sizing:inherit;color:rgb(237, 28, 38);font-weight:bold;"><span style="font-size:17.3333px;">used</span></a><span style="font-size:17.3333px;"> a vaccinia virus, another large DNA virus that also belongs to the poxvirus family, to carry two cytokines—IL-7 and IL-12—to stimulate an anti-cancer immune response. The therapy also appeared to work in synergy with anti-PD-1 or anti-CTLA-4 antibodies.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">With promising animal data, OncoMyx is now working on programs to enable a first-in-human clinical trial for its lead program, dubbed OM101. “We can focus on large unmet needs in major cancer areas, for example, lung, gastro-intestinal, gynecologic, etc., and then look at patients within these populations where the mechanisms of interest are driving their tumor growth and will be most likely to benefit from therapy,” Potts said.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">The company raised a $25 million series A funding round in 2019, led by Boehringer Ingelheim Venture Fund, Delos Capital and Xeraya Capital.​<br style=""></span></p><span style="font-size:17.3333px;"> </span><span style="font-size:17.3333px;" id="ms-rterangepaste-end"></span><span style="font-size:17.3333px;"> </span><p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/112/rabbit.jpg2020-11-12T07:00:00ZOncoMyx Therapeutics
Event: Cell and Gene Therapy - CMC Challenges and Mitigation Strategies Free webinar on November 11th at 10 a.m. PST Event: Cell and Gene Therapy - CMC Challenges and Mitigation Strategies Free webinar on November 11th at 10 a.m. PST <div class="ExternalClass10D6C0EBDE4342549586F863AEBF9BA7"><html> <p>​<span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">Chemistry, manufacturing, and controls (CMC) is an integral aspect of cell and gene therapy development. Cell and gene therapy development presents unique CMC challenges because of inherent properties such as shorter shelf life, variability in starting and ancillary materials, manufacturing and logistical complexities, and cost. FDA cell and gene therapy information requests often contain more CMC related inquiries than traditional products. In this webinar, experts from Cardinal Health Regulatory Sciences discuss CMC challenges and potential mitigation strategies illustrated through multiple case studies. Cell and gene therapy developers, research scientists, regulatory and legal professionals are all encouraged to attend.</span></p> <p> <span id="ms-rterangepaste-start"></span>​<span id="ms-rterangepaste-end"></span><br></p> <p> <em>Register here:</em> <em> </em> <a target="_blank" href="https://urldefense.com/v3/__https:/pages.questexnetwork.com/LS-Custom-Webinar-CardinalHealth-111120-116773_LandingPage.html?source=fb-listing&_ga=2.94241237.970585205.1603979996-1547069854.1603979996__%3b%21%21LkjWUF49MRd51_ry%21Ngkdi0porSQmHXAiePEODjsVWAF9YOwk53wmkG25sPGv7UKsfVGghbZUJarwGtICIm9Tjvw3KRI$">Cell and Gene Therapy – CMC Challenges and Mitigation Strategies [pages.questexnetwork.com]</a>. <br></p> <p> <br> </p> </html></div>2020-11-09T07:00:00ZPhoenix Bio News
OncoMyx Therapeutics Appoints Dr. Charles Baum Chairperson of Board of DirectorsOncoMyx Therapeutics Appoints Dr. Charles Baum Chairperson of Board of Directors<div class="ExternalClass0D9346B372E04256B630F2278D26C35B"><html> <p>​<span style="text-align:justify;background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">PHOENIX, November 6, 2020 – </span><a style="text-align:justify;background-color:window;font-family:inherit;font-size:10pt;" href="https://oncomyx.wpengine.com/" target="_blank">OncoMyx Therapeutics</a><span style="text-align:justify;background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">, a privately-held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company's board of directors. Dr. Baum is currently president and chief executive officer of Mirati Therapeutics, which develops novel therapeutics that target the genetic and immunologic drivers of cancer. He has more than 25 years of experience leading the clinical development of precision oncology drugs, including axitinib (Inlyta®), crizotinib (Xalkori®), sunitinib (Sutent®), and temozolomide (Temodar®).</span></p> <p style="text-align:justify;"> </p> <p style="text-align:justify;">“We cannot think of a better person to chair our board of directors than Chuck Baum, who led Mirati Therapeutics in building an impressive oncology therapeutics pipeline and a strong leadership team," said Steve Potts, Ph.D., MBA, cofounder and chief executive officer of OncoMyx. “Chuck is also a classically trained immunologist, who built one of the earliest immuno-oncology programs in pharma and has successfully developed several targeted cancer therapies through clinical trials to market. His guidance and expertise in the development of targeted cancer therapies will be very valuable as OncoMyx is preparing to advance into clinical trials our first multi-armed myxoma virotherapy for cancer with a novel precision medicine and pan-tumor treatment approach."</p> <p style="text-align:justify;"> </p> <p style="text-align:justify;">“OncoMyx has assembled the top oncolytic virus team with extensive experience in advancing targeted cancer treatments, immunotherapies, and virotherapies and successfully bringing new cancer drugs to market," said Dr. Baum. “Oncolytic viruses are an extremely promising therapeutic approach to expanding the patient population that can benefit from immunotherapies, and OncoMyx's myxoma platform has numerous best-in-class advantages for multi-armed, systemically-delivered oncolytic immunotherapies."</p> <p style="text-align:justify;"> </p> <p style="text-align:justify;">At Mirati, Dr. Baum built a world-class precision oncology leadership team, took the company public on Nasdaq, and focused the company on targeted development of receptor tyrosine kinase and histone deacetylase inhibitors in various cancers. Prior to joining Mirati in 2012, he was at Pfizer since 2003, serving in roles of increasing responsibility including as Senior Vice President for Biotherapeutic Clinical Research within Pfizer's Worldwide Research and Development division; Vice President and Head of Oncology Development; and Chief Medical Officer for Pfizer's Biotherapeutics and Bioinnovation Center. Dr. Baum serves on the board of directors the BCTG Acquisition Corp and is a member of the scientific advisory board for ALX Oncology. Dr. Baum served on the board of directors of Array BioPharma and Immunomedics until each company was acquired for $11 billion by Pfizer, Inc. and $21 billion by Gilead Sciences, Inc., respectively. He received his M.D. and Ph.D. in immunology from Washington University School of Medicine in St. Louis and completed his post-graduate training at Stanford University. Dr. Baum has published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.</p> <p style="text-align:justify;"> <strong> </strong> </p> <p style="text-align:justify;"> <strong>About OncoMyx Therapeutics</strong> </p> <p style="text-align:justify;">OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have the potential to be a safe and effective complement to other immunotherapy approaches. The company's MYXV platform, exclusively licensed from Arizona State University, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients. For more information, please visit <a href="http://www.oncomyx.com/" target="_blank">www.oncomyx.com</a> and connect with the company on <a href="https://www.linkedin.com/company/oncomyx" target="_blank">LinkedIn</a> and <a href="https://twitter.com/oncomyx" target="_blank">Twitter</a>.</p> <p style="text-align:justify;"> </p> <p style="text-align:justify;"> <strong>Corporate Contact: </strong>Michael G. Wood, Cofounder & COO, <a href="mailto:mw@oncomyx.com" target="_blank">mw@oncomyx.com</a></p> <p style="text-align:justify;"> </p> <p> <strong>Media Contact:</strong> Jessica Yingling, Ph.D., <a href="http://www.litldog.com/" target="_blank">Little Dog Communications Inc.</a>, <a href="mailto:jessica@litldog.com" target="_blank">jessica@litldog.com</a> , +1.858.344.8091​<br></p> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/110/mirati0026.jpg2020-11-06T07:00:00ZOncoMyx Therapeutics
Event: Connect2STEM 2021 Reimagined! Saturday, January 30, 2021Event: Connect2STEM 2021 Reimagined! Saturday, January 30, 2021<div class="ExternalClass0F5791E4152045CE92B43741C4EDCFA1"><html> <p>​<span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">Register to attend the (free) 7</span><sup style="background-color:window;color:windowtext;font-family:inherit;">th</sup><span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;"> Annual Connect2STEM event on Saturday, January 30, 2021 starting at 10 am. There will be two ways for families to experience Connect2STEM 2021 - via the drive-through experience or Connect2STEM TV. Load up the car with your favorite nerds for a drive-through STEM experience. The entire family can enjoy fun activities while maintaining safe social distance.  See live performances, visit discovery zones and solve mysteries of science — and medicine throughout your drive. Due to space restrictions, limited tickets and time slots will be offered. Can't attend? Connect2STEM TV will be live throughout the day, showcasing some truly amazing STEM experiences for the whole family.</span></p> <p>For more information and to register go to: <a target="_blank" href="https://phoenixmed.arizona.edu/c2s">https://phoenixmed.arizona.edu/c2s</a> ​<br></p> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/111/Connect2STEM Image.jpg2020-11-04T07:00:00ZUA
Event: Open Invitation for Tours – 850 N 5th Street Innovation Center by Wexford Science + TechnologyEvent: Open Invitation for Tours – 850 N 5th Street Innovation Center by Wexford Science + Technology<div class="ExternalClassD6A5839987B146ED8E93B707FCD8FB47"><html> <p>​<br></p><p>After years of visioning, planning, and construction, 850 N 5th Street is available for tours. The building is a collaborative effort between the City of Phoenix, Arizona State University, and Wexford Science & Technology, LLC. Totaling 227,000 SF with 100,000 SF of commercial lab or office space on the top three floors above Arizona State University research and innovation and GateWay Community College's Center for Entrepreneurial Innovation. 850 N 5th Street will be a gathering hub for life science and biomedical innovation. The building is part of ongoing expansion on the Phoenix Biomedical Campus, connecting the downtown biomedical campus to the Roosevelt Row Arts District. Designed to integrate research, entrepreneurial activity, and corporate engagement, 850 N 5th Street serves as a bridge between the surrounding neighborhoods, the academic community, and the professional community. The building's design purposefully invites the neighborhood to participate in its success through the first-floor program elements that are visually porous and accessible. A portion of the building will include turn-key lab space for private research, growing companies, or a soft-landing option for larger companies locating in Phoenix.</p><p> </p><p>To schedule a tour or receive information about available lease space please contact Kyle Jardine at <a target="_blank" href="mailto:%20Kyle.Jardine@wexfordscitech.com"><strong>Kyle.Jardine@wexfordscitech.com​</strong></a>  480.779.7181<br></p><p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/108/HKs wexford 2018 v1-NE.jpg2020-11-02T07:00:00ZWexford
Event: Biomedical Innovation Speaker Series Friday, November 6, 2020 11:00 am - 12:00 pm MST Lessons from The Long Fix: Biomedical Science and Engineering as Critical Levers in the Future of Health Care with Dr. Vivian LeeEvent: Biomedical Innovation Speaker Series Friday, November 6, 2020 11:00 am - 12:00 pm MST Lessons from The Long Fix: Biomedical Science and Engineering as Critical Levers in the Future of Health Care with Dr. Vivian Lee<div class="ExternalClass879F64768B1348CEBB9CC62E98691C03"><html> ​<strong style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;"><em>​Lessons from The Long Fix: Biomedical Science and Engineering as Critical Levers in the Future of Health Care with Dr. Vivian Lee</em></strong><br> <p>Vivian S. Lee, M.D., Ph.D., M.B.A., author of <em>The Long Fix: Solving America's Health Care Crisis with Strategies that Work for Everyone</em>, President of Health Platforms at Verily Life Sciences, physician and health care executive, and senior lecturer at Harvard Medical School will talk with ASU's Managing Director of Health and Clinical Partnerships, Susan M. Pepin, MD, MPH, about how technology has changed the future of medicine and healthcare delivery, from diagnosis and treatment to population health and the reduction of social disparities. Dr. Lee will also touch on how the field of biomedical science represents a rich landscape for innovation, entrepreneurship, and collaboration.<em> Sponsored by Arizona Biomedical Research </em></p> <p>Register here: <a href="https://urldefense.com/v3/__https:/asuevents.asu.edu/content/asu-biomedical-innovation-speaker-series__%3b%21%21LkjWUF49MRd51_ry%21N-9rLWzj0zWAKFacS7zFj_1wAGJnAF0dnLh2PwcgdG5vScdppO90lXW9cb_yIgg9eaYam1bCtdg$" target="_blank">https://asuevents.asu.edu/content/asu-biomedical-innovation-speaker-series [asuevents.asu.edu]</a>​<br></p> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-10-30T07:00:00ZASU
Event: Biomedical Innovation Speaker Series Friday, November 13, 2020 11:00 am - 12:00 pm MST Bridging the Gap Between Data Science and Medicine with Dr. Melissa Haendel and Dr. Anthony Philippakis Event: Biomedical Innovation Speaker Series Friday, November 13, 2020 11:00 am - 12:00 pm MST Bridging the Gap Between Data Science and Medicine with Dr. Melissa Haendel and Dr. Anthony Philippakis <div class="ExternalClass2DA0FC84AEA94DFEAB6DC3B9B36FB289"><html> <p>​<span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">Vivian S. Lee, M.D., Ph.D., M.B.A., author of </span><em style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">The Long Fix: Solving America's Health Care Crisis with Strategies that Work for Everyone</em><span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">, President of Health Platforms at Verily Life Sciences, physician and health care executive, and senior lecturer at Harvard Medical School will talk with ASU's Managing Director of Health and Clinical Partnerships, Susan M. Pepin, MD, MPH, about how technology has changed the future of medicine and healthcare delivery, from diagnosis and treatment to population health and the reduction of social disparities. Dr. Lee will also touch on how the field of biomedical science represents a rich landscape for innovation, entrepreneurship, and collaboration.</span><em style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;"> Sponsored by Arizona Biomedical Research</em></p> <p>Register here: <a href="https://urldefense.com/v3/__https:/asuevents.asu.edu/content/asu-biomedical-innovation-speaker-series__%3b%21%21LkjWUF49MRd51_ry%21N-9rLWzj0zWAKFacS7zFj_1wAGJnAF0dnLh2PwcgdG5vScdppO90lXW9cb_yIgg9eaYam1bCtdg$" target="_blank">https://asuevents.asu.edu/content/asu-biomedical-innovation-speaker-series [asuevents.asu.edu]</a>​<br></p> <p> <br> </p> </html></div>2020-10-30T07:00:00ZASU
Event: Biomedical Innovation Speaker Series Friday, November 20, 2020 11:00 am - 12:00 pm MST Creating Innovation Ecosystems to Drive Knowledge-Led Inclusive Economic Development with Thomas Osha Event: Biomedical Innovation Speaker Series Friday, November 20, 2020 11:00 am - 12:00 pm MST Creating Innovation Ecosystems to Drive Knowledge-Led Inclusive Economic Development with Thomas Osha <div class="ExternalClass9D1638AB946B4C7687BA6671E3FB38F1"><html> <p>​<span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">T</span><span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">homas Osha (Senior Vice President of Innovation and Economic Development at Wexford Science and Technology) will discuss how universities can leverage their research and technologies and collaborate across institutions and sectors to create knowledge-led economic development locally and globally. </span><em style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">Sponsored by Arizona Biomedical Research</em></p> <p>Register here: <a href="https://urldefense.com/v3/__https:/asuevents.asu.edu/content/asu-biomedical-innovation-speaker-series__%3b%21%21LkjWUF49MRd51_ry%21N-9rLWzj0zWAKFacS7zFj_1wAGJnAF0dnLh2PwcgdG5vScdppO90lXW9cb_yIgg9eaYam1bCtdg$" target="_blank">https://asuevents.asu.edu/content/asu-biomedical-innovation-speaker-series [asuevents.asu.edu]</a><br></p> <p>​<br><br></p> </html></div>2020-10-30T07:00:00ZASU
PBC TODAYPBC TODAY<div class="ExternalClass7EC6D615A65B4814A4AF17CD3898932F"><html> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div>​<br></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-style:italic;font-weight:bold;">An update on the People, Places and Possibilities of the Phoenix Biomedical Campus in Downtown Phoenix • Oversight Provided by Arizona State University President Michael Crow, Northern Arizona University President Rita Cheng, University of Arizona President Robert Robbins, Arizona Board of Regents Executive Director John Arnold, and the City of Phoenix led by Mayor Kate Gallego</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">October 29, 2020</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="color:rgb(83, 102, 127);font-weight:bold;">Mark Your Calendars for the ASU Biomedical Innovation Speaker Series</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Over the next four Fridays, join Arizona State University and the Arizona Biomedical Research Centre to hear top experts in the biomedical field. </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://na.eventscloud.com/ereg/index.php?eventid=581203&">Register here</a> <span style="font-size:12px;color:rgb(0, 0, 0);">.  </span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">How Biology will Build the Next Technology Revolution</span> </div> <div align="left"> <span style="font-size:12px;color:rgb(235, 169, 66);font-weight:bold;">Friday, Oct. 30, 2020, 11 a.m. to Noon</span> <span style="font-size:12px;color:rgb(0, 0, 0);font-weight:bold;"></span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Susan Hockfield, Ph.D., world-renowned neuroscientist, president emerita at MIT and the author of "The Age of Living Machines: How Biology will Build the Next Technology Revolution," will discuss how discoveries at the convergence of biology and engineering can help us solve the greatest humanitarian, medical, and environmental issues of our time.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Lessons from the Long Fix: Biomedical Science and Engineering as Critical Levers in the Future of Health Care</span> </div> <div align="left"> <span style="font-size:12px;color:rgb(235, 169, 66);font-weight:bold;">Friday, Nov. 6, 2020, 11 a.m. to Noon</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Vivian S. Lee, M.D., Ph.D., MBA, author of "The Long Fix: Solving America's Health Care Crisis with Strategies that Work for Everyone," president of Health Platforms at Verily Life Sciences, physician and health care executive and senior lecturer at Harvard Medical School, will talk with Susan M. Pepin, M.D., MPH, ASU's managing director of health and clinical partnerships, about how technology has changed the future of medicine and health care delivery, from diagnosis and treatment to population health and the reduction of social disparities. Dr. Lee will also touch on how the field of biomedical science represents a rich landscape for innovation, entrepreneurship and collaboration.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Bridging the Gap Between Data Science and Medicine</span> </div> <div align="left"> <span style="font-size:12px;color:rgb(235, 169, 66);font-weight:bold;">Friday, November 13, 2020, 11 a.m. to Noon</span> <span style="font-size:12px;color:rgb(0, 0, 0);font-weight:bold;"></span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Join Anthony Philippakis, M.D., Ph.D., chief data scientist and institute scientist, the Broad Institute of MIT and Harvard, and Melissa Haendel, Ph.D., FACMI, director, director of the Center for Data to Health (CD2H) at Oregon Health & Science University and the Director of Translational Data Science at Oregon State University, will discuss how to leverage big data and collaborate across sectors and institutions in order to improve current understandings of population health, drive data-driven health research, improve patient outcomes, and reduce health disparities.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Creating Innovation Ecosystems to Drive Knowledge-Led Inclusive Economic Development</span> </div> <div align="left"> <span style="font-size:12px;color:rgb(235, 169, 66);font-weight:bold;">Friday, Nov. 20, 2020, 11 a.m. to Noon</span> <span style="font-size:12px;color:rgb(0, 0, 0);font-weight:bold;"></span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Thomas Osha, senior vice president of innovation and economic development at Wexford Science and Technology, will discuss how universities can leverage their research and technologies and collaborate across institutions and sectors to create knowledge-led economic development locally and globally.</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PARTICULARS</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;font-family:"times new roman";font-size:medium;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text editor-text "> <div></div> <div class="text-container galileo-ap-content-editor"> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Contact:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(0, 0, 0);">David Krietor, Executive Director, 602-741-5580, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:david.krietor@asu.edu">david.krietor@asu.edu</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Website:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=">biomedicalphoenix.com</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">Claudia Whitehead</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">claudia.whitehead@phoenix.gov</a> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Events Calendar:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://asuevents.asu.edu/">ASU</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.pxu.org/Page/38">Bioscience H.S.</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://events.nau.edu/?view=grid&search=y">NAU</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://puhsaa.com/">PUHS Alumni Assoc.</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/giving/events/">TGen</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://uahs.arizona.edu/events">UArizona</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Jobs:</span> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://careers.insidehighered.com/jobs/?Keywords=%22phoenix+biomedical+campus%22#browsing">Inside Higher Ed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.indeed.com/jobs?q=%22phoenix%20Biomedical%20Campus%22&l=Phoenix%2c%20AZ&radius=0&vjk=9d8bff47682c0b93">Indeed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://jobs.azbio.org/">AZBio Job Center</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Getting Around:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://phoenixmed.arizona.edu/campus">Campus Map</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.valleymetro.org/maps-schedules">Public Transit</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="http://gridbikes.com/">Bike Share</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://parking.arizona.edu/parking/biomedical-campus/index.php?referral=compurchase">Parking</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;"> <a style="text-decoration-line:underline;color:rgb(83, 102, 127);" href="https://campaign.r20.constantcontact.com/render?ca=5ddc6f16-817d-48a0-a18c-b6c93f8a10fa&preview=true&m=1102821891921&id=preview" target="_blank">View as Webpage</a> </span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <p> <br> </p> </html></div>2020-10-29T07:00:00ZPhoenix Bio News
PBC TODAYPBC TODAY<div class="ExternalClass5EC5CAAFF60C4162AA7EA2B0761AC2FE"><html> ​ <span id="ms-rterangepaste-start"></span> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="line-height:1;font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;padding:10px 40px;" valign="top" align="left" class="editor-text editor-text "> <div class="text-container galileo-ap-content-editor"> <div> <span style="font-size:9px;color:rgb(0, 0, 0);">On October 19, 2020, the Tohono O'odham Nation committed $1 million to Arizona State University and the University of Arizona</span> </div> <div> <span style="font-size:9px;color:rgb(0, 0, 0);">to help researchers fight COVID-19. Attending the press conference at the Phoenix Biomedical Campus were, left to right, Regent Karrin Taylor Robson, Arizona Board of Regents, Nation Chairman Ned Norris Jr., Timothy Joaquin, the Nation's legislative chairman offering a blessing, UArizona President Robert Robbins, and ASU President Michael Crow. (Photo: Sun Belous/UArizona College of Medicine–Phoenix)</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"><tbody></tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:11px;color:rgb(83, 102, 127);font-style:italic;font-weight:bold;">An Update on the People, Places, and Possibilities of the Phoenix Biomedical Campus in Downtown Phoenix • Oversight provided by Arizona State University (Michael Crow, President), Northern Arizona University (Rita Cheng, President), University of Arizona (Robert Robbins, President), Arizona Board of Regents (John Arnold, Executive Director), and City of Phoenix led by Mayor Kate Gallego • October 28, 2020</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Expanding Our View</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:11px;color:rgb(0, 0, 0);">The perception of the Phoenix Biomedical Campus (PBC) is too narrow. The best example is Arizona State University (ASU). Judith Karshmer, Dean of the ASU Edson College of Nursing and Health Innovation, and Deborah Helitzer, Dean of the ASU College of Health Solutions, are not technically located on our 30-acre campus, but they can walk there in five minutes. Likewise, the students they teach and the researchers they collaborate with are all over the PBC. They populate the Arizona Biomedical Collaborative Building and Mercado, fronting both sides of East Van Buren Street, and will soon become an important presence in the Wexford/ASU Innovation building at 5th Street and Garfield.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:11px;color:rgb(0, 0, 0);">Given the thousands of students in these Downtown colleges and their natural connectivity to the PBC, we need to think bigger when we talk about the people, places, and possibilities – and our efforts to showcase their work and achievements. While we most often refer to the PBC as a center of biomedical research and education, we need to find room to include “health” in our PBC description. I welcome your suggestions and ideas. Give me a call at 602-741-5580 or </span> <a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:david.krietor@asu.edu?subject=Expanding%20our%20(PBC)%20View">send me an email</a> <span style="font-size:11px;color:rgb(0, 0, 0);">.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Volunteers Aid TGen’s Research</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:11px;color:rgb(0, 0, 0);">The researchers at the </span> <span style="font-size:11px;color:rgb(0, 0, 0);font-weight:bold;">Translational Genomics Research Institute</span> <span style="font-size:11px;color:rgb(0, 0, 0);"> (TGen) are pioneers in precision medicine and believe that every genome tells a story. Whether eye color, laughter, freckles or smile, our genes shape who we are in so many distinct and different ways. So, too, do they play more than a passing role in how we develop and react to disease, and as important, how we react to treatment. To understand complex diseases, TGen enrolls healthy and affected volunteers in TGen's research studies. This may be as simple as donating ten minutes to take a memory quiz or offering a saliva sample from a family pet. In other instances, participation may be restricted to those suffering from a particular genetic condition. The researchers at TGen invite you to participate in their current studies and forward them with those who may share your interest. </span> <a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/patients/participate-in-our-research/overview/">Click here to learn more and enroll</a> <span style="font-size:11px;color:rgb(0, 0, 0);">.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Take a (Virtual) Tour of TGen</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:11px;color:rgb(0, 0, 0);">Would you like to view the next generation sequencing technology and biomedical research laboratories where TGen scientists unlock the mysteries of cancer, diabetes, rare, and neurological disease? Unfortunately, in light of COVID-19, TGen employees are not able to bring guests into their building for a tour – but they can bring the tour to you… virtually. They have developed a digital walkthrough to provide a look inside their Phoenix Biomedical Campus headquarters, Center for Rare Childhood Disorders, TGen North in Flagstaff, and Pathogen and Microbiome Division. </span> <a style="text-decoration-line:underline;font-size:11px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/education/tour-tgen/">Click here to learn more and sign-up</a> <span style="font-size:11px;color:rgb(0, 0, 0);">.</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PEOPLE </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Noteworthy individuals making a difference</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/nau.occupational.therapy/posts/3598232496934946">NAU among recipients of 2020 ArizOTA Recognition Awards & Research Grants</a> (NAU, 10-26-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://news.yahoo.com/chances-getting-medical-school-145541368.html">What are your chances of getting into medical school?</a> (US News & World Report, 10-15-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PLACES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Properties and new developments where good things happen</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.cbre.us/research-and-reports/US-Life-Sciences-Report-2020">The bio-boom intensifies: Phoenix ranked #5 among U.S. top 10 emerging clusters</a> (CBRE, 10-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.bizjournals.com/phoenix/news/2020/10/11/downtown-phoenix-towers-capital-investment.html">Sky-defining projects, capital investment crafting denser downtown Phoenix</a> (Phoenix Business Journal, 10-11-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">POSSIBILITIES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Significant research & educational opportunities going on</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;text-align:left;font-size:12px;color:rgb(0, 0, 0);"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.wildcat.arizona.edu/article/2020/10/sc-cp-causes">New study challenges previous understanding about the causes of cerebral palsy</a> (UArizona, 10-20-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.medicalnewstoday.com/articles/poor-health-and-screen-time-on-different-devices-what-is-the-link">“Poor health” and screen time on different devices: What is the link?</a> (ASU, 10-10-20) </li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.eurekalert.org/pub_releases/2020-10/uoah-mnl100620.php">Many Non-Hodgkin's Lymphoma patients can skip radiation, collaborative study finds</a> (UArizona, 10-06-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;text-align:left;font-size:12px;color:rgb(0, 0, 0);"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="/news-events/92">TGen and Avery Therapeutics collaborate on development of engineered heart tissue</a> (TGen, 10-05-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://asunow.asu.edu/20201001-solutions-watching-your-waste">ASU researcher leads intervention to reduce household food waste</a> (ASU, 10-01-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);text-align:center;display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div style="text-align:left;" align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PANDEMIC RESPONSE</span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">PBC-affiliated experts weigh in on timely issue</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);text-align:center;display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.azfamily.com/news/continuing_coverage/coronavirus_coverage/phoenix-bar-prepares-to-begin-karaoke-again/article_4f292852-14e8-11eb-ad31-f7a3f02c5dae.html">Despite COVID-19, Phoenix bar prepares to begin karaoke again</a> (AZ Family, 10-22-20)</li> </ul> <div style="text-align:left;" align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;text-align:left;font-size:12px;color:rgb(0, 0, 0);"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://news.arizona.edu/story/tohono-oodham-nation-commits-1m-uarizona-combat-covid-19">Tohono O'odham Nation commits $1M to UArizona to combat COVID-19</a> (UArizona, 10-19-20)</li> </ul> <div style="text-align:left;" align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;text-align:left;font-size:12px;color:rgb(0, 0, 0);"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.azfamily.com/news/continuing_coverage/coronavirus_coverage/airlines-hope-safety-measures-can-lure-back-holiday-travelers/article_403d9348-0e7e-11eb-94c9-d75e0d3c1466.html">Airlines hope COVID-19 safety measures can lure back holiday travelers</a> (AZ Family, 10-14-20)</li> </ul> <div style="text-align:left;" align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://uahs.arizona.edu/news/uarizona-health-sciences-study-shows-sars-cov-2-antibodies-provide-lasting-immunity">UArizona Health Sciences study shows SARS-CoV-2 antibodies provide lasting immunit</a> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://uahs.arizona.edu/news/uarizona-health-sciences-study-shows-sars-cov-2-antibodies-provide-lasting-immunity">y</a> (UArizona, 10-12-20)</li> </ul> <div style="text-align:left;" align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://ktar.com/story/3610328/uarizona-researchers-study-pain-relief-caused-by-coronavirus/">UArizona researchers study pain relief caused by COVID-19</a> (KTAR Radio, 10-07-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PARTICULARS</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text editor-text "> <div></div> <div class="text-container galileo-ap-content-editor"> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Contact:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(0, 0, 0);">David Krietor, Executive Director, 602-741-5580, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:david.krietor@asu.edu">david.krietor@asu.edu</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Website:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=">biomedicalphoenix.com</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">Claudia Whitehead</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">claudia.whitehead@phoenix.gov</a> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Events Calendar:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://asuevents.asu.edu/">ASU</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.pxu.org/Page/38">Bioscience H.S.</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://events.nau.edu/?view=grid&search=y">NAU</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://puhsaa.com/">PUHS Alumni Assoc.</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/giving/events/">TGen</a> <span style="font-size:12px;color:black;">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://uahs.arizona.edu/events">UArizona</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Jobs:</span> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://careers.insidehighered.com/jobs/?Keywords=%22phoenix+biomedical+campus%22#browsing">Inside Higher Ed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.indeed.com/jobs?q=%22phoenix%20Biomedical%20Campus%22&l=Phoenix%2c%20AZ&radius=0&vjk=9d8bff47682c0b93">Indeed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://jobs.azbio.org/">AZBio Job Center</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Getting Around:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://phoenixmed.arizona.edu/campus">Campus Map</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.valleymetro.org/maps-schedules">Public Transit</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="http://gridbikes.com/">Bike Share</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://parking.arizona.edu/parking/biomedical-campus/index.php?referral=compurchase">Parking</a> </div> <div> <br>​<br></div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/113/Donation Press Conference-4657.jpg2020-10-28T07:00:00ZPhoenix Bio News
TGEN APPOINTS DR. SUNIL SHARMA PHYSICIAN-IN-CHIEFTGEN APPOINTS DR. SUNIL SHARMA PHYSICIAN-IN-CHIEF<div class="ExternalClassF2D403924E694DFA81AF730AD7C72B76"><html> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;"> <ul class="list-inline posted-info" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span class="uBlogsy_author_name" style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" title="Steve Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">Steve Yozwiak</a></span></div> </li> </ul> <ul class="list-inline posted-info" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Tuesday October 27, 2020<br><br></li> </ul> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">New title reflects growing role and responsibility in helping guide TGen research across multiple scientific disciplines</em> </p> </div> </div> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — Oct. 27, 2020</span> — The <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a target="_blank" href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">City of Hope</a>, today announced the appointment of <a target="_blank" href="https://www.tgen.org/faculty-profiles/sunil-sharma/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Sunil Sharma</a>, M.D., F.A.C.P., M.B.A., as Physician-in-Chief. Dr. Sharma succeeds <a target="_blank" href="https://www.tgen.org/faculty-profiles/daniel-von-hoff/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Daniel D. Von Hoff</a>, M.D., F.A.C.P., a leading expert in pancreatic cancer, who was instrumental in developing key clinical and research programs at TGen.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr. Von Hoff, who joined TGen in 2003, will continue as a Distinguished Professor and Executive Vice President, Molecular Medicine, to further his work in pancreatic cancer research and clinical trials.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Dr. Von Hoff's commitment to TGen and patients with pancreas cancer is second to none,” said <a target="_blank" href="https://www.tgen.org/faculty-profiles/jeffrey-trent/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Dr. Jeffrey Trent</a>, TGen President and Research Director. “This transition provides him the opportunity to focus his energies solely on pancreas cancer research and treatment, a disease against which he’s made profound advances.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr. Trent added: “Dr. Sharma’s appointment as Physician-in-Chief recognizes the important role he has played across TGen’s many biomedical disciplines since his arrival. He is a distinguished researcher and clinician. In addition to his leadership at TGen, he is rapidly bringing research in clinical efforts in immune treatments to the forefront of patient benefit.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a target="_blank" href="https://www.tgen.org/news/2017/september/29/dr-sunil-sharma-joins-tgen/?search=Sunil" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Dr. Sharma joined TGen</a> in 2017 as Deputy Director of Clinical Sciences, Professor, and Head of TGen’s Applied Cancer Research and Drug Discovery Division, but Dr. Von Hoff knew him years before that.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“It has been a privilege to know and work with Dr. Sharma over many decades, and I look forward to his leadership in the years ahead," said Dr. Von Hoff. "His intellect, drive, insights and innovative approaches will serve TGen — but more importantly patients — well. With this outstanding physician scientist, there is no doubt the office of Physician-in-Chief is in incredibly capable hands."</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr. Sharma is also a Professor of Medical Oncology at City of Hope, a world-renowned comprehensive cancer center that also treats diabetes and other life-threatening diseases, and co-leader of City of Hope’s Developmental Cancer Therapeutics Program.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a target="_blank" href="https://www.cityofhope.org/faculty/steven-rosen" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Steven Rosen</a>, M.D., Provost and Chief Scientific Officer at City of Hope, said: “Over the past three years, Dr. Sunil Sharma has proven to be a catalyst for innovative research and has successfully collaborated with others to combine research resources at TGen and City of Hope. We have every confidence that in his new role, Dr. Sharma will assist in further strengthening the leading-edge research ties between City of Hope and TGen.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr. Sharma’s nearly three-decade career spans the areas of research, drug and clinical trial development. At TGen, he broadened his research and clinical portfolio beyond his specialty of gastrointestinal cancers (colon, pancreatic) to include drug development — immunotherapeutic treatments in particular — for COVID-19, Alzheimer’s disease, memory performance, and other cancers, including breast and ovarian cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">"I am grateful for the opportunity this new role provides, and humbled to follow in the footsteps of Dr. Von Hoff,” said Dr. Sharma. “I look forward to collaborating more broadly across the institute in search of new opportunities for patient benefit, and am committed to keeping TGen at the forefront of precision medicine.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Prior to TGen, Dr. Sharma served as Deputy Director of Huntsman Cancer Institute (HCI) in Salt Lake City, a National Cancer Institute-designated Comprehensive Cancer Center. At Huntsman, he co-led the Experimental Therapeutics Program, where he developed new therapeutics, including image-guided and targeted drug delivery systems. He also worked as a physician in the Division of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center in New York, and he built a phase I clinical trial program at the Nevada Cancer Institute in Las Vegas.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada, said: “Dr. Sharma has been at the forefront of anti-cancer drug development for over two decades. Having trained with Dr. Von Hoff, he expanded his innovative work at Novartis, the Nevada Cancer Institute, the Huntsman and now as Physician-in-Chief at TGen. He is a kind, yet driven, leader in the mold of Drs. Von Hoff and Trent. He understands the complex pathways that drive cancer and the immune response to it. We, in the cancer research world, are fortunate to have Dr. Sharma now leading TGen to even greater breakthroughs.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition to his clinical efforts, Dr. Sharma has worked with a number of pharmaceutical companies, including Swiss-based Novartis, where he helped develop ceritinib, one of the most widely used anti-lung cancer agents; Merck & Co.’s pembrolizumab; and Bristol-Myers Squibb’s nivolumab, the latter two immunotherapy drugs, both of which help the body’s own immune system attack cancer cells.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">John Sweetenham, M.D., a Professor of Medicine and Associate Director of Clinical Affairs at the University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, said: “A distinguished physician-scientist and clinical investigator, Dr. Sharma is also a highly skilled and compassionate physician and an exceptional leader. His success in guiding drug development from discovery science to meaningful patient impact speaks for itself. Congratulations to Dr. Sharma for this recognition of his exceptional contribution, and congratulations to TGen for appointing a truly outstanding Physician-in-Chief.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr. Sharma, a Fellow of the American College of Physicians, earned his medical degree at the University of Delhi in New Delhi, India, and his M.B.A. from the University of Massachusetts, Amherst.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hop</span> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">e<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a target="_blank" href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">www.tgen.org</a>. Follow TGen on <a target="_blank" href="https://www.facebook.com/helptgen" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Facebook</a>, <a target="_blank" href="https://www.linkedin.com/company/tgen/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">LinkedIn</a> and <a target="_blank" href="https://twitter.com/TGen" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Twitter @TGen</a>.<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="mailto:syozwiak@tgen.org" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">syozwiak@tgen.org</a> </p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div class="uBlogsy_tag_container" style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <ul class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;"></ul> </div> <div class="uBlogsy_label_container" style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <div class="uBlogsy_labels_container" style="box-sizing:border-box;border-radius:0px;"></div> </div> </aside> <br> </div> </div> <p> <br> </p> </html></div>2020-10-27T07:00:00ZTGen
Asking Algorithms and Ourselves the Right QuestionsAsking Algorithms and Ourselves the Right Questions<div class="ExternalClass98E9DAE9DAFE4AF98404EB45B1871B94"><html> <p>​<span style="color:rgb(155, 155, 155);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;text-transform:uppercase;background-color:window;box-sizing:border-box;" class="field field--name-title field--type-string field--label-hidden">TERESA JOSEPH</span><span style="color:rgb(155, 155, 155);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;text-transform:uppercase;background-color:window;"></span></p><div><div class="field field--name-field-news-media-contact-ref field--type-entity-reference field--label-hidden field__item" style="box-sizing:border-box;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:16px;"><article role="article" class="node node--type-media-contact node--promoted node--view-mode-default" style="box-sizing:border-box;"><div class="d-flex flex-nowrap align-items-center mb-4" style="box-sizing:border-box;display:flex !important;flex-wrap:nowrap !important;align-items:center !important;margin-bottom:1.5rem !important;"> <a class="field_media_contact_twitter_url" target="_blank" href="https://twitter.com/uazmedphx/" style="box-sizing:border-box;background-color:transparent;color:rgb(1, 28, 72);"> <em></em> </a> </div> </article> </div> <div class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item" style="box-sizing:border-box;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;font-size:1.25rem;color:rgb(33, 33, 33) !important;">Dr. Ziad Obermeyer Discussed the Opportunities and Challenges of Algorithms in Health Care at Buffmire Lecture</div> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item" style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:15px;line-height:20px;margin-bottom:3rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Algorithms might be the answer to some of health care’s most challenging questions — from measuring health care management to understanding health disparities and bias. <a target="_blank" href="https://publichealth.berkeley.edu/people/ziad-obermeyer/" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">Ziad Obermeyer, MD</a>, an associate professor of Health Policy and Management at UC Berkeley School of Public Health, discussed how these algorithms can benefit the health care system, but can also stumble when asking tough questions.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p> <figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:250px;height:auto;background-color:rgb(232, 237, 243) !important;"> <div class="figure-img" style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;"> <img alt="Ziad Obermeyer, MD" class="img-fluid" data-entity-type="file" data-entity-uuid="a6b438b1-4500-4c4d-ab14-a25808ead63a" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/buffmire-story.jpg" title="Ziad Obermeyer, MD" style="box-sizing:border-box;border-width:0px;vertical-align:middle;max-width:100%;margin:5px;width:0px;" /> </div> <figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;font-size:14px;line-height:20px;margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;"> <em style="box-sizing:border-box;">Ziad Obermeyer, MD</em> </figcaption> </figure>On Oct. 22, <a target="_blank" href="https://youtu.be/WUlPfDgwKzo" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">Dr. Obermeyer presented at the Flinn Foundation Buffmire Lecture Series</a>, which introduces renowned medical educators and practitioners to Arizona. The University of Arizona College of Medicine <span lang="EN" style="box-sizing:border-box;">–</span> Phoenix and Flinn Foundation event took place via Zoom.<p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Obermeyer started his presentation by discussing specific, measurable, attainable, relevant and time-based (SMART) setting goals. He provided a few examples of ways to set these realistic and measurable goals, including the goal of having a good life. In order to measure the goal of having a good life, you need to define a proxy. </p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Obermeyer said that these proxies remind him of a genre of joke called the literal genie joke. These are jokes that start like, “I want to be rich,” and the genie says, “okay, Rich. What is your second wish?”</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“We need to be careful what we wish for in life with proxy measures and algorithms, because algorithms are the genie that you can ask anything you want, but you have to be really careful,” he said.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Obermeyer’s work is related to population health management. The idea of improving clinical health outcomes of a defined group of individuals by being proactive and intervening before patients get sick. An example of this is highly trained nurses who are on call when patients have a problem. If that phone call leads the nurse to worry that a patient needs help, that nurse can arrange for a same day primary care visit, do at-home visits, rearrange medication and refill prescriptions.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“The problem is, all of that stuff is expensive,” Dr. Obermeyer said. “We cannot do this for everyone; we just don’t have the resources to do it. We need to target those things for the people who really need it. That is where algorithms come in.”</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Algorithms make decisions about population health management interventions for the majority of the U.S. population, according to Dr. Obermeyer. They predict the patients who will get sick, need hospitalization, rehabilitation and patients who will consume a lot of health care resources. However, these algorithms sometimes stumble.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Obermeyer provided an example of an algorithm that was designed to predict who will be using a lot of health care resources within the next year. Imagine there are two patients and the algorithm predicts both these patients will have a high-risk score of 97.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“It stands to reason that these two patients should go on to have the same needs for that health care and population health management, regardless of the color of their skin,” Dr. Obermeyer said.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">However, that is not the case. Researchers found that the first patient, who was white, had mild depression, took citalopram, had a knee replacement earlier in the year and is now healthy. The second patient, who was black, had diabetes, heart failure and COPD. He was on insulin and seven other medications. Over the course of this year, where they predicted his utilization, he had two ER visits, two hospitalizations, one ending up in a prolonged rehab stay.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“In general, when we looked at patients who had the same algorithm score, patients of color had more active chronic illness; they had biomarkers consistent with worse health, like higher blood pressure, worse kidney function, worse anemia, etc. It doesn’t matter how you measure this health. What we saw was black patients with the same score who were on average far less healthy,” Dr. Obermeyer said.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">According to that algorithm, only 18 percent of the high-risk group was black. In an unbiased world, that number should have been about 47 percent. When researching the issue, Dr. Obermeyer’s team discovered that it was the question the algorithm was answering — which was high health care costs, rather than health care needs. When they refocused the question on health care needs, the algorithm reduced its bias by 84 percent.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">This discovery led to Dr. Obermeyer’s team developing an initiative to help organizations fix algorithm bias and build up data sets to allow the opportunity for more algorithms to be created and adjusted.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“We worry a lot about algorithmic bias, and I think a lot of that work is well founded, but I think there is great cause for optimism,” Dr. Obermeyer said. “Just as algorithms can be biased, they can also be unbiased. Just as they can replicate existing problems with scientific knowledge, they can discover new knowledge by listening to patients. It is going to be up to what data we have available to build algorithms, what seemingly small technical choices we make when we train them. I think that is why this area is so exciting for me, because small things like making data sets available, making the right choice when you are training an algorithm, can make a huge difference.”</p><ul style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><li style="box-sizing:border-box;"><a target="_blank" href="https://youtu.be/WUlPfDgwKzo" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">Watch the full lecture</a>.​<br></li></ul></div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-10-27T07:00:00ZUA
ONCOMYX ANNOUNCES PRESENTATION OF PRECLINICAL DATA FOR NOVEL ONCOLYTIC VIROTHERAPY AT AACR TUMOR IMMUNOLOGY AND IMMUNOTHERAPY VIRTUAL CONFERENCEONCOMYX ANNOUNCES PRESENTATION OF PRECLINICAL DATA FOR NOVEL ONCOLYTIC VIROTHERAPY AT AACR TUMOR IMMUNOLOGY AND IMMUNOTHERAPY VIRTUAL CONFERENCE<div class="ExternalClassF2027DDBE947470991B7F23CFEEE2B79"><html> <p>​<a target="_blank" href="https://oncomyx.wpengine.com/" style="font-family:raleway, sans-serif;font-size:18px;background-color:transparent;box-sizing:inherit;text-decoration-line:underline;color:rgb(78, 162, 196);transition:color 110ms ease-in-out 0s;">OncoMyx Therapeutics</a><span style="color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;background-color:window;">, a privately-held viral immunotherapy company, announced the presentation of preclinical data at the</span><span style="color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;background-color:window;"> </span><a target="_blank" href="https://www.aacr.org/meeting/tumor-immunology-and-immunotherapy-2020/" style="font-family:raleway, sans-serif;font-size:18px;background-color:transparent;box-sizing:inherit;text-decoration-line:underline;color:rgb(78, 162, 196);transition:color 110ms ease-in-out 0s;">AACR Virtual Special Conference</a><a target="_blank" href="https://www.aacr.org/meeting/tumor-immunology-and-immunotherapy-2020/" style="font-family:raleway, sans-serif;font-size:18px;background-color:transparent;box-sizing:inherit;text-decoration-line:underline;color:rgb(78, 162, 196);transition:color 110ms ease-in-out 0s;margin-bottom:0px;">: Tumor Immunology and Immunotherapy</a><span style="color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;background-color:window;"> </span><span style="color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;background-color:window;">taking place October 19 to 20. The data are the first to demonstrate preclinical therapeutic activity alone and in combination with immune checkpoint inhibitors of the company’s armed myxoma virotherapy in development to improve cancer treatment.</span></p> <p style="box-sizing:inherit;margin:32px 0px;max-width:100%;color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;">The talk entitled, “Armed Myxoma Virus Demonstrates Therapeutic Activity Alone and in Combination with Immune Checkpoint Inhibitors in Preclinical Xenograft Models,” will be presented virtually by OncoMyx’s Chief Scientific Officer, Leslie L. Sharp, Ph.D., on October 20 at 11:55-12:25 ET.</p> <p style="box-sizing:inherit;margin:32px 0px;max-width:100%;color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;">“The myoxma virus is highly immuno-interactive and can selectively infect and kill a broad range of cancer cell types,” said Dr. Sharp. “Myxoma’s large genome is ideal for multi-arming to create a unique precision medicine approach to oncolytic viruses. We are also especially encouraged by this data that is the first to demonstrate efficacy of our myxoma virotherapy in a number of tumor models across multiple disease indications, suggesting we could pursue a pan-tumor approach. The further synergy of our myxoma virotherapy with immune checkpoint inhibitors could expand the therapeutic effectiveness of immunotherapies.”</p> <p style="box-sizing:inherit;margin:32px 0px;max-width:100%;color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;">Myxoma is a large dsDNA pox virus suitable for intratumoral or intravenous oncolytic virotherapy and is engineerable to carry multiple transgenic payloads with robust transgene production and function. The data further show that OncoMyx’s myxoma virotherapy is efficacious in multiple <em style="box-sizing:inherit;margin-top:0px;">in vitro </em>and <em style="box-sizing:inherit;margin-bottom:0px;">in vivo </em>tumor models, including subcutaneous and metastatic syngeneic tumor models, and provides combinatorial efficacy with immune checkpoint inhibitors.</p> <p style="box-sizing:inherit;margin:32px 0px;max-width:100%;color:rgb(97, 98, 101);font-family:raleway, sans-serif;font-size:18px;"> <span style="box-sizing:inherit;font-weight:bolder;margin-top:0px;margin-bottom:0px;">About OncoMyx Therapeutics</span> OncoMyx Therapeutics develops viral immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement. The company’s MYXV platform, exclusively licensed from Arizona State University, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients.​<br></p> <p> <br> </p> </html></div>2020-10-19T07:00:00ZOncoMyx Therapeutics
Participate in our ResearchParticipate in our Research<div class="ExternalClass3324F7F65CD7463C893B4EBDF7FEF36C"><html> <p>​<span style="color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;">At TGen, we are pioneers in precision medicine and believe that every genome tells a story. Whether eye color, laughter, freckles or smile, our genes shape who we are in so many distinct and different ways. So, too, do they play more than a passing role in how we develop and react to disease, and as important, how we react to treatment. </span></p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 10px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"><br style="box-sizing:border-box;border-radius:0px;">To understand complex diseases, we enroll healthy and affected volunteers in TGen's research studies. This may be as simple as donating ten minutes of your time to take a memory quiz or offering a saliva sample from a family pet. In other instances, participation may be restricted to those suffering from a particular genetic condition. We invite you to participate in our current studies and forward them with those who may share your interest. Thank you in advance for helping advance our research.<br></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 10px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <a target="_blank" href="https://www.tgen.org/patients/participate-in-our-research/overview/">C<span style="background-color:window;">URRENT STUDIES​</span></a> </p> </html></div>2020-10-07T07:00:00ZTGen
Event: Sign up for virtual tours of TGen October 20, 2020; November 18, 2020 and December 11, 2020 Event: Sign up for virtual tours of TGen October 20, 2020; November 18, 2020 and December 11, 2020<div class="ExternalClass2075461456724FF7A56B3F39AB3FEBA6"><html> <p>​<span id="ms-rterangepaste-start"></span><strong>Event: </strong><a href="https://www.tgen.org/education/tour-tgen/" target="_blank"><strong>Sign up for virtual tours of TGen October 20, 2020; November 18, 2020 and December 11, 2020</strong></a><strong> </strong>View the next generation sequencing technology and biomedical research laboratories where TGen scientists unlock the mysteries of cancer, diabetes, rare and neurological disease.​<span id="ms-rterangepaste-end"></span><br></p> </html></div>2020-10-07T07:00:00ZTGen
Event: The Foundation, Development, and Evolution of a Self-Management Support System TUESDAY, OCTOBER 13, 2020 2:00 PM TO 2:45 PMEvent: The Foundation, Development, and Evolution of a Self-Management Support System TUESDAY, OCTOBER 13, 2020 2:00 PM TO 2:45 PM<div class="ExternalClassB58A0D76759948A48BF6A4CB3C889FD2"><html> <p>​<span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;">Event: </span><a target="_blank" href="https://phoenixmed.arizona.edu/about/events/tech-talk-tuesdays" style="font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;"><strong>The Foundation, Development, and Evolution of a Self-Management Support System</strong></a><strong style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;"> </strong><span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;">TUESDAY, OCTOBER 13, 2020 2:00 PM TO 2:45 PM</span><span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;">​</span></p><span id="ms-rterangepaste-start"></span><h2 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);">The Foundation, Development, and Evolution of a Self-Management Support System</h2><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">Technology can play a critical role in guiding self-management for older adults. Learn how research findings have led to the development of technologies such as smartphone apps to improve medication adherence and other beneficial  behavioral interventions for an aging population.</p><h3 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);">Presenter</h3><ul style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;"><li style="box-sizing:border-box;">Kathie Insel, PhD, RN, professor and chair, Biobehavioral Health Sciences Division, UArizona College of Nursing</li></ul><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">Upon <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://arizona.zoom.us/meeting/register/tJMlceqvqDkrGdNu1_tcheLeCVY0KAUXytIC" target="_blank">completion of registration</a>, Zoom details will be included in a confirmation email.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;"><span style="box-sizing:border-box;font-weight:bolder;">For inquiries about access</span> or to request any disability-related accommodations that will facilitate your full participation, please contact the Health Sciences Engagement Office at <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="mailto:uahsevents@email.arizona.edu" target="_blank">uahsevents@email.arizona.edu</a> | 520-621-4436.<br style="box-sizing:border-box;"><br style="box-sizing:border-box;"><span style="box-sizing:border-box;font-weight:bolder;">For more information</span>, contact: Kaitlyn Armendariz Shergill, Manager, Outreach and Engagement at <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="mailto:karmendariz@email.arizona.edu" target="_blank">karmendariz@email.arizona.edu</a> | 520-621-4436.​<br></p><span id="ms-rterangepaste-end"></span><p><span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;"><br></span></p> <p> <br> </p> </html></div>2020-10-07T07:00:00ZUA
TGEN, AVERY THERAPEUTICS COLLABORATION STUDIES MECHANISM OF ACTION IN ENGINEERED HEART TISSUETGEN, AVERY THERAPEUTICS COLLABORATION STUDIES MECHANISM OF ACTION IN ENGINEERED HEART TISSUE<div class="ExternalClassC69398967DEC40DC98615DD68D732637"><html> <p>​<span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a>​</span></p> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="list-inline posted-info"> </ul> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen’s analysis of proteins and metabolites could pave the way for Avery Therapeutics to gain FDA approval of human clinical trials</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX and TUCSON, Ariz. — Oct. 5, 2020 —</span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://averythera.com/" target="_blank">Avery Therapeutics Inc.</a> of Tucson has  developed an engineered heart tissue, a lab-grown cardiac membrane that can help heal the heart, either following a heart attack or as a result of progressive heart disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The heart tissue, called MyCardia™, could revolutionize the treatment of cardiovascular disease, and someday might be applied to other failing organs.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To better understand how MyCardia works — at the infinitesimally small molecular level — Avery has partnered with the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, following an introduction made by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://flinn.org/bioscience/arizonas-bioscience-roadmap/entrepreneurship-program/" target="_blank">Flinn Foundation</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Avery turned to TGen to understand which of their membranes are releasing molecules that produce therapeutic benefits,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/patrick-pirrotte/" target="_blank">Dr. Patrick Pirrotte</a>, Assistant Professor and Director of TGen’s Collaborative Center for Translational Mass Spectrometry. “Our collaboration will help them understand the mechanism of action on the molecular level, and the potential benefits to patients.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">TGen is conducting mass spectrometry analysis of the proteins and metabolites at work in MyCardia’s healing effect on heart-muscle tissue. This supporting data will be used in Avery’s submissions to the Food and Drug Administration (FDA) that could lead to human clinical trials. Up to now, Avery has studied the processes in laboratory and preclinical experiments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Avery’s technology is amazing,” Dr. Pirrotte said, noting that the MyCardia membranes actually beat like a heart. “Their idea is that, for a heart that is potentially weak, an inserted cardiac membrane could support regeneration of heart tissue.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Avery licensed the technology for MyCardia from the University of Arizona, where Avery scientists had worked on developing engineered regenerative tissues to treat cardiovascular disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Key to the technology is the advancement in recent years of induced pluripotent stem cells (iPSCs), which can propagate indefinitely and theoretically give rise to every other cell type in the body. They represent a source of cells that could be used to replace those lost to damage or disease. Advancements in iPSC technology led to a Nobel Prize in 2012.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“It’s the concept of being able to take essentially any cell in the body and convert it into an embryonic-like cell, and then being able to make any cell. That’s how we are making our heart-muscle cells,” said Dr. Jordan Lancaster, Avery’s Chief Executive Officer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Dr. Jen Koevary, Avery’s Chief Operating and Financial Officer, added: “We created the material based on the idea that you can use healthy cells to treat an unhealthy tissue and make it healthy again.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">The Nation’s leading cause of death</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">More than 30 million Americans have heart disease, resulting in over $39 billion annually in medical treatment costs. Nearly 600,000 patients are newly diagnosed each year, and <span style="box-sizing:border-box;border-radius:0px;">650,000 Americans die annually, making it the nation’s leading cause of death.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The condition is most often treated with drugs, but those efforts eventually fail. Heart transplants can help, but suitable donors are scarce, enabling fewer than 3,000 transplants each year. Mechanical hearts that run on battery packs also can help, but they are expensive; patients are often left with limited mobility, poor quality of life and frequent hospital visits.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">How MyCardia works</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;">Through</span> minimally invasive laparoscopic or robotic surgery, MyCardia is precisely grafted onto the surface of a damaged heart. It is loaded with a therapeutic cellular payload; a proprietary combination of cardiomyocytes (heart-muscle cells) and fibroblasts (general cells of the body).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Over time, the MyCardia membrane secretes proteins and metabolites, collectively called the secretome, which helps enable the heart to heal itself. The MyCardia eventually disappears. It’s the unique secretome that is being studied at TGen.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We have lots of data, but we really don’t know what makes it tick,” Dr. Lancaster said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">There are hundreds of factors involved in the MyCardia process, explained Dr. Koevary: “Figuring out exactly how it works is very complex. It’s important for us to know how it’s working so we can, in the future, identify the best patients who would be candidates for treatment.”​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <br> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/92/patrick-pirrotte.png2020-10-05T07:00:00ZTGen
Phoenix Union Bioscience High School was recently notified that Principal Dr. Holly Batsell has earned the 2020 Maricopa County Exemplary Principal Award.Phoenix Union Bioscience High School was recently notified that Principal Dr. Holly Batsell has earned the 2020 Maricopa County Exemplary Principal Award.<div class="ExternalClass6DC17C32A0AD45378B512E7090824B99"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">The Maricopa County Exemplary Principal Award, formerly known as the Rodel Exemplary Principal Award, recognizes principals in Maricopa County who exemplify practices and leadership that contribute to high expectations and exceptional student learning. Principals are chosen based on a robust nomination process that includes five phases. Aspects of the process involve a site visit, interviews with staff members, classroom walkthroughs, and an observation of a leadership team meeting.</p> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">The process includes a review of the last three years of achievement data to identify schools with a history of high student achievement, student growth, and teacher retention. Superintendents are then invited to nominate principals who meet the established criteria.</p> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">“Bioscience High School, with Dr. Holly Batsell’s steady leadership for the past four years, is routinely ranked as one of the top high schools in Arizona, earning an “A” for the past two years”, said PXU Superintendent Dr. Chad Gestson. “With an emphasis on an integrated, rigorous curriculum while incorporating science, technology, engineering, and math, Dr. Batsell has successfully focused on increasing ACT scores and increasing student enrollment and retention. She has high expectations for herself and her staff.” Dr. Gestson continued, “these expectations have translated into positive and supportive school culture. This, in turn, consistently promotes student success. Bioscience students receive hundreds of thousands of dollars in scholarships each year and many go on to successful STEM careers. The honor of being named a National Blue Ribbon School is a reflection of the hard work and dedication of all Bioscience staff.”​<br></p> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/90/Dr. Holly Batsell.png2020-10-02T07:00:00ZPhoenix Bio News
ASU professor receives Fulbright award to improve medical trainingASU professor receives Fulbright award to improve medical training<div class="ExternalClass1BE61456D0A444E8BCF4C235288AB66F"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <p style="box-sizing:border-box;margin:0px 0px 24px;max-width:800px;line-height:24px;color:rgb(42, 42, 42);font-family:roboto, "helvetica neue", helvetica, arial, sans-serif;font-size:16px;"> <a style="box-sizing:border-box;background:transparent;color:rgb(163, 0, 70);border-bottom:1px dotted rgb(163, 0, 70);transition:all 0.25s ease-in-out 0s;" href="https://isearch.asu.edu/profile/3181636" target="_blank"> <span style="box-sizing:border-box;">David Sklar</span> </a> <span style="box-sizing:border-box;">, a physician and professor at Arizona State University’s</span> <a style="box-sizing:border-box;background:transparent;color:rgb(163, 0, 70);border-bottom:1px dotted rgb(163, 0, 70);transition:all 0.25s ease-in-out 0s;" href="https://chs.asu.edu/" target="_blank"> <span style="box-sizing:border-box;"> College of Health Solutions</span> </a> <span style="box-sizing:border-box;">, has received a Fulbright U.S. Scholar Program award in medical education research and lecturing to work with faculty at the </span> <a style="box-sizing:border-box;background:transparent;color:rgb(163, 0, 70);border-bottom:1px dotted rgb(163, 0, 70);transition:all 0.25s ease-in-out 0s;" href="https://www.rcsi.com/dublin/" target="_blank"> <span style="box-sizing:border-box;">Royal College of Surgeons in Ireland</span> </a> <span style="box-sizing:border-box;"> to improve population health training for their medical students.</span> </p> <p style="box-sizing:border-box;margin:0px 0px 24px;max-width:800px;line-height:24px;color:rgb(42, 42, 42);font-family:roboto, "helvetica neue", helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;">Sklar, who is also a senior adviser to the ASU provost, will spend next summer in Ireland as part of a yearlong effort to develop a new curriculum for Royal College of Surgeons in Ireland students that advances knowledge and skills to improve overall individual and community health beyond basic diagnosis and treatment of disease. This includes teaching ways to lower health care costs, improve health care providers’ mental and physical well-being, and raise awareness about other factors that affect a patient’s health, such as socioeconomic status, education level, and the surrounding environment.</span> <span style="box-sizing:border-box;overflow:auto;border-top:none;border-bottom:none;padding-top:20px;padding-bottom:20px;margin-bottom:12.5px;margin-top:12.5px;width:371px;display:block;border-left:none;border-right:1px solid rgb(238, 238, 238);padding-right:20px;margin-right:25px;float:left;" class="image-with-caption image-with-caption-border-right image-with-caption-float-left"> <img class="" style="box-sizing:border-box;border-width:0px;border-style:initial;vertical-align:middle;max-width:100%;width:350px;margin:5px;" src="https://asunow.asu.edu/sites/default/files/styles/asu_news_article_image/public/sklar-david-0135_1.jpg?itok=Q2Hs_nTw" alt="David Sklar" /> <span style="box-sizing:border-box;margin-top:10px;color:rgb(118, 118, 118);font-size:13px;display:block;float:left;width:350px;" class="description">David Sklar.</span> <span style="box-sizing:border-box;margin-top:10px;color:rgb(118, 118, 118);font-size:13px;display:block;float:left;width:350px;" class="description"> <a style="box-sizing:border-box;background:transparent;color:rgb(163, 0, 70);border-bottom:1px dotted rgb(163, 0, 70);transition:all 0.25s ease-in-out 0s;" href="https://asunow.asu.edu/sites/default/files/sklar-david-0135_1.jpg" target="_blank">Download Full Image</a> </span> </span> </p> <p style="box-sizing:border-box;margin:0px 0px 24px;max-width:800px;line-height:24px;color:rgb(42, 42, 42);font-family:roboto, "helvetica neue", helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;">Because the Royal College of Surgeons in Ireland is a medical school that includes campuses in Ireland, Bahrain and Malaysia, with a student body from all over the world, this socio-ecological curriculum model promotes a global perspective in medical education that aims to motivate students to serve populations most in need of health care.</span> </p> <p style="box-sizing:border-box;margin:0px 0px 24px;max-width:800px;line-height:24px;color:rgb(42, 42, 42);font-family:roboto, "helvetica neue", helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;">“This model emphasizes the dynamic interplay of the individual and the various influences of family, community, health policy, the environment and other global effects,” Sklar said. “We will be integrating innovations that are being developed and tested all over the world and strive to match them with the unique interests and needs of (the college).” </span> </p> <p style="box-sizing:border-box;margin:0px 0px 24px;max-width:800px;line-height:24px;color:rgb(42, 42, 42);font-family:roboto, "helvetica neue", helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;">ASU Provost Mark Searle commended Sklar for his work to promote population health from a medical training perspective.</span> </p> <p style="box-sizing:border-box;margin:0px 0px 24px;max-width:800px;line-height:24px;color:rgb(42, 42, 42);font-family:roboto, "helvetica neue", helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;">“ASU is proud to contribute to global health through the Fulbright program and is confident that Dr. Sklar will improve international collaboration through his work on innovations in health professions education at the Royal College of Surgeons in Ireland,” he said.</span> </p> <p style="box-sizing:border-box;margin:0px 0px 24px;max-width:800px;line-height:24px;color:rgb(42, 42, 42);font-family:roboto, "helvetica neue", helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;">Sklar is one of more than 800 U.S. citizens who will conduct research and teach abroad through the Fulbright U.S. Scholar Program in the coming year. Since 1946, the Fulbright Program has enabled more than 390,000 students, scholars, artists, teachers and professionals of all backgrounds to study, teach and conduct research, exchange ideas and find solutions to shared international concerns. The program is sponsored by the U.S. government and is funded annually by the U.S. Department of State. ​</span> </p> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-10-01T07:00:00ZASU
National Blue Ribbon School 2020National Blue Ribbon School 2020<div class="ExternalClassC9AE471B315A43DDAAE053AB6B84BE06"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">The National Blue Ribbon Schools Program recognizes public and private elementary, middle, and high schools based on their overall academic excellence or their progress in closing achievement gaps among student subgroups. “Every year, the U. S. Department of Education seeks out and celebrates great American schools which demonstrate that all students can achieve to high levels. The coveted National Blue Ribbon School award affirms the hard work of students, educators, families, and communities in creating safe and welcoming schools where students master challenging and engaging content.” (<a style="cursor:pointer;" href="https://nationalblueribbonschools.ed.gov/background/" target="_blank">National Blue Ribbon School Website</a>) </p> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">“Bioscience High School, with Dr. Holly Batsell’s steady leadership for the past four years, is routinely ranked as one of the top high schools in Arizona, earning an “A” for the past two years”, said PXU Superintendent Dr. Chad Gestson. “With an emphasis on an integrated, rigorous curriculum while incorporating science, technology, engineering, and math, Dr. Batsell has successfully focused on increasing ACT scores and increasing student enrollment and retention. She has high expectations for herself and her staff.” Dr. Gestson continued, “these expectations have translated into a positive and supportive school culture. This, in turn, consistently promotes student success. Bioscience students receive hundreds of thousands of dollars in scholarships each year and many go on to successful STEM careers. The honor of being named a National Blue Ribbon School is a reflection of the hard work and dedication of all Bioscience staff.”​<br></p> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-10-01T07:00:00ZCity of Phoenix
SINGLE-CELL RNA SEQUENCING REVEALS DETAILS ABOUT INDIVIDUAL CELLS IN PANCREATIC TUMORSSINGLE-CELL RNA SEQUENCING REVEALS DETAILS ABOUT INDIVIDUAL CELLS IN PANCREATIC TUMORS<div class="ExternalClassC5788228BE4A4D53B31356F7F1C02CD4"><html> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">​Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Tuesday September 29, 2020</li></ul> <br> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen and HonorHealth investigators suggest this granular analysis could lead to better treatments for pancreatic cancer patients</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">SCOTTSDALE, Ariz. — Sept. 29, 2020 —</span> Led by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, and by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth Research and Innovation Institute</a><span style="box-sizing:border-box;border-radius:0px;">, </span>an international team of researchers have described in detail the individual cells that comprise the pancreatic cancer microenvironment, a critical step in devising new treatment options for patients with this aggressive and difficult-to-treat disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study results were published today in the scientific journal <em style="box-sizing:border-box;border-radius:0px;">Genome Medicine</em>, a publication of <em style="box-sizing:border-box;border-radius:0px;">Springer</em> <em style="box-sizing:border-box;border-radius:0px;">Nature</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Researchers used a relatively new technique known as single-cell sequencing to genetically identify cell types, and subtypes, that occur in pancreatic tumors, and identify the various cells in the tumor’s stroma, a substance surrounding the tumor that can hide the cancer from the body’s immune system.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While single-cell transcriptomics has been used previously to study the cellular composition of primary tumor tissues of pancreatic ductal adenocarcinoma (PDAC), this study also used the technology to profile individual cells from dissociated primary tumors and biopsies of metastatic tissues, those cancerous lesions that have spread throughout the body from the primary tumor.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This study was carried out in collaboration with investigators from <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.samsunghospital.com/gb/language/english/main/index.do" target="_blank">Samsung Medical Center</a> and City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. Primary tumors and core needle biopsies of metastatic lesions from PDAC patients were sequenced using the Chromium single cell RNA-Seq platform.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Single-cell transcriptome analysis can offer important clinical insights on individual cell subpopulations and provide clues for developing novel therapeutic strategies for both targeted therapies and immunotherapies,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/haiyong-han/" target="_blank">Haiyong Han</a>, Ph.D., a professor in TGen’s Molecular Medicine Division and head of the institute’s Pancreatic Cancer Research Laboratory.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Understanding the diversity and complexity of the PDAC tumor and stromal compartments in individual tumors may help identify unique intervention points and potentially inform treatment and maintenance strategies for patients with advanced disease,” said Dr. Han, the study’s senior author.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Distinct cell types and subtypes were identified in the analysis, including tumor cells, endothelial cells, cancer associated fibroblasts, and immune cells, and the expression levels of various genes in the individual cell populations correlated with patient clinical outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Working with our partners and colleagues by utilizing the technology of singe cell sequencing, we can continue to learn more about the biology of pancreas cancer.  These insights may potentially help us determine more treatment options for our patients,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/physicians/erkut-borazanci" target="_blank">Erkut Borazanci</a>, M.D., M.S., a medical oncologist and physician-investigator at HonorHealth Research and Innovation Institute, a clinical associate professor at TGen, and one of the paper’s authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Pancreatic cancer is an aggressive disease that carries a high mortality rate. It is the third-leading cause of cancer death in the U.S., following lung and colorectal cancers. In 2020, the five-year survival rate for pancreatic cancer is only about 10%, though that represents progress from the dismal 6% rate in 2014.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Next, researchers plan to use more advanced single-cell spatial transcriptomics analysis to further investigate the cellular relationships related to survival rates using real-time methods. Broader use of this technology could potentially guide the search for new agents to treat pancreatic cancer. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">For more information about pancreatic cancer research studies at HonorHealth Research and Innovation Institute, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/company/research-institute" target="_blank">HonorHealth.com/research</a>, call 480-323-1364 or email <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:clinicaltrials@honorhealth.com" target="_blank">clinicaltrials@honorhealth.com</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This research was supported by: the National Foundation for Cancer Research; SU2C-CRUK-Lustgarten Foundation Pancreatic Dream Team Research Grant (SU2C-AACR-DT-20-16); Baylor Scott & White Research Institute (BSWRI) and Translational Genomics Research Institute (TGen) Collaboration in Oncology Research; and the Korean Health Technology R&D Project  (HI14C2640).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study — <em style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-020-00776-9" target="_blank">Single-Cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions</a> — </em>was published in the scientific journal <em style="box-sizing:border-box;border-radius:0px;">Genome Medicine</em>.</p> <br> <br> </div> </div> <p> <br> </p> </html></div>2020-09-29T07:00:00ZTGen
TGEN LAUNCHES VIDIUM ANIMAL HEALTHTGEN LAUNCHES VIDIUM ANIMAL HEALTH<div class="ExternalClassE31BAFC3FABC460DA9375CB91D510B3B"><html> ​ <span id="ms-rterangepaste-start"></span> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;"> <ul class="list-inline posted-info" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span class="uBlogsy_author_name" style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" title="Steve Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Monday September 28, 2020</li></ul> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen subsidiary offers genomic diagnostics in support of veterinary oncologists and pet parents treating canine cancer</em> </p> </div> </div> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — Sept. (28), 2020 —</span> After more than a decade of pioneering the study of naturally occurring cancer in pet dogs, the <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a target="_blank" href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">City of Hope</a>, announced today the commercial launch of <a target="_blank" href="http://vidiumah.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Vidium Animal Health</a>, providing genomic-based precision-medicine to veterinary oncologists and pet parents.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">As a veterinarian, Vidium President Dr. David Haworth has seen first-hand the pain and concern that veterinarians and pet parents experience when a dog is diagnosed with cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Vidium is built around the human-animal bond, and the fact that the majority of pet owners feel their pet is part of their family,” Dr. Haworth said. “When a pet is diagnosed with cancer, it can be a really scary time for everyone, so we want to offer the very best information, and hope, that science can offer.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To increase a pets’ chance of survival, Vidium created <em style="box-sizing:border-box;border-radius:0px;">SearchLight DNA™</em>, a test designed specifically to identify any of the nearly 120 known cancer-associated genetic mutations in dogs, and use the molecular profile of misbehaving genes to help guide diagnosis and treatment.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Vidium Founder and Chief Science Officer Dr. Will Hendricks, an Assistant Professor in TGen’s Integrated Cancer Genomics Division, has spent much of the past decade dedicated to the pursuit of <a target="_blank" href="https://ccr.cancer.gov/comparative-oncology-program" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">comparative oncology</a>, the study of naturally occurring cancers in animals to better understand human cancers and vice versa.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“It’s clearly a two-way street, with both humans and dogs benefiting from the exchange,” he said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">As a prime example, Dr. Hendricks points to <a target="_blank" href="https://www.tgen.org/news/2019/august/20/tgen-and-ohio-state-link-gene-to-canine-lung-cancer/?search=canine" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">a landmark 2019 study</a> conducted by TGen and The Ohio State University, which found that — like many women who develop a particular type of breast cancer — the same gene, HER2, also appears to play an important role in lung cancer in many dogs.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Vidium was born from our finding that the genetic underpinnings of canine cancers reflected the same fundamental science that allowed us to apply precision medicine toward treating human cancers,” Dr. Hendricks said. “Cancer gene mutations that have clinical importance in canine oncology are abundant, and with <em style="box-sizing:border-box;border-radius:0px;">SearchLight DNA</em> our goal is to equip veterinarians with the best information possible to help guide the clinical management of the dogs in their care.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Katie Banovich, Vidium’s Director of Operations, said the absence of genomic technology in the care of pets is a tremendous void that Vidium hopes to fill, but only with the participation of veterinarians and pet parents.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Through application of multi-disciplinary genomic science, we want to position Vidium as a partner in the veterinary care team,” Banovich said. “We want to be a guide. We want to work with veterinarians.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">SearchLight DNA</em> reports will be customized with technical language designed for clinicians and easier-to-understand lay language for pet parents that fully communicates the details of their pet’s condition.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While Vidium’s efforts will initially be put toward canine cancer, its goal is to expand its genomic analysis to the treatment of other diseases, and other animals.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Beyond assisting with the diagnosis, prognosis and treatment of dogs with cancer, Vidium will play a continuing role in the discovery of new associations between gene mutations, specific types of cancers in specific breeds of dogs, and clinical outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We are going to play an active role in changing the landscape of veterinary care, both through expanding our understanding of genetic biomarkers, and by facilitating access to targeted therapeutics that may make a difference in specific genetic settings,” Dr. Hendricks said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Vidium Animal Health is a subsidiary of TGen. Learn more at: <a target="_blank" href="http://vidiumah.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">vidiumah.com</a>.​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-09-28T07:00:00ZTGen
Genetic Sleuthing Reveals Multiple Introductions Of Coronavirus To ArizonaGenetic Sleuthing Reveals Multiple Introductions Of Coronavirus To Arizona<div class="ExternalClass840E64380487488DB78CAE3B569438B3"><html> <p>​<span class="submitted" style="box-sizing:border-box;color:rgb(119, 119, 119);font-size:0.75em;line-height:1.25;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;letter-spacing:0.08px;word-spacing:0.4px;"><span class="submitted-label" style="box-sizing:border-box;">By</span> <span class="name" style="box-sizing:border-box;text-transform:uppercase;"><a target="_blank" href="https://www.knau.org/people/melissa-sevigny" rel="author" style="box-sizing:border-box;color:rgb(61, 61, 61);line-height:inherit;background:transparent;">MELISSA SEVIGNY</a></span></span><span style="color:rgb(61, 61, 61);font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;"> </span>​<br></p> <p> <span style="color:rgb(61, 61, 61);font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;">A</span><a style="box-sizing:border-box;color:rgb(22, 141, 217);line-height:inherit;background:transparent;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;" target="_blank" href="https://mbio.asm.org/content/11/5/e02107-20"> new study</a><span style="color:rgb(61, 61, 61);font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;"> shows the virus that causes COVID-19 arrived in Arizona in at least eleven separate introductions in February and March. That’s the result of genetic detective work done by scientists at Arizona’s three state universities and the Translational Genomics Research Institute in Flagstaff. KNAU’s Melissa Sevigny spoke with Jolene Bowers of TGen North about how sequencing the genome of the coronavirus can help public health professionals track the disease through time and space.</span><br> </p><span id="ms-rterangepaste-start"></span><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">What can you learn from looking at the genetic material of the coronavirus?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">What we’re doing is we’re sequencing a whole bunch of virus genomes to try to understand how the virus is spreading in and around Arizona. The way we do that is we’re sequencing these genomes and looking for these small mutations that will tell us who is related to whom. These mutations are constantly happening. They’re being passed down from generation to generation. So when we see two viruses that share a certain mutation, then we can be confident that they’re related.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">So you sequenced the genome of the very first case in Arizona, and what did you learn from that?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">Actually the CDC sequenced that first case… This was in late January. A young man was returning from travel and he presented to a health care center with mild symptoms…. He was very quickly diagnosed and quarantined… We were able to show that none of the viruses that we sampled in Arizona were related to that virus genome at all… So public health response efforts really work.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">So you’ve sequenced many more genomes since that first case happened in January. What have you learned since then?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">What we were able to show is a lot of our viruses in Arizona are most closely related to other viruses that are circulating in other states in the United States…. And we determined that very likely the virus was introduced into Arizona probably in mid to late February, but we didn’t start seeing it until cases starting coming to light in early and mid-March…. This was when the virus really started taking off in Arizona, and it probably all arrived here through domestic travel. Probably not surprising because that was when some of the travel restrictions were put in place and international travel was being discouraged.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">One of the things your team discovered was that there were at least 11 separate introductions of the virus to Arizona. I’m curious, did that surprise you or were you expecting that?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">It’s not surprising at all that we had that many virus introductions into Arizona. Arizona’s not in a bubble and people are still moving around. What did surprise me is we were able to detect at least 11 different introductions to the virus. Because the way we’re doing that, we’re comparing the genomes of the virus, so these genomes have to be different enough to detect these differences in the virus, so we can trace these lineages or these variants of these viruses back to different ancestors. That’s how we determined there were probably at least 11 introductions. We think that’s probably an underestimate really.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">What are the next steps, or questions you still want to answer?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">We definitely want to take another big picture look now that we have thousands of genomes sequenced and see how the pandemic has evolved in Arizona, Do we see any of these super spreader events? One of our major goals is really to demonstrate the value of this genomic epidemiology and make it routine, so that it becomes an everyday thing.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">Jolene Bowers, thank you for speaking with me today.</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">Thank you for having me.​<br></p><span id="ms-rterangepaste-end"></span><p><br></p> </html></div>2020-09-25T07:00:00ZNAU
NewsletterNewsletter<div class="ExternalClassDD13B7C84EFB4E83B3554560B99C9073"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div class="bgcolor" style="background-color:rgb(230, 230, 230);"> <table class="bgimage" width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#e6e6e6" style="border-collapse:collapse;table-layout:auto;"> <tbody> <tr> <td align="center"> <table class="main-width" width="690" align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;table-layout:fixed;width:690px;"> <tbody> <tr> <td class="layout" align="center" valign="top" style="padding:15px 5px;"> <table width="100%" align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="layout-container-border" align="center" valign="top" bgcolor="#56a6ad" style="background-color:rgb(86, 166, 173);padding:0px;"> <table width="100%" align="center" border="0" cellpadding="0" cellspacing="0" bgcolor="#56a6ad" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="layout-container" align="center" valign="top" bgcolor="#ffffff" style="background-color:rgb(255, 255, 255);padding:0px;"> <div class=""> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class=" editor-col OneColumnMobile" width="100%" align="" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);text-align:center;display:block;line-height:1.2;padding:10px 40px;"> <div class="text-container galileo-ap-content-editor"> <div align="left" style="text-align:left;"> <span style="font-size:22px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:22px;font-weight:bold;"> </span> <span style="font-size:22px;font-weight:bold;color:rgb(235, 169, 66);">TODAY</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-style:italic;font-weight:bold;">An Update on the People, Places, and Possibilities of the Phoenix Biomedical Campus in Downtown Phoenix • Oversight provided by Arizona State University (Michael Crow, President), Northern Arizona University (Rita Cheng, President), University of Arizona (Robert Robbins, President), Arizona Board of Regents (John Arnold, Executive Director), and City of Phoenix led by Mayor Kate Gallego • September 22, 2020</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">In the photograph in our masthead, Dr. Cara Christ, director of the Arizona Department of Health Services, joined Arizona Governor Doug Ducey and other local health leaders to announce </span> <a href="https://azgovernor.gov/governor/news/2020/08/governor-ducey-and-health-leaders-urge-arizonans-get-flu-shot" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">important next steps</a> <span style="font-size:12px;color:rgb(0, 0, 0);"> vaccinating more Arizonans against the flu as we continue to mitigate the spread of COVID-19. The press conference was held at the Virginia G. Piper Auditorium in historic Building 2 of the University of Arizona College of Medicine–Phoenix. Since its renovation in the mid-2000s, the auditorium is a special Phoenix Biomedical Campus and Downtown Phoenix gathering place for events, meetings, classes, and student activities.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Bioscience advocates share stories on responding to COVID-19</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Tune in to watch “</span> <a href="https://youtu.be/KYYn1a1fiZU" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Celebrating Life & Science</a> <span style="font-size:12px;color:rgb(0, 0, 0);">,” an inspirational and educational program highlighting how Arizona's bioscience community is working together to make life better before, during, and after COVID-19. The guest speakers joining host Joan Koerber-Walker, President & CEO of the Arizona Bioindustry Association (AZBio), include:</span> </div> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Doug Ducey, Governor, State of Arizona</li> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Dr. Jeffrey Trent, President & Research Director, TGen</li> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Dr. Joshua LaBaer, Executive Director, ASU Biodesign Institute</li> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Sandra Watson, President & CEO, Arizona Commerce Authority (ACA)</li> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Michelle McMurry-Heath, President & CEO, Biotechnology Innovation Organization</li> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Dr. Rosa Krajmalnik-Brown, Arizona Bioscience Researcher of the Year</li> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Dr. Carl Yamashiro, Arizona Bioscience Educator of the Year</li> </ul> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Starting at 28:00 into the hour-long program is a visual tour of the Phoenix Biomedical Campus</span> <span style="font-size:12px;color:rgb(0, 0, 0);font-weight:bold;">.</span> <span style="font-size:12px;color:rgb(0, 0, 0);"> “Celebrating Life & Science” is presented by AZBio and ACA with additional support from the City of Phoenix and Flinn Foundation.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC Partner Spotlight: Northern Arizona University</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Numerous companies, organizations, and higher education institutions call the Phoenix Biomedical Campus home. Starting today, we’ll shine a spotlight on recent news of an individual PBC partner. In this issue, Northern Arizona University.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">For the Fall 2020 academic calendar, NAU’s Athletic Training (AT) Program welcomed 18 new students, Occupational Therapy (OT) welcomed 45 students, and both Physical Therapy (PT) and Physician Assistant Studies (PAS) welcomed 50.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">The PAS Class of 2021 began its first day of clinical rotations on the front lines on August 24. The deadline to apply for the Class of 2023 was September 1. Over 3,000 applications were received. The PAS program was awarded an Area Health Education Center/Rural Health Professions Program (AHEC/RHPP) grant totaling $243,338. This grant supports student placement during the clinical year in medically underserved communities with an emphasis on rural areas. AHEC and RHPP students are supported with travel, lodging, and meal stipends during select clinical rotations. PA students are also supported with additional academic resources for point-of-care decision-making and reference tools on their mobile units. For more information about NAU at the PBC, </span> <a href="https://nau.edu/phoenix-biomedical-campus" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">click here</a> <span style="font-size:12px;color:rgb(0, 0, 0);">.</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PEOPLE </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Noteworthy individuals making a difference</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.azregents.edu/news-releases/david-krietor-appointed-phoenix-biomedical-campus%e2%80%99-first-executive-director" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">David Krietor appointed as PBC’s first executive director</a> (ABOR, 08-28-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.azregents.edu/news-releases/applications-open-regents%e2%80%99-cup-event-debate-competition-celebrates-free-speech-offers" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">ABOR accepting applications for the Regents’ Cup, a student debate competition celebrating free speech, civil discourse, and democratic engagement</a> (ABOR, 09-02-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PLACES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Properties and new developments where good things happen</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.azcentral.com/in-depth/news/local/arizona-science/2020/09/13/bioscience-and-health-care-industries-expand-and-add-jobs-phoenix/3392691001/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Phoenix invests big in health care and biosciences, hoping to boost economy and add jobs</a> (Arizona Republic, 09-16-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.bizjournals.com/losangeles/news/2020/09/01/thriving-life-sciences-sector-demands-strategic-r.html" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Thriving life sciences sector demands strategic real estate knowledge</a> (Phoenix Business Journal, 09-01-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">POSSIBILITIES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Significant research & educational opportunities going on</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://crowdfund.foundationnau.org/project/21729/updates/1" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">NAU Department of Occupational Therapy launches new program, “OT Easing the Transition: An independent living skills curriculum for youth aging out of foster care”</a> (NAU Foundation, 09-01-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://asunow.asu.edu/20200818-solutions-identifying-facts-sex-trafficking-and-internet" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Identifying the facts on sex trafficking and the internet</a> (ASU, 08-18-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="http://news.nau.edu/racial-disparities/#.X1KLkGepFE5" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Examining the role racial disparities play in mortality rates of rural, urban residents</a> (NAU, 08-06-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://asunow.asu.edu/20200709-discoveries-why-hydration-so-important-when-hiking-heat-summer" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Why hydration is so important when hiking in the heat of summer</a> (ASU, 07-09-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://asunow.asu.edu/20200611-arizona-impact-study-finds-correlation-between-vaccination-rates-disease-immunity" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Study finds correlation between vaccination rates, disease immunity</a> (ASU, 06-11-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://asunow.asu.edu/20200428-solutions-personalized-education-key-deploying-nurses-icu-0" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Personalized education key to deploying nurses to ICU</a> (ASU, 04-28-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://asunow.asu.edu/20200424-solutions-fighting-burnout-facebook-asu-grad-student" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Fighting burnout with Facebook</a> (ASU, 04-24-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;text-align:left;font-size:12px;color:rgb(0, 0, 0);"> <a href="https://asunow.asu.edu/20200408-discoveries-why-older-adults-really-should-drink-their-health" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Why older adults really should drink to their health</a> (ASU, 04-10-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class=" editor-col OneColumnMobile" width="100%" align="" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);text-align:center;display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left" style="text-align:left;"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PANDEMIC RESPONSE</span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">PBC-affiliated experts weigh in on timely issue</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class=" editor-col OneColumnMobile" width="100%" align="" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);text-align:center;display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.medscape.com/viewarticle/937468" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Should social distancing measures be enforced?</a> (Medscape, 09-16-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://eurekalert.org/pub_releases/2020-09/ttgr-acg091420.php" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Arizona COVID-19 Genomics Union tracks strains of SARS-CoV-2</a> (TGen, 09-15-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.nbcnews.com/news/latino/arizona-pulmonologist-dr-thomas-ardiles-says-americans-have-unite-beat-n1239812" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Arizona pulmonologist Dr. Thomas Ardiles says Americans have to unite to beat coronavirus “war”</a> (NBC News, 09-14-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.biospace.com/article/releases/coronavirus-breakthrough-senhwa-reports-first-eind-silmitasertib-treated-severe-covid-19-patient-discharged-following-five-days-of-treatment/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Senhwa reports first eIND Silmitasertib treated severe COVID-19 patient discharged following five days of treatment</a> (Biospace, 09-11-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.azcentral.com/story/entertainment/life/health/2020/09/10/is-it-safe-get-haircut-go-to-dentist-eat-at-restaurant-use-public-bathroom-go-to-gym-covid-19/5717730002/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Is it safe to get a haircut? Here are the risks of 5 everyday activities during COVID-19</a> (Arizona Republic, 09-10-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://kjzz.org/content/1616693/brain-fog-one-lingering-symptoms-covid-19" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">“Brain Fog” one of the lingering symptoms of COVID-19</a> (KJZZ, 09-09-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://kjzz.org/content/1616179/older-adults-often-left-out-clinical-trials-vaccines" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Older adults often left out of clinical trials for vaccines</a> (KJZZ, 09-07-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://academic.oup.com/ppar/advance-article/doi/10.1093/ppar/praa024/5901344?guestAccessKey=649b431f-030d-4b09-83bb-4a654af0e7fd" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Addressing the needs of rural caregivers of individuals with Alzheimer’s Disease and related dementias during and beyond COVID-19</a> (Gerontological Society of America, 09-04-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://kjzz.org/content/1615597/dont-repeat-mistakes-memorial-day-weekend-public-health-expert-warns-against-rise" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Public health expert warns against rise in Arizona's COVID-19 cases</a> (KJZZ, 09-04-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.azfamily.com/news/arizona_schools/phoenix-area-doctor-weighs-in-on-hybrid-instruction-holiday-weekend-safety/article_d0979790-ee58-11ea-99ab-a3b0783a65a2.html" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Phoenix-area doctor weighs in on hybrid instruction, holiday weekend safety during COVID-19</a> (AZ Family, 09-03-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://kjzz.org/content/1614359/herd-immunity-isnt-smart-strategy-fighting-covid-19-more-arizona-businesses-open" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">“Herd Immunity” isn't smart strategy for fighting COVID-19 as more Arizona businesses open</a> (KJZZ, 09-01-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://azbigmedia.com/business/psychiatrist-here-are-covid-19-and-mental-health-concerns-as-kids-go-back-to-school/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Psychiatrist: Here are COVID-19 and mental health concerns as kids go back to school</a> (AZ Big Media, 08-31-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.12news.com/article/news/how-to-combat-possible-screen-time-related-health-challenges-for-kids/75-616cf31b-8eb4-447c-bdf4-f3a2787c2a3f" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">How to combat possible screen time related health challenges for kids during COVID-19</a> (12 News, 08-31-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://azbigmedia.com/business/preparing-for-flu-season-during-covid-19/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Preparing for flu season during COVID-19</a> (AZ Big Media, 08-31-20)</li> </ul> <div align="left" style="text-align:left;"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;text-align:left;font-size:12px;color:rgb(0, 0, 0);"> <a href="https://asunow.asu.edu/20200624-solutions-asu-faculty-respond-global-health-crisis-innovative-ideas" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">ASU faculty respond to global health crisis with innovative ideas</a> (ASU, 06-24-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PARTICULARS</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class=" editor-col OneColumnMobile" width="100%" align="" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text editor-text " align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Contact:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(0, 0, 0);">David Krietor, Executive Director, 602-741-5580, </span> <a href="mailto:david.krietor@asu.edu" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">david.krietor@asu.edu</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Website:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">biomedicalphoenix.com</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="mailto:claudia.whitehead@phoenix.gov" rel="noopener noreferrer" target="_blank" style="font-size:12px;color:rgb(0, 0, 0);">Claudia Whitehead</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="mailto:claudia.whitehead@phoenix.gov" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">claudia.whitehead@phoenix.gov</a> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Events Calendar:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a href="https://asuevents.asu.edu/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">ASU</a> <span style="font-size:12px;color:black;">, </span> <a href="https://www.pxu.org/Page/38" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Bioscience H.S.</a> <span style="font-size:12px;color:black;">, </span> <a href="https://events.nau.edu/?view=grid&search=y" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">NAU</a> <span style="font-size:12px;color:black;">, </span> <a href="https://puhsaa.com/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">PUHS Alumni Assoc.</a> <span style="font-size:12px;color:black;">, </span> <a href="https://www.tgen.org/giving/events/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">TGen</a> <span style="font-size:12px;color:black;">, </span> <a href="https://uahs.arizona.edu/events" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">UArizona</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Jobs:</span> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> <a href="https://careers.insidehighered.com/jobs/?Keywords=%22phoenix+biomedical+campus%22#browsing" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Inside Higher Ed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="https://www.indeed.com/jobs?q=%22phoenix%20Biomedical%20Campus%22&l=Phoenix%2c%20AZ&radius=0&vjk=9d8bff47682c0b93" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Indeed</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="https://jobs.azbio.org/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">AZBio Job Center</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Getting Around:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a href="https://phoenixmed.arizona.edu/campus" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Campus Map</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="https://www.valleymetro.org/maps-schedules" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Public Transit</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="http://gridbikes.com/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Bike Share</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="https://parking.arizona.edu/parking/biomedical-campus/index.php?referral=compurchase" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Parking</a> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="divider-container editor-col OneColumnMobile" width="100%" align="left" valign="top"> <div class="gl-contains-divider"> <table class="editor-divider" width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="divider-container" align="center" valign="top"> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-content-editor" style="border-collapse:collapse;table-layout:fixed;cursor:default;min-width:100%;"> <tbody> <tr> <td class="divider-base divider-solid" width="100%" align="center" valign="top" style="padding:9px 0px;"> <table cellpadding="0" cellspacing="0" border="0" align="center" style="border-collapse:collapse;table-layout:fixed;width:680px;min-width:100%;height:1px;"> <tbody> <tr> <td height="1" align="center" bgcolor="D6D6D6" style="background-color:rgb(214, 214, 214);border-bottom-style:none;height:1px;line-height:1px;padding-bottom:0px;"> <img alt="" border="0" hspace="0" vspace="0" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" style="display:block;width:5px;margin:5px;" class="" /> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class=" editor-col OneColumnMobile" width="100%" align="" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text editor-text " align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Feel free to share this e-newsletter with people you think would find it of interest. To subscribe or share news, send us an email.</span> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="content editor-col OneColumnMobile" width="100%" align="left" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">PBC </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">| </span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">David Krietor, Executive Director</span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> 602</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">-741-5880 </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">|</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> </span> <a href="mailto:david.krietor@asu.edu" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">david.krietor@asu.edu</a> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> biomedicalphoenix.com</span> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="spacer editor-col OneColumnMobile" width="100%" align="left" valign="top"> <div class="gl-contains-spacer"> <table class="editor-spacer" width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="spacer-container" align="center" valign="top"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="spacer-base" width="100%" align="center" valign="top" style="padding-bottom:10px;height:1px;line-height:1px;"> <img alt="" border="0" hspace="0" vspace="0" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" style="display:block;width:5px;margin:5px;" class="" />​<br></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/99/2020.08.31 Governor Press Conference -3920-FB.jpg2020-09-22T07:00:00ZPhoenix Bio News
Women in Medicine Fighting COVID-19: Drs. Hale, Herbst-Kralovetz and MahnertWomen in Medicine Fighting COVID-19: Drs. Hale, Herbst-Kralovetz and Mahnert<div class="ExternalClass3FD55060215B483CB856C46289507452"><html>​<span id="ms-rterangepaste-start"></span><h5 style="box-sizing:border-box;margin-top:0px;margin-bottom:0px !important;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:normal;line-height:18px;color:rgb(155, 155, 155);font-size:15px;margin-right:0.5rem !important;text-transform:uppercase !important;font-style:normal;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field_title text-uppercase mb-0 mr-2"><span style="box-sizing:border-box;" class="field field--name-title field--type-string field--label-hidden">TERESA JOSEPH</span></h5><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><span id="ms-rterangecursor-start"></span><span id="ms-rterangecursor-end"></span>​<br></h4><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><div style="box-sizing:border-box;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(33, 33, 33) !important;font-size:1.25rem;font-style:normal;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item">Collaborative Research Analyzes Impact of Stress, Pregnancy and COVID-19</div></h4><div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:15px;line-height:20px;margin-bottom:3rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><em>In honor of this year’s <a href="https://phoenixmed.arizona.edu/diversity/wims" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Women in Medicine and Science</a> month, the University of Arizona College of Medicine – Phoenix has asked a few faculty to share their inspiring stories and work that is helping our community through the <a href="https://phoenixmed.arizona.edu/covid-19" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">coronavirus pandemic</a>.</em></p></h4><h2 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);">Meet Drs. Hale, Herbst-Kralovetz and Mahnert</h2><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Three faculty members at the University of Arizona College of Medicine – Phoenix are working on a highly collaborative research project related to the COVID-19 pandemic, stress and pregnancy.</p><figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:250px;height:auto;background-color:rgb(232, 237, 243) !important;"><div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"><img data-entity-type="file" data-entity-uuid="ce39543b-ef6e-4b31-a7ff-6009b25382a9" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/hale-story_0.jpg" alt="Taben Hale, PhD" style="margin:5px;border:0px;width:142px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Taben Hale, PhD" /></div><figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"><em style="box-sizing:border-box;">Taben Hale, PhD</em></figcaption></figure><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The research is being conducted by Melissa Herbst-Kralovetz, PhD, an associate professor in<span> </span><a href="https://phoenixmed.arizona.edu/bms" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Basic Medical Sciences</a><span> </span>and<span> </span><a href="https://phoenixmed.arizona.edu/obgyn" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Obstetrics and Gynecology</a>, Taben Hale, PhD, an associate professor in<span> </span><a href="https://phoenixmed.arizona.edu/bms" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Basic Medical Sciences</a>, and Nichole Mahnert, MD, a clinical assistant professor in<span> </span><a href="https://phoenixmed.arizona.edu/obgyn" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Obstetrics and Gynecology</a>.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The collaborative study began from a graduate medical education project. Obstetrics and Gynecology residents complete a research project over the course of their four-year training. First-year resident Dr. Bryan Grover’s interest in maternal-fetal medicine and translational science inspired this project. He asked how COVID-19 infections affect a woman’s pregnancy and fetus. To tackle this question, a highly collaborative team was assembled with an infectious disease/ reproductive immunologist (Dr. Herbst-Kralovetz), maternal stress/cardiovascular researcher (Dr. Hale), OB/GYN and surgeon (Dr. Mahnert) and Dr. Grover.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">Describe the research in layman’s terms.</strong></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">We are interested in studying the impact of maternal stress, SARS-CoV-2 infection on pregnancy and newborn outcomes. We know that maternal stress can have a negative health impact on fetal development and future disease risk in adulthood. In this study, we are interested in evaluating how the COVID-19 pandemic impacts pregnant moms and their babies. As we have learned over the past several months, SARS-CoV-2 infection affects multiple organ systems including cardiovascular function and can have long-term health effects. Stress also causes global health effects and can exacerbate underlying health issues by increasing inflammation. In this study, we aim to evaluate the impact of pandemic stress and SARS-CoV-2 infection on maternal health and newborn offspring by measuring signatures of stress and inflammation.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Even in the absence of SARS CoV-2 infection, there is a significant degree of added stress due to the pandemic. The stress associated with fear of contracting the virus, added pressures of working from home, and managing remote learning for other children all result in an increased burden on the mother and associated risk to fetal development and long-term health.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;"></strong></p><figure class="bg-light figure img-fluid align-left" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 1rem 1rem 0px;float:left;max-width:250px;height:auto;background-color:rgb(232, 237, 243) !important;"><strong style="box-sizing:border-box;font-weight:bolder;"><div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"><img data-entity-type="file" data-entity-uuid="bef0696e-a3d3-4714-9f02-f1d0fea3416b" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/herbst-kralovetz-story_0.jpg" alt="Melissa Herbst-Kralovetz, PhD" style="margin:5px;border:0px;width:226px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Melissa Herbst-Kralovetz, PhD" /></div><figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"><em style="box-sizing:border-box;">Melissa Herbst-Kralovetz, PhD</em></figcaption></strong></figure><strong style="box-sizing:border-box;font-weight:bolder;">Why is this research important?</strong><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">This has potential long-term impact on women and their babies. It is important that we study how the pandemic stress and SARS-CoV-2 infection impacts health outcomes during pregnancy and beyond. The health outcomes we are interested in studying touch on some of those organ systems, including indicators of stress and inflammation, as well as cardiovascular outcomes.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">There is ample evidence that the in utero environment can have long-term consequences on cardiovascular function and future disease risk. We know that prenatal stress can lead to altered blood pressure and heart rate regulation, as well as increased risk of depression and anxiety in adults. Understanding the impact of COVID on maternal stress and fetal development will lead to improved care of the maternal-fetal dyad.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">What is the research goal?</strong></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">We are interested in understanding the level to which pandemic stress and/or SARS-CoV-2 infection increases inflammation or stress markers in pregnant moms and their newborns. Inflammation and markers of stress could be a driver for adverse effects on women and their offspring.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">What do you want our community to know about this?</strong></p><figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:250px;height:auto;background-color:rgb(232, 237, 243) !important;"><strong style="box-sizing:border-box;font-weight:bolder;"><div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"><img data-entity-type="file" data-entity-uuid="96b25183-92ff-4a1d-99c0-c79469f9172b" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/mahnert-story.jpg" alt="Nichole Mahnert, MD" style="margin:5px;border:0px;width:166px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Nichole Mahnert, MD" /></div><figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"><em style="box-sizing:border-box;">Nichole Mahnert, MD</em></figcaption></strong></figure><strong style="box-sizing:border-box;font-weight:bolder;"></strong><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Studies have shown that women are experiencing elevated symptoms of anxiety and depression during the COVID-19 pandemic relative to pre-pandemic pregnancy cohorts. As such, these stress levels could have long-term health impacts on their children. Healthy lifestyle factors could help to mitigate these negative effects and include social support and exercise.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Mindfulness, yoga and other stress reduction techniques are more important than ever. Thus far, the risk of transmission of COVID-19 from mom to fetus is unlikely, but further research on this topic is so important, which is part of why we are doing this study.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">Why did you want to study this?</strong></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">We know women are bearing the burden of caregiving stress and are disproportionately impacted during pandemics over the course of history. That stress could be having a negative impact on women’s health, including during pregnancy. There are so many unknowns with COVID-19 pandemic and we would like to contribute to expanding our knowledge base and the impact it is having on women’s health.</p></h4></div><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><br><br></h4><p><br></p></html></div>https://biomedicalphoenix.com/Lists/News/Attachments/83/hale-feature.jpg2020-09-18T07:00:00ZUA
Celebrating Life & Science in ArizonaCelebrating Life & Science in Arizona<div class="ExternalClassBA1ACB881CD54EDEAAF0AA6E6E6F9EFC"><html> <p>​Watch <span style="color:#444444;">Celebrating Life & Science for inspiring stories of Arizonans working together and using science to make life better before, during and after the COVID-19 emergency. </span><a href="https://www.youtube.com/AZBio1" target="_blank">https://www.youtube.com/AZBio1</a> <span style="color:#444444;">​</span></p> <p><br></p></html></div>2020-09-17T07:00:00ZArizona BioIndustry Assoc
NCI FUNDS RESEARCH INTO WHY GLIOBLASTOMA HITS MALES HARDER THAN FEMALESNCI FUNDS RESEARCH INTO WHY GLIOBLASTOMA HITS MALES HARDER THAN FEMALES<div class="ExternalClass3D6E76197F37431295ACCB487936F28B"><html> <p>​</p> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span> </span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a href="https://www.tgen.org/news/?author=Steve+Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Steve Yozwiak" target="_blank"> <span style="box-sizing:border-box;border-radius:0px;">Steve Yozwiak</span> </a> </span> </div> </li> <span> </span> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Thursday September 17, 2020</li> </ul> </h4> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">​<span id="ms-rterangecursor-start"></span><span id="ms-rterangecursor-end"></span>TGen technology is key to brain cancer research consortium led by Cleveland Clinic and Case Western Reserve University</em> </p> </h4> </div> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — Sept. 17, 2020 —</strong> <span> </span>The<span> </span><a href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of<span> </span><a href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">City of Hope</a>, will employ two relatively new technologies in a study led by Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine into why men are stricken with glioblastoma brain cancer far more often than women, and why women survive the disease almost twice as long as men.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">As part of a five-year $10.4 million grant announced today from the National Cancer Institute (NCI), researchers will delve into the molecular-level biology of glioblastoma — the most common and deadliest adult brain tumor — seeking new therapies against the disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We’ve known for some time that glioblastoma multiforme (GBM) affects men more than women,” said<span> </span><a href="https://www.tgen.org/faculty-profiles/michael-berens/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Dr. Michael Berens</a>, a TGen Deputy Director and Head of the institute’s Glioma Research Lab. “It’s been in front of us all along. We just haven’t taken a deep enough dive to appreciate in what ways they are different, and — more significantly from a precision-medicine perspective — how the sex of the patient might inform tailored treatment strategies.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr. Berens will study the tumor microenvironment, and the effect of immune cells on the tumor. A major goal of the study is to find out how to make the normal host cells in the brain more resilient against the tumor; specifically how women respond to the disease, and how to apply those findings to provide better treatment outcomes for men.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">First, TGen will employ “single-cell transcriptomics,” which will enable researchers to genetically identify every type of cell that occurs in the tumor, and identify all of the various normal brain cells that surround the tumor.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Then, for the first time in GBM, TGen will use a new technology called “spatial transcriptomics,” which will show the locations of the various cells and how they interact with each other.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We will be able to see who is there, who is misbehaving, who is next to who and, hopefully, who is influencing who,” Dr. Berens said of the various cellular interactions his team will investigate.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Two specific questions Dr. Berens wants to answer are: Why brain tumor cells connect with neurons, the functioning cells of the brain that determine memory and action; and why brain tumor cells appear to recruit special blood cells from bone marrow known as Myeloid Derived Suppressor Cells (MDSCs), which suppress the body’s immune system.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Previous research, including pioneering work at TGen, has shown that glioblastoma occurs at a rate 60 percent higher in males than in females. And, females have a significant survival advantage over males with a median improved survival of up to 10 months. However, while these sex differences are known, they are poorly understood and are not yet considered when treating glioblastoma.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Glioblastomas are aggressive and rare: fewer than 4 per 100,000 in the U.S. from 2012-16, according to the most recent data available from the<span> </span><a href="https://cbtrus.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Central Brain Tumor Registry</a><span> </span>of the United States (CBTRUS). The median survival time is 12 to 14 months, and only about 5% of patients survive more than five years.   </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">Leaders of the study</strong> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The research team is led by co-principal investigators Justin Lathia, Ph.D., of Cleveland Clinic’s Lerner Research Institute, and Jill Barnholtz-Sloan, Ph.D., of Case Western Reserve University School of Medicine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We have the molecular profiling technology and the computing and analytical strength to lead in this effort to better understand the role of sex differences in cancer, particularly for glioblastoma,” said Dr.<span> </span><a href="https://case.edu/cancer/members/member-directory/jill-s-barnholtz-sloan" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Barnholtz-Sloan</a>, the Sally S. Morley Designated Professor in Brain Tumor Research and associate director of Data Sciences at the Case Comprehensive Cancer Center, Case Western Reserve School of Medicine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“This next phase of research relies on vast, varied, and complex datasets — in animals and humans — and promises to be a game-changer in how we understand the role of sex in tumor formation and disease outcomes. This comprehensive approach has applications to all forms of cancer, as well as other diseases,” Dr. Barnholtz-Sloan said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr.<span> </span><a href="https://www.lerner.ccf.org/cms/lathia/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Lathia</a><span> </span>is the vice chair of the Department of Cardiovascular and Metabolic Sciences and co-director of the Brain Tumor Research & Therapeutic Development Center of Excellence at Lerner Research Institute, and co-leader of the Molecular Oncology Program at the Case Comprehensive Cancer Center.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Sex differences are inherent drivers of glioblastoma incidence and survival and we are taking a multidimensional approach to uncover a better understanding of this differentiation,” Dr. Lathia said. “We are incorporating data from tumor cells and their surrounding micro-environment, as well as genetic programs responsible for tumor growth, and underlying epigenetic differences that may be responsible for sex differences. We aim to gain a better understanding of how these variables interrelate to better understand disease mechanism, which in turn defines better diagnostics and more personalized therapies for patients.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The multi-disciplinary project involves established investigators with complementary expertise and a strong collaborative history. Along with Dr. Lathia and Dr. Barnholtz-Sloan, participating principal investigators include: Dr. Berens of TGen; Joshua Rubin, M.D., Ph.D. of<span> </span><span style="box-sizing:border-box;border-radius:0px;">Washington University School of Medicine in St. Louis</span>; and James Connor, Ph.D., of Penn State College of Medicine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The study’s three related research projects will delve into the basic biology and cellular mechanisms that drive sex differences in glioblastoma formation and progression. These related research projects will inform, synergize and depend on each other. Findings from the labs based on their animal models will then be queried against data from human clinical samples across multiple institutions. The vast amount of data generated from these studies requires robust data management and sophisticated data analysis for a comprehensive view of sex differences across these diverse but related inquiries.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Comprehensive findings will inform future clinical research design, the search for targets for new therapeutics, or the use of existing therapeutics that may be applied differently depending on a patient’s sex.   </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This NCI grant —<span> </span><em style="box-sizing:border-box;border-radius:0px;">Sex-based Differences in Glioma</em><span> </span>— was awarded under number 1P01CA245705.</p> </div> </div> <br> <br> </h4> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/82/dr_michael_berens.jpg2020-09-17T07:00:00ZTGen
Women in Medicine Fighting COVID-19: Denege Ward-Wright, MDWomen in Medicine Fighting COVID-19: Denege Ward-Wright, MD<div class="ExternalClass2BBCC94ADDF24203A1E00A742FAF37DA"><html> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:16px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field field--name-field-news-media-contact-ref field--type-entity-reference field--label-hidden field__item"><article class="node node--type-media-contact node--promoted node--view-mode-default" role="article" style="box-sizing:border-box;display:block;"><div style="margin-bottom:1.5rem !important;display:flex;box-sizing:border-box;flex-wrap:nowrap !important;align-items:center !important;" class="d-flex flex-nowrap align-items-center mb-4"> <h5 style="box-sizing:border-box;margin-top:0px;margin-bottom:0px !important;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:normal;line-height:18px;color:rgb(155, 155, 155);font-size:15px;margin-right:0.5rem !important;text-transform:uppercase !important;" class="field_title text-uppercase mb-0 mr-2"><span style="box-sizing:border-box;" class="field field--name-title field--type-string field--label-hidden">TERESA JOSEPH</span> </h5> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <a target="_blank" href="https://twitter.com/uazmedphx/" style="box-sizing:border-box;background-color:transparent;color:rgb(1, 28, 72);text-decoration:none;" class="field_media_contact_twitter_url"> <em></em> </a> </h4> </div> </article> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;margin-bottom:1rem !important;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(33, 33, 33) !important;font-size:1.25rem;font-style:normal;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item">Hospitalist Helped Develop Inpatient COVID Tele-Visits to Reduce Physician Exposure</div> </h4> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:17px;line-height:23px;margin-bottom:3rem;padding-bottom:1rem;border-bottom:1px solid rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <em>In honor of this year’s <a target="_blank" href="https://phoenixmed.arizona.edu/diversity/wims" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;">Women in Medicine and Science</a> month, the University of Arizona College of Medicine – Phoenix has asked a few faculty to share their inspiring stories and work that is helping our community through the <a target="_blank" href="https://phoenixmed.arizona.edu/covid-19" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;">coronavirus pandemic</a>.</em> </p> </h4> <h2 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);font-size:2.1875rem;"> <figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:0px;height:auto;background-color:rgb(232, 237, 243) !important;"> <div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"> <img data-entity-type="file" data-entity-uuid="01f5a41d-2f5b-4a42-9598-a99d6480d4ed" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/wright-story.jpg" alt="Denege Ward-Wright, MD" style="margin:5px;border:0px;width:0px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Denege Ward-Wright, MD" /> </div> <figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"> <em style="box-sizing:border-box;">Denege Ward-Wright, MD</em> </figcaption> </figure>Denege Ward-Wright, MD</h2> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">During the pandemic, Denege Ward-Wright, MD, has led the way in helping the hospital set-up telehealth and video conferences for inpatient COVID cases, which is designed to decrease physician exposure while still providing quality patient care.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Ward-Wright is a clinical associate professor in the Division of Hospital Medicine at the University of Arizona College of Medicine – Phoenix. She has been affiliated with the medical school since 2018.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">Describe your experience working during the pandemic</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Personally, I have been practicing for about 30 years and during my residency, HIV and AIDS were just being discovered and treated. So, I was experienced in managing patients with unknown pathology and disease process, as well as the anxiety it brings for patients and health care workers treating patients with high rates of fatality and little known treatment options. As an attending in internal medicine, I was also treating patients during the H1N1 pandemic, the threat of SARS-COV1 and MERS possible pandemics and then most recently preparing for the possible Ebola pandemic that fortunately did not materialize.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">I had some anxiety and fear during those times, but I think my curiosity for infectious disease and treating patients superseded my fears. I’ve learned that you must respect diseases and take the most appropriate precautions to mitigate infections and to follow the science. During this pandemic with COVID-19, I was fortunate to have expert pulmonologists, infectious disease specialists and cardiologists who supported and educated the hospitalist in management. Our hospitalist teams were organized and we disseminated information in a controlled and precise manner to alleviate misinformation and help develop standards of care and algorithms for this population of patients. There was daily support in our management. The most amazing experience is working with nurses, nurse practitioners, physician assistants, dieticians, clerks and environmental services who worked with these patients and provided 24-hour care with no visible anxiety and comforted these patients daily.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Working with COVID-19 patients has helped me accept the mitigation practices all of us need to take to prevent the spread. The constant politicizing of this disease has made it difficult as there are still some patients and families that cannot accept the measures needed to ensure public safety and that has also been challenging.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">What advice or words of encouragement do you have for other physicians during this time of uncertainty?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Paying attention to the science and public health policies is a pathway of understanding, and that is helpful in trying to protect each other’s safety. I think if we respect this disease and accept that lifestyles have changed then it helps to move forward. Try to look at the positives that have come out of this, prioritizing what is important in our happiness such as the closeness that we developed or rediscovered in our families and communities. Also, to be mindful of our feelings and take steps to our own wellness — whether it be reading, exercising, listening to music or tapping in to whatever creative talents you may have.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">What would you like the community to know about your work during this time as a woman in medicine and science?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">I feel anxious at times; I am sometimes fearful of what the future may bring. However, paying attention to how patients have recovered and watching the trends improve in our cities and states brings about promise. I think women in medicine are mothers and daughters and have the same concerns for their family and communities. Also, we follow the science and public health experts to deliver the best care possible.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">What does your day-to-day look like right now?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Usually, I begin my day earlier to review charts and before I do my rounds, I put on all my PPE and see my patients. Not much has changed in my rounding with patients. I’ve gotten used to talking through masks and a face shield, and I notice patients have, as well. This pandemic has made it to where I can no longer give a patient a hug. I also find myself no longer going back and forth to the patient rooms as much as before to limit exposure.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">Can you describe the inpatient telehealth system you helped set-up?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Banner has been using telehealth in the ambulatory setting to facilitate patient appointments. In the inpatient setting, we have some designated rooms where there is a camera attached to the TV and physicians can communicate with those patients who are able through a secure program at a hospital workstation or website for a tele-visit. This currently operates only while in the hospital with the goal to limit exposure to COVID positive patients. It has limitations, as the patient needs to be able to communicate and is only present in designated rooms.</p> </h4> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <br>​<br></h4> <p> <br> </p> </html></div>2020-09-16T07:00:00ZUA
Ashion Analytics announces innovative cancer treatment partnership with Elevation OncologyAshion Analytics announces innovative cancer treatment partnership with Elevation Oncology<div class="ExternalClassDA589023AF34469082BC9DF9D4102CB6"><html> <p></p><span id="ms-rterangepaste-start"></span><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"><span style="box-sizing:border-box;" class="xn-location">PHOENIX</span>,<span> </span><span style="box-sizing:border-box;" class="xn-chron">Sept. 16, 2020</span><span> </span>/PRNewswire/ -- <a rel="nofollow" target="_blank" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Ashion Analytics LLC</a><span> </span>today announced a partnership with<span> </span><span style="text-decoration:underline;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=2236143105&u=http://www.elevationoncology.com/&a=Elevation+Oncology" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Elevation Oncology</a></span>, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra® test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">NRG1 gene fusions are a rare genomic alteration implicated as a driver of tumorigenesis and growth across many types of solid tumors, including lung, breast, pancreatic, ovarian, and colorectal cancers.<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=2157809113&u=https://nrg1fusion.com/&a=CRESTONE" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">CRESTONE</a><span> </span>— or<span> </span><span style="text-decoration:underline;">C</span>linical study of<span> </span><span style="text-decoration:underline;">RE</span>sponse to<span> </span><span style="text-decoration:underline;">S</span>eribantumab in<span> </span><span style="text-decoration:underline;">T</span>um<span style="text-decoration:underline;">O</span>rs with<span> </span><span style="text-decoration:underline;">NE</span>uregulin 1 (NRG1) fusions — provides an investigational treatment opportunity for patients with any advanced solid tumor who have not responded or are no longer responding to standard cancer treatment, and whose tumor has tested positive for an<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=802101388&u=https://nrg1fusion.com/wp-content/uploads/2020/07/EO0003-001-000_NRG1-fusion-1-pager.pdf&a=NRG1" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">NRG1</a><span> </span>fusion.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This partnership creates a new dynamic in the way cancer patients can be matched to precision medicine therapeutics. By first identifying a genetic driver that has an available targeted therapy option, in this case an NRG1 fusion and the investigational therapy seribantumab, the diagnostic technology, data insights, and network reach at Ashion Analytics can be leveraged to efficiently identify and directly match eligible patients to the CRESTONE trial using test results that are already available today, while also maximizing the value of every additional test.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">"The comprehensive nature of the GEM ExTra test means that its value grows directly with each new genomic driver that is identified and each new precision therapy under development," said<span> </span><span style="box-sizing:border-box;" class="xn-person">Laurie Goodman</span>, Ph.D., Ashion Analytics Director of Business Development and Medical Affairs. "Partnerships like this enable us to continuously facilitate the ability for our patients to receive the most up-to-date information about the emerging treatment opportunities available to them today."</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=862518699&u=https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/&a=Ashion+Analytics+recently+announced" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Ashion Analytics recently announced</a><span> </span>that Medicare has approved coverage of its proprietary cancer profiling test,<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=638858039&u=http://ashion.com/physicians-2/&a=GEM+ExTra" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">GEM ExTra</a>®, one of the nation's most comprehensive genomic cancer analysis tests. Medicare coverage enables potentially 44 million more patients to afford this test, which aims to match patients with best available treatments for their disease.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=915260637&u=https://www.tgen.org/news/2020/june/11/tgen-s-ashion-certified-for-nci-match/&a=GEM+ExTra" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">GEM ExTra</a><span> </span>detects tumor-specific mutations in both DNA and RNA, allowing physicians to make the best-available treatment recommendations for patients with advanced solid tumors. An Ashion study poster presented at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=3353191598&u=https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u%3D6b0e128788a10661a1fb2d549%26id%3D80cc45bf65%26e%3Dbcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOToaeHqm$&a=Employing+RNA+Sequencing+to+Enhance+Treatment+Options+for+Cancer+Patients" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</a>.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This leading-edge test provides treating physicians with vital interpreted information needed to understand changes to a patient's genomic profile. It outlines a therapeutic treatment plan best suited for each patient. Conditions that may benefit from this approach include treatment of refractory, rare or aggressive cancers.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">"We are partnering with Ashion Analytics because we recognize the sensitivity and continuing potential of their GEM ExTra cancer profiling test," said<span> </span><span style="box-sizing:border-box;" class="xn-person">Shawn Leland</span>, PharmD, RPh, Founder and Chief Business Officer of Elevation Oncology. "Elevation Oncology is committed to expanding the benefit of precision medicine to all patients with cancer by developing therapies that make results from tests like GEM ExTra clinically actionable, no matter how rare the finding. Close collaboration between diagnostic and therapeutic developers is critical to re-thinking our approach to clinical trial enrollment as an industry and finding more efficient ways to bring the right treatment opportunities to the patients that need them."</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">For more information about seribantumab and the CRESTONE study, please visit<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=1504483846&u=http://www.nrg1fusion.com/&a=www.NRG1fusion.com" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">www.NRG1fusion.com</a>.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Ashion Analytics is a clinical laboratory of the<span> </span><span style="text-decoration:underline;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=4084671636&u=https://www.tgen.org/&a=Translational+Genomics+Research+Institute+%28TGen%29" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Translational Genomics Research Institute (TGen)</a></span>, an affiliate of<span> </span><span style="text-decoration:underline;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=4122051859&u=https://www.cityofhope.org/homepage&a=City+of+Hope" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">City of Hope</a></span>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.​<br></p><span id="ms-rterangepaste-end"></span><p>​​<br></p> </html></div>2020-09-16T07:00:00ZAshion Analytics
Discovering New Medicines in Arizona: 2nd Annual Drug Discovery and Development Summit Watch on DemandDiscovering New Medicines in Arizona: 2nd Annual Drug Discovery and Development Summit Watch on Demand<div class="ExternalClassC32C90E66DBF4EF28C0D5A79EF8BCBC6"><html> <p>​<span style="color:#333333;">Presented by the <a href="https://www.pharmacy.arizona.edu/centers/arizona-center-drug-discovery" target="_blank"><strong><span style="color:#ab0520;text-transform:uppercase;">ARIZONA CENTER FOR DRUG DISCOVERY</span></strong></a> and the <a href="https://cancercenter.arizona.edu/" target="_blank"><strong><span style="color:#ab0520;text-transform:uppercase;">UNIVERSITY OF ARIZONA CANCER CENTER</span></strong></a>. The Discovering New Medicines in Arizona Summit will highlight key areas of research in discovering effective drug candidates in prevalent diseases in Arizona while establishing collaborations that enable success in these key areas. Speakers include leaders from Bristol Myers Squibb, TGen, University of Arizona Cancer Center, Arizona State University <span style="background:white;">Center for Immunotherapy, Vaccines and Virotherapy.</span></span><span style="color:black;background:white;"> Watch it <a href="https://www.pharmacy.arizona.edu/event/2020/discovering-new-medicines-arizona-2nd-annual-drug-discovery-and-development-summit" target="_blank">here</a>. </span><span style="color:#333333;"> ​</span></p> <p><br></p></html></div>2020-09-15T07:00:00ZUA
ARIZONA COVID-19 GENOMICS UNION TRACKS STRAINS OF SARS-COV-2ARIZONA COVID-19 GENOMICS UNION TRACKS STRAINS OF SARS-COV-2<div class="ExternalClassDF28E954B8354AFABD2C361F544659DC"><html> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span> </span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Steve Yozwiak"> <span style="box-sizing:border-box;border-radius:0px;">Steve Yozwiak</span> </a> </span> </div> </li> <span> </span> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;"></li> </ul> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;">Posted Tuesday September 15, 2020<br></li> </ul> </h4> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Molecular clock analysis showed no widespread ‘community’ distribution of the highly contagious coronavirus disease in Arizona until mid-February</em> </p> </h4> </div> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">FLAGSTAFF, Ariz. — Sept. 15, 2020 —</strong> <span> </span>Initial findings reported by the Arizona COVID-19 Genomics Union (ACGU) suggest that following Arizona’s first reported case of COVID-19 in late January, the state experienced no cases that went undetected and was COVID-free until at least 11 distinct incursions occurred between mid-February and early April.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The published results appear in the scientific journal<span> </span><em style="box-sizing:border-box;border-radius:0px;">mBio</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Faculty at the<span> </span><a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Translational Genomics Research Institute (TGen)</a>, an affiliate of<span> </span><a target="_blank" href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">City of Hope</a>, Northern Arizona University (NAU), University of Arizona (UArizona) and Arizona State University (ASU) launched the ACGU in April with the express purpose of tracking the causative agent of COVID-19, SARS-CoV-2: how it evolves and how it spreads into, within and out of Arizona.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The ACGU sequenced the SARS-CoV-2 genomes in as many virus-positive patient samples in Arizona as possible, and working with Arizona’s public health officials, applied the results toward statewide efforts to test and track patients, as well as provide guidance for Arizona public policy makers.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Quick action by ASU and Maricopa County public health officials, ACGU scientists agree, likely kept the first identified COVID-19 patient in Arizona — a student who had just returned from Hubei, the Chinese province where the disease originated — from igniting an outbreak, and prevented Arizona from becoming an early epicenter for the contagion.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“This is a great example of how a rapid and thorough public health response can be successful in preventing the spread of this disease,” said ACGU Director<span> </span><a target="_blank" href="https://www.tgen.org/faculty-profiles/paul-keim/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. Paul Keim</a>, Regents’ Professor of Biological Sciences and Cowden Endowed Chair in Microbiology at NAU and Executive Director of NAU’s Pathogen and Microbiome Institute.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“Similar steps could be taken when shaping future efforts to reopen businesses and schools, even though the virus continues to circulate and people remain susceptible,” added Keim, who is also a Distinguished Professor and Co-Director of TGen’s Pathogen and Microbiome Division.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://profiles.arizona.edu/person/worobey" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. Michael Worobey</a>, an ACGU co-founder and the head of University of Arizona’s Department of Ecology and Evolutionary Biology, agrees.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“It’s a combination of the patient doing the right things to isolate himself and be aware that he possibly had this disease, and public health officials doing all the right things. Stopping an incursion of COVID-19 was a victory for the state of Arizona,” Dr. Worobey said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This bought Arizona valuable time for preparedness efforts. The first reported case of “community” transmission occurred in Arizona in early March descended from the Washington state outbreak that was discovered in February. More than 80% of the SARS-CoV-2 genome sequences from Arizona COVID-19 cases descended from at least 11 separate lineages that were initially circulating widely in Europe, and by travel have since dominated the outbreak throughout the U.S. None of the observed transmission clusters are epidemiologically linked to the original travel-related case in the Arizona, suggesting successful early isolation and quarantine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The ACGU uses state-of-the-art sequencers, custom computational analysis workflows, and supercomputers to determine the sequence of the virus’s RNA genome, which is just under 30,000 bases long. In contrast, there are nearly 3 billion bases in the human genome, which determine traits as simple as eye and hair color, and as complex as an individual’s propensity for cancer and other disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">TGen has so far sequenced SARS-CoV-2 genomes from nearly 3,000 COVID-19 positive samples for the ACGU, and additional sequencing was performed at ASU and UArizona, from among the more than 200,000 positive cases in Arizona, making it one of the most robust such efforts in the nation. ACGU receives Arizona samples collected by state, county, tribal and private healthcare systems.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">ACGU scientists take advantage of small changes or mutations in the virus’ genome, which naturally occur over time as the virus reproduces, to track the spread of the virus. By comparing mutations observed in Arizona to those present in strains circulating across the globe, they can determine when and from where the virus has been introduced to Arizona.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Using molecular clock analyses, researchers found that the majority of Arizona sequences are represented by two lineages — and several sub-lineages — most of which were likely introduced through domestic travel, but with some evidence for international importation.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“Through the ACGU, we are harnessing expertise in virology, genomics, evolution and bioinformatics from throughout Arizona in order to rapidly distill these genomic data into actionable insights that can complement the state’s public health response,” Dr. Keim said. “These results demonstrate the power of public health contact tracing and self-isolation following a positive test for stemming the tide of infections moving forward.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://www.tgen.org/faculty-profiles/david-engelthaler/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. David Engelthaler</a>, Director of TGen North in Flagstaff, which includes the institute’s infectious disease branch, said the initial ACGU findings show how each community, each state is writing its own story for what is happening in the COVID-19 pandemic.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“We need to understand all of those plot lines that have led to where we are now,” said Dr. Engelthaler, another of the co-founders of the ACGU. “Once this disease was detected in Arizona on Jan. 26, public health immediately jumped in to make sure that all contacts were identified, samples were collected and the patient was watched very closely for the next couple of weeks to make sure there were not any more cases.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">In the coming months, he said, it will be necessary to track COVID-19 outbreaks and build epidemiological walls around each case, especially for those most at risk: persons older than 65, those in long-term care facilities, prisons, and those with pre-existing health problems.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“When you don’t have eyes on this, when you don’t have contact tracing, then it can really easily move from person-to-person,” Dr. Engelthaler said. “It’s really useful for public policy makers to be making locally-informed decisions.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://biodesign.asu.edu/efrem-lim" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. Efrem Lim</a>, a virologist who leads the ASU team, said the SARS-CoV-2 genome sequence data can give health care providers and public policy makers an edge in fighting the pandemic.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“Tracking the transmission of the virus and its mutations ensures that therapeutics and vaccines being developed are on the right course,” said Dr. Lim, an assistant professor at ASU’s Biodesign Institute. “We now have a handle on what the SARS-CoV-2 virus in our communities looks like at the sequence level.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This study —<span> </span><a target="_blank" href="https://mbio.asm.org/content/11/5/e02107-20" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;"><em style="box-sizing:border-box;border-radius:0px;">An Early Pandemic Analysis of SARS-CoV-2 Population Structure and Dynamics in Arizona</em></a><span> </span>— was supported by: The NARBHA Institute, Flinn Foundation, The Virginia G. Piper Charitable Trust, Blue Cross and Blue Shield of Arizona, the National Institutes of Health, the David and Lucile Packard Foundation, the University of Arizona College of Science and Office of Research Innovation and Impact, and BIO5 Institute.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The authors acknowledge the critical role the Arizona Department of Health Services and multiple county and tribal health departments play in directing samples to the ACGU to be sequenced. Computational analyses were run on Northern Arizona University’s Monsoon computing cluster, funded by Arizona’s Technology and Research Initiative Fund (TRIF), administered by the Arizona Board of Regents. Additional analysis efforts also were funded by TRIF. Software development efforts were funded in part by the Chan-Zuckerberg Initiative and the Alfred P. Sloan Foundation. The Cowden Endowment for Microbiology provided funds to support salaries.</p> <br class="Apple-interchange-newline"> </div> </div> <br>​<br></h4> <span id="ms-rterangepaste-end"></span> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;font-weight:400;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;font-style:normal;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://www.tgen.org/news/2020/september/15/acgu-initial-findings-of-the-pandemic/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Arizona COVID-19 Genomics Union tracks strains of SARS-CoV-2"> <span style="box-sizing:border-box;border-radius:0px;"></span> </a> </h2> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <br>​<br></h4> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/81/download (1).jpg2020-09-15T07:00:00ZTGen
TGEN AND MAYO CLINIC RESEARCHERS ID POTENTIAL TARGETS FOR THE MOST-DEADLY FORM OF PANCREATIC CANCERTGEN AND MAYO CLINIC RESEARCHERS ID POTENTIAL TARGETS FOR THE MOST-DEADLY FORM OF PANCREATIC CANCER<div class="ExternalClass2F585DFEE9694C8983894C91757DDC12"><html> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">​Written by</span> <span> </span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a href="https://www.tgen.org/news/?author=Steve+Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Steve Yozwiak" target="_blank"> <span style="box-sizing:border-box;border-radius:0px;">Steve Yozwiak</span> </a> </span> </div> <span id="ms-rterangecursor-start"></span> <span id="ms-rterangecursor-end"></span> <br> </li> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;">Posted Monday September 14, 2020<br><br></li> </ul> </h4> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Multi-year study published today tees-up clinical trials using patient-specific therapies</em> </p> </h4> </div> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX and SCOTTSDALE, Ariz. — Sept. 14, 2020 —</strong> <span> </span>A team of researchers led by<span> </span><a href="https://www.mayoclinic.org/about-mayo-clinic?_ga=2.193260206.246406646.1597880436-433202803.1558387184" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Mayo Clinic</a><span> </span>and the<span> </span><a href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of<span> </span><a href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">City of Hope</a>, has identified specific potential therapeutic targets for the most aggressive and lethal form of pancreatic cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In what is believed to be the most comprehensive analysis of<span> </span><em style="box-sizing:border-box;border-radius:0px;">adenosquamous cancer of the pancreas</em><span> </span>(ASCP), the Mayo Clinic and TGen team identified, in preclinical models, therapeutic targets for this extremely fast-moving and deadly form of pancreatic cancer, and identified already available cancer inhibitors originally designed for other types of cancer, according to a study published today in<span> </span><em style="box-sizing:border-box;border-radius:0px;">Cancer Research</em>, a journal of the American Association for Cancer Research (AACR). </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“The rarity of ASCP, the scarcity of tissue samples suitable for high resolution genomic analyses, and the lack of validated preclinical models, has limited the study of this particularly deadly subtype of pancreatic cancer,” said<span> </span><a href="https://www.tgen.org/faculty-profiles/daniel-von-hoff/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Dr. Daniel Von Hoff</a>, Distinguished Professor and TGen’s Physician-In-Chief, considered one of the nation’s foremost authorities on pancreatic cancer, and one of the study’s authors. “We need entirely new possible approaches for our patients with ASCP.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Pancreatic ductal adenocarcinoma</em> <span> </span>(PDAC) is the most common form of pancreatic cancer, which this year is projected to kill nearly 57,600 Americans, making it the nation’s third leading cause of cancer-related death, according to the American Cancer Society. Among pancreatic cancer patients, a small percentage (less than 4%) are diagnosed with ASCP, a particularly aggressive form of pancreatic cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“ASCP currently has no effective therapies. Unlike PDAC, ASCP is defined by the presence of more than 30% squamous (skin-like) epithelial cells in the tumor. The normal pancreas does not contain squamous cells,” said the study’s senior author,<span> </span><a href="https://www.mayo.edu/research/faculty/barrett-michael-t-ph-d/bio-20178838" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Michael Barrett, Ph.D., who holds a joint research appointment at Mayo Clinic and TGEN.</a></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Our study has shown that ASCPs have novel ‘hits’ (mutations and deletions) in genes that regulate tissue development and growth superimposed on the common mutational ‘landscape’ of a typical PDAC. As a consequence, cells within the tumor have the ability to revert to a stem-cell-like state that includes changes in cell types and appearance, and the activation of signaling pathways that drive the aggressive nature of ASCP,’ said Dr. Barrett.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">While this activated aggressive stem-cell-like state is very resistant to current therapies for pancreatic cancer, Dr. Barrett said, the study has shown that ASCP can be targeted by drugs currently in clinical use for other cancers as well as non-cancer related conditions.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using multiple cancer analysis methods and platforms — including: flow cytometry, copy number analysis, whole exome sequencing, variant calling and annotation, ATAC-seq, immunofluorescence, immunohistochemistry, single cell sequencing, and organoid cultures and treatments — the Mayo Clinic and TGen research team conducted what is believed to be the most in-depth analysis of ASCP tissue samples.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Researchers identified multiple mutations and genomic variants that are common to both PDAC and the more aggressive ASCP. “Of significant interest,” the study says, the team also identified two potential therapeutic targets unique to ASCP genomes: FGFR signaling, including an<span> </span><em style="box-sizing:border-box;border-radius:0px;">FGFR1-ERLIN2</em><span> </span>gene fusion, and a pancreatic cancer stem cell regulator known as<span> </span><em style="box-sizing:border-box;border-radius:0px;">RORC</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">These data provide a unique description of the ASCP genomic and epigenomic landscape and identify candidate therapeutic targets for this lethal cancer, the study says.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using organoids, which are laboratory cultures derived from samples of patient tumors, researchers tested the activity and functional significance of candidate therapeutic targets. According to the study: “Specifically, organoids carrying the<span> </span><em style="box-sizing:border-box;border-radius:0px;">FGFR1-ERLIN2</em><span> </span>fusion show a significant response to pharmacological FGFR inhibition,” providing new candidate targets for developing therapies for patients with ASCP.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition, the study says, “To our knowledge, this is the first study to apply DNA content sorting to the genomic analysis of ASCP,” a method that purifies the cancer DNA from other cells and parts of cells, thereby eliminating any biological “noise” that might impede the precision of the analysis.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using an interrogation tool known as ATAC-seq, researchers also identified<span> </span><em style="box-sizing:border-box;border-radius:0px;">RORC</em><span> </span>as another distinguishing feature of ASCP.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Of significant interest will be clinical trials with<span> </span><em style="box-sizing:border-box;border-radius:0px;">FGFR</em><span> </span>and<span> </span><em style="box-sizing:border-box;border-radius:0px;">RORC</em><span> </span>inhibitors that include correlative studies of genomic and epigenomic lesions in both ASCP and PDAC,” the study concludes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Also contributing to this study —<span> </span><a href="https://cancerres.aacrjournals.org/content/early/2020/09/12/0008-5472.CAN-20-0078" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas</em></a><span> </span>— were: Virginia G Piper Cancer Center at HonorHealth; University of California, San Diego School of Medicine; Salk Institute for Biological Studies; Memorial Sloan Kettering Institute; and University of Nebraska Medical Center (UNMC). </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Funding for this study was provided by: the Lee Hanley Foundation; TGen’s annual<span> </span><em style="box-sizing:border-box;border-radius:0px;">stepNout</em><span> </span>pancreatic cancer fundraising; a Pancreatic Cancer Dream Team Research Grant through Stand Up to Cancer (SU2C) and Lustgarten-Cancer Research UK (CRUK); Damon Runyon Cancer Research Foundation; the National Institutes of Health (NIH); the Pancreatic Cancer Collective New Therapies Challenge; and a fellowship through the Tobacco Related Disease Research Program.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition, Mayo Clinic Cancer Center is supported by a Cancer Center Support Grant from the National Institute of Cancer (NCI).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The UNMC Tissue Bank Rapid Autopsy Program for Pancreas is supported by the following:<span> </span><span style="box-sizing:border-box;border-radius:0px;">Specialized Program of Research Excellence (</span>SPORE) in Pancreatic Cancer; Pancreatic Cancer Detection Consortium; an NCI Cancer Center Support Grant; and an NCI Research Specialist.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The authors declare no conflicts of interest.</p> </div> </div> <br> <br> </h4> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/79/dr_daniel_von_hoff (1).jpg2020-09-14T07:00:00ZTGen
Phoenix Invests Big in Health Care and Biosciences, Hoping to Boost Economy and Add JobsPhoenix Invests Big in Health Care and Biosciences, Hoping to Boost Economy and Add Jobs<div class="ExternalClassC16BDC2AFC5C4F219786D1BB1BCBC61A"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;">Claudia Whitehead turns from her computer screen and picks up her phone. The caller is the CEO of a Phoenix-based biosciences company calling to tell the program manager in the Phoenix Community and Economic Development Department that it landed $1 million in seed money to advance its contribution in the search to cure cancer. The company needs help in expanding its workforce. ​​​​</em> <br style="box-sizing:border-box;"> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;"></em> <img src="https://www.phoenix.gov/econdevsite/MediaAssets/STAFF-20180222-Whitehead-Claudia-450PX.jpg" alt="Photo, Claudia Whitehead, program manager" style="margin:5px;border:0px;width:200px;vertical-align:baseline;max-width:100%;box-sizing:border-box;" /> <em style="box-sizing:border-box;">To get the ball rolling, Whitehead will confer with a teammate at the Phoenix Business and Workforce Development Center, part of the city's Arizona@Work career program. A representative from GateWay Community College’s LabForce will be swept into that conversation. Within a matter of hours, work begins to set up a custom training program to help the company grow out of its incubator. It's just another service from city of Phoenix to the growing bioscience healthcare industry sector in the city.</em> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;">"Bioscience healthcare has become one of our core industry sectors," said Whitehead. "When we started talking with Amanda Morris, bioscience reporter for The Arizona Republic, it became apparent that Phoenix is a major global center for life-changing bioscience achievements. The work being accomplished with precision medicine and cancer research is like something from science fiction. In Phoenix, we have the ecosystem in bioscience to take the future of medicine from discovery to delivery."</em> <br style="box-sizing:border-box;"> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;">Amanda Morris, the bioscience reporter for the The Arizona Republic, pulls back the curtain and unveils how 7,000 new jobs in bioscience healthcare are to be dispersed around the growth in the sector.</em> <br style="box-sizing:border-box;"> </p> </h4> <h3 style="margin-top:3px;margin-right:0px;margin-bottom:10px !important;margin-left:0px;font-weight:600;font-family:montserrat, "open sans", sans-serif !important;color:rgb(0, 0, 0);font-size:26px;display:block;letter-spacing:-0.4px;line-height:28px !important;box-sizing:border-box;font-style:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Companies are investing billions in Phoenix's bioscience and health care industries, which is expected to bring 7,000 new jobs.<br style="box-sizing:border-box;"></h3> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;text-align:center;"> <em style="box-sizing:border-box;">By Amanda Morris for The Arizona Republic</em> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Phoenix recovered more slowly than the rest of the nation after the Great Recession, taking years to recoup lost jobs. <br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">But this time around, the region might see faster recovery from the COVID-19 recession.<br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">One big reason is the city’s changing economic landscape, which has begun to rely less on construction and focus increasingly on sectors like health care and bioscience.<br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Those industries are more resilient in the face of economic changes, said Christine Mackay, community and economic development director for the city of Phoenix. She said the city has seen significant growth in health care and bioscience over the past few years.<br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">​Read the full story in<span> </span><a target="_blank" href="https://www.azcentral.com/in-depth/news/local/arizona-science/2020/09/13/bioscience-and-health-care-industries-expand-and-add-jobs-phoenix/3392691001/" style="color:rgb(32, 173, 149);text-decoration:none;background:transparent;font-family:hind, sans-serif;transition:all 0.2s ease-in-out 0s;box-sizing:border-box;">The Arizona Republic</a>.</p> <br>​​<br></h4> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/85/Newsroom_CED_0057.jpg2020-09-14T07:00:00ZCity of Phoenix
NewsletterNewsletter<div class="ExternalClass8E6BC8B3F87649F4A2DEF5127D19F113"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div class="bgcolor" style="background-color:rgb(230, 230, 230);"> <table class="bgimage" width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#e6e6e6" style="border-collapse:collapse;table-layout:auto;"> <tbody> <tr> <td align="center"> <table class="main-width" width="690" align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;table-layout:fixed;width:690px;"> <tbody> <tr> <td class="layout" align="center" valign="top" style="padding:15px 5px;"> <table width="100%" align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="layout-container-border" align="center" valign="top" bgcolor="#56a6ad" style="background-color:rgb(86, 166, 173);padding:0px;"> <table width="100%" align="center" border="0" cellpadding="0" cellspacing="0" bgcolor="#56a6ad" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="layout-container" align="center" valign="top" bgcolor="#ffffff" style="background-color:rgb(255, 255, 255);padding:0px;"> <div class=""> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:22px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:22px;font-weight:bold;"> </span> <span style="font-size:22px;font-weight:bold;color:rgb(235, 169, 66);">TODAY</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;font-style:italic;">An Update on the People, Places, and Possibilities of the Phoenix Biomedical Campus in Downtown Phoenix • Oversight provided by Arizona State University (Michael Crow, President), Northern Arizona University (Rita Cheng, President), University of Arizona (Robert Robbins, President), Arizona Board of Regents (John Arnold, Executive Director), and City of Phoenix led by Mayor Kate Gallego • August 27, 2020</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">In my Zoom meetings, phone calls, and emails to gain a better understanding of all that is happening at the Phoenix Biomedical Campus, I learn about things that appear in the media, but other things that haven’t yet reached the newspaper, airwaves, or social media. They’re just as important but may be considered activities that organizations simply do or create during the normal course of work to make a place function effectively and well. Here are two examples that just crossed by desk:</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Strong Partnership with VA Healthcare System</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Since opening in 2007, the University of Arizona College of Medicine – Phoenix has partnered with the Phoenix Veterans Administration Healthcare System to prepare the college’s medical students and residents on the diverse health needs of veterans. As part of that collaboration, many third-year medical students rotate through the Phoenix VA during their clerkships where they learn first-hand from top doctors how to provide excellent care to veterans.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">The college has more than 155 faculty members with affiliation at the Phoenix VA who serve as department chairs, committee chairs, mentors, and advisors. These faculty members also participate in the doctoring program, clerkships, core lecture series, and scholarly projects. The partnership has grown through the years through many departments, including radiology, neurology, internal medicine, and most recently, informatics. For more information, contact Allison Otu </span> <a href="mailto:allisonotu@arizona.edu" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">here</a> <span style="font-size:12px;color:rgb(0, 0, 0);">.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Black, African American, Caribbean (BAAC) Employee Resource Group Formed</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">A new Black, African American, Caribbean (BAAC) Employee Resource Group has been formed to support the BAAC community on the Phoenix Biomedical Campus and be a collective voice that promotes and encourages advancement, leadership, and networking for BAAC faculty and staff in all roles at all organizations within the PBC. The resource group is led by Yasmeen Chanes, Administrative Associate, Pathway Scholars Program, University of Arizona College of Medicine–Phoenix. It meets each month over the lunch hour currently via Zoom due to COVID-19. For more information, contact Yasmeen </span> <a href="https://phoenixmed.arizona.edu/directory/augusto-yasmeen" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">here</a> <span style="font-size:12px;color:rgb(0, 0, 0);">.</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PEOPLE </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Noteworthy individuals making a difference</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://phoenixmed.arizona.edu/newsroom/news/second-year-medical-student-receives-vrp-grant-cardiovascular-research" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Second-year UArizona medical student receives VRP grant for cardiovascular research</a> (UArizona, 08-21-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://theshow.kjzz.org/content/1611234/arizona-health-expert-warns-about-dangers-becoming-covid-19-complacent" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">UArizona health expert, Farshad Fani Marvasti, warns about the dangers of becoming COVID-19 complacent</a> (KJZZ, 08-20-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.pharmaceutical-technology.com/features/biggest-influencers-cardiovascular/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Dr. Martha Gulati among biggest influencers in cardiovascular in Q2 2020</a> (Pharmaceutical Technology, 08-20-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.statepress.com/article/2020/08/spcommunity-university-reports-second-largest-freshman-class" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">ASU reports second-largest freshman class</a> (State Press, 08-20-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://phoenixmed.arizona.edu/newsroom/news/medical-students-explore-efficacy-potential-covid-19-therapeutic" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">UArizona medical students explore efficacy of potential COVID-19 therapeutic</a> (UArizona, 08-18-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://phoenixmed.arizona.edu/newsroom/news/second-year-medical-student-awarded-grant-further-scholarly-project-studying-pectus" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Second-year medical student awarded grant to further scholarly project studying Pectus Excavatum</a> (UArizona, 08-07-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.aapa.org/news-central/2020/07/aapa-congratulates-jaapas-new-editor-in-chief-rick-dehn/#:~:text=The%20Journal%20of%20the%20American%2cas%20Editor-in-Chief." rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Richard Dehn named Editor-in-Chief of the Journal of the American Academy of Physician Assistants</a> (NAU, 07-07-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://nau.edu/athletic-training/hayley-root-athletic-training/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Dr. Haley Root joins NAU Athletic Training Program as an assistant clinical professor</a> (NAU, 07-01-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://phoenixmed.arizona.edu/newsroom/news/christopher-glembotski-phd-appointed-director-center-translational-cardiovascular" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Dr. Christopher Glembotski appointed inaugural director of the Center of Translational Cardiovascular Research</a> (UArizona, 05-27-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://phoenixmed.arizona.edu/newsroom/news/nathaniel-soper-md-appointed-chair-colleges-department-surgery" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Dr. Nathaniel Soper appointed UACOM-Phoenix chair of the Department of Surgery</a> (UArizona, 05-18-20)</li> </ul> <div> <br> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PLACES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Properties and new developments where good things happen</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;">Wexford Science + Technology's 850 North 5th Street building is completely enclosed and air-conditioned. The building core, shell, and tenant improvements will be complete in a few months, with the building opening before the holidays. The remaining space on levels 5, 6, and 7 are available now as shell floors, ready to be leased and built out for commercial lab and/or office users. For more information, contact Kyle Jardine at Wexford Science + Technology at 801-450-2043 or <a href="mailto:Kyle.Jardine@wexfordscitech.com" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">email</a>.</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;text-align:left;font-size:12px;color:rgb(0, 0, 0);"> <a href="https://www.phoenixnewtimes.com/restaurants/blue-house-coffee-is-giving-us-the-old-school-milkman-delivery-treatment-11485811" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">Blue House Coffee, located at NAU’s PBC location, is giving us the old school milkman delivery treatment</a> (Phoenix New Times, 08-07-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="spacer editor-col OneColumnMobile" width="100%" align="left" valign="top"> <div class="gl-contains-spacer"> <table class="editor-spacer" width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="spacer-container" align="center" valign="top"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="spacer-base" width="100%" align="center" valign="top" style="padding-bottom:10px;height:1px;line-height:1px;"> <img alt="" border="0" hspace="0" vspace="0" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" style="display:block;width:5px;margin:5px;" class="" /> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">POSSIBILITIES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Significant research & educational opportunities going on</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.newsweek.com/gym-reopening-6-experts-how-stay-safe-still-feel-burn-1525820" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">The gym is reopening! 6 experts on how to stay safe and still feel the burn</a> (Newsweek, 08-20-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.aamc.org/news-insights/covid-19-disrupted-health-care-other-serious-conditions-now-physicians-worry-about-long-term" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">COVID-19 disrupted health care for other serious conditions. Now, physicians worry about the long-term consequences</a> (AAMC, 08-20-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://news.nau.edu/hrsa-grant/#.X0WUb9OpFE4" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">NAU dental hygiene and occupational therapy programs awarded $6.5M grant to support students from disadvantaged backgrounds</a> (NAU, 08-18-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.tgen.org/news/2020/august/19/gut-microbial-diversity-in-patients-with-cancer/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">City of Hope, TGen researchers find link between gut microbiome and cancer treatment outcomes</a> (TGen, 08-19-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.tgen.org/news/2020/august/14/tgen-review-shows-postmenopausal-women-risk-nafld/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">TGen review article suggests postmenopausal women at risk for nonalcoholic fatty liver disease</a> (TGen, 08-14-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://www.kold.com/2020/08/12/million-gift-uarizona-alumni-bolsters-nursings-health-care-simulations/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">$1M from UArizona alumni bolsters nursing’s health care simulations</a> (KOLD, 08-12-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://phoenixmed.arizona.edu/newsroom/news/medical-students-provide-care-rural-community-during-pandemic-through-integrative" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">UArizona medical students provide care to rural community during pandemic through integrative clerkship</a> (UArizona, 06-18-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a href="https://news.nnlm.gov/psr-latitudes/digital-resources-from-subawards/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;color:rgb(0, 0, 0);">NAU’s Cline Library at PBC organizes national summit on gender diversity and sports</a> (National Network of Libraries of Medicine, 05-06-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="center-text content editor-col OneColumnMobile" width="100%" align="left" valign="top" style="text-align:center;"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text center-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PARTICULARS</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class=" editor-col OneColumnMobile" width="100%" align="" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text editor-text " align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Contact:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(0, 0, 0);">David Krietor, Executive Director, 602-741-5580, </span> <a href="mailto:david.krietor@asu.edu" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">david.krietor@asu.edu</a> </div> <div> <a href="mailto:claudia.whitehead@phoenix.gov" rel="noopener noreferrer" target="_blank" style="font-size:12px;color:rgb(0, 0, 0);">Claudia Whitehead</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="mailto:claudia.whitehead@phoenix.gov" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">claudia.whitehead@phoenix.gov</a> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Website:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">bio</a> <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">medicalphoenix.com</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="https://www.phoenix.gov/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">phoenix.gov</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Events Calendar:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a href="https://asuevents.asu.edu/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">ASU</a> <span style="font-size:12px;color:black;">, </span> <a href="https://www.pxu.org/Page/38" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Bioscience H.S.</a> <span style="font-size:12px;color:black;">, </span> <a href="https://events.nau.edu/?view=grid&search=y" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">NAU</a> <span style="font-size:12px;color:black;">, </span> <a href="https://puhsaa.com/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">PUHS Alumni Assoc.</a> <span style="font-size:12px;color:black;">, </span> <a href="https://www.tgen.org/giving/events/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">TGen</a> <span style="font-size:12px;color:black;">, </span> <a href="https://uahs.arizona.edu/events" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">UArizona</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Directory:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(33, 41, 51);">Coming soon!</span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Getting Around:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a href="https://phoenixmed.arizona.edu/campus" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Campus Map</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="https://www.valleymetro.org/maps-schedules" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Public Transit</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="http://gridbikes.com/" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Bike Share</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a href="https://parking.arizona.edu/parking/biomedical-campus/index.php?referral=compurchase" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);">Parking</a> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="divider-container editor-col OneColumnMobile" width="100%" align="left" valign="top"> <div class="gl-contains-divider"> <table class="editor-divider" width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="divider-container" align="center" valign="top"> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-content-editor" style="border-collapse:collapse;table-layout:fixed;cursor:default;min-width:100%;"> <tbody> <tr> <td class="divider-base divider-solid" width="100%" align="center" valign="top" style="padding:9px 0px;"> <table cellpadding="0" cellspacing="0" border="0" align="center" style="border-collapse:collapse;table-layout:fixed;width:680px;min-width:100%;height:1px;"> <tbody> <tr> <td height="1" align="center" bgcolor="D6D6D6" style="background-color:rgb(214, 214, 214);border-bottom-style:none;height:1px;line-height:1px;padding-bottom:0px;"> <img alt="" border="0" hspace="0" vspace="0" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" style="display:block;width:5px;margin:5px;" class="" /> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class=" editor-col OneColumnMobile" width="100%" align="" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text editor-text " align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Feel free to share this e-newsletter with people you think would find it of interest. To subscribe or share news, send us an email.</span> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="content editor-col OneColumnMobile" width="100%" align="left" valign="top"> <div class="gl-contains-text"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="editor-text content-text" align="left" valign="top" style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;"> <div></div> <div class="text-container galileo-ap-content-editor"> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">PBC </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">| </span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">David Krietor, Executive Director</span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> 602</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">-741-5880 </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">|</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> </span> <a href="mailto:david.krietor@asu.edu" rel="noopener noreferrer" target="_blank" style="text-decoration-line:underline;font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">david.krietor@asu.edu</a> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> biomedicalphoenix.com</span> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table width="100%" cellpadding="0" cellspacing="0" border="0" class="galileo-ap-layout-editor" style="border-collapse:collapse;table-layout:fixed;min-width:100%;"> <tbody> <tr> <td class="spacer editor-col OneColumnMobile" width="100%" align="left" valign="top"> <div class="gl-contains-spacer"> <table class="editor-spacer" width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="spacer-container" align="center" valign="top"> <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;table-layout:fixed;"> <tbody> <tr> <td class="spacer-base" width="100%" align="center" valign="top" style="padding-bottom:10px;height:1px;line-height:1px;"> <img alt="" border="0" hspace="0" vspace="0" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" style="display:block;width:5px;margin:5px;" class="" />​<br><br></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> <span id="ms-rterangepaste-end"></span> <p> <br> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/98/Okland Wexford Project 8-23-20 _10_.jpg2020-08-27T07:00:00ZPhoenix Bio News
CITY OF HOPE, TGEN RESEARCHERS FIND LINK BETWEEN GUT MICROBIOME AND CANCER TREATMENT OUTCOMESCITY OF HOPE, TGEN RESEARCHERS FIND LINK BETWEEN GUT MICROBIOME AND CANCER TREATMENT OUTCOMES<div class="ExternalClass75E1D49F7BFA49A5AAEE69D41DA3CD37"><html> <p style="text-align:left;"><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span><span class="uBlogsy_author_name" style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;"><a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" title="Steve Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">Steve Yozwiak</a></span></p> <p style="text-align:center;"><br></p> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"><div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"><em style="box-sizing:border-box;border-radius:0px;">​Study highlights positive impact of microbial diversity on immunotherapy response and suggests that cancer patients should eat a high-fiber diet with fruits, vegetables and grains with resistant starches</em></p></div></div><div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"><div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">FLAGSTAFF, Ariz. and </span><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">DUARTE, Calif. — Aug. 19, 2020 —</span> Physicians at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, working in collaboration with scientists at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens. Their findings are outlined in a study published today in the journal <em style="box-sizing:border-box;border-radius:0px;">European Urology.</em></p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We also reported the changes over time in the gut microbiome that occur during the course of therapy — the cumulative findings from our report open the door to therapies directed at the microbiome,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/people/pal-sumanta" target="_blank">Sumanta Pal</a>, M.D., one of the study’s senior authors and co-director of the Kidney Cancer Program at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The gut microbiome is composed of microbes like bacteria and viruses that reside in the gastrointestinal tract. In recent years, an increase in knowledge about the microbiome in relation to general health has led to deeper explorations of its role in disease states, as well as how the organisms may interact with treatments.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Previous studies have suggested a relationship between the gut microbiome and response to immunotherapy in solid tumors, including metastatic kidney cancer,” said Nicholas Salgia, B.Sc., a clinical research assistant at City of Hope and the paper’s lead author. “The results from our study build on earlier findings and reaffirm that the diversity and composition of patients’ microbiomes are associated with clinical responses to anti-cancer therapies.”</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study, which collected data from 31 people with metastatic kidney cancer, features the first reports of comparing microbiome sequencing at different time points in cancer patients. Participants were asked to provide up to three stool samples: at baseline, four weeks into therapy and 12 weeks into therapy.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Using the clinical trial results, the team was able to identify changes in the microbiome over time in kidney cancer patients receiving immunotherapy. The findings found that a greater variety of organisms was associated with a benefit to the patients, and also suggested that modulating the gut microbiome during the course of treatment may impact responses to therapy.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The patients with the highest benefit from cancer treatment were those with more microbial diversity, but also those with a higher abundance of a specific bacterium known as <em style="box-sizing:border-box;border-radius:0px;">Akkermansia muciniphila</em>,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/sarah-highlander/" target="_blank">Sarah Highlander</a>, Ph.D., a research professor in TGen’s Pathogen and Microbiome Division and one of the study’s senior authors. “This organism has been associated with benefit in other immunotherapy studies.”</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Highlander says one potential takeaway is that oncologists might encourage patients to pay attention to their gut microbiome by eating a high-fiber diet, including fruits and vegetables high in fructo-oligosaccharides such as bananas, dried fruit, onions, leeks, garlic, asparagus and artichokes, as well as grains with resistant starches such as barley or uncooked potato starch, for example.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Highlander says that next steps should include expanding the relatively small study to a much larger group of patients that are followed over a longer time period. At City of Hope, researchers have already embarked on a clinical trial to further explore the idea that modulating the microbiome during therapy could have an impact on clinical outcomes.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We have randomized patients with metastatic kidney cancer to receive a probiotic supplement in addition to an FDA-approved immunotherapy regimen or the immunotherapy alone,” explained Salgia. “This work provided a strong framework for such a study.” </p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The collaborations between clinical experts at City of Hope and basic science colleagues at TGen have contributed to advancements in the understanding of not just the microbiome, but also in cancer biology and clinical outcomes at large.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Our strong relationship with the microbiome team at TGen has fruitfully produced novel insights into the clinical implications of the microbiome in kidney cancer, among other cancer types,” said Pal, who is an internationally recognized leader in the area of genitourinary cancers.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Just last month, City of Hope and TGen <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/breakthroughs/creating-personalized-roadmaps-to-treat-kidney-cancer" target="_blank">launched a project</a> to use one of the world’s most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“This current study is a further testament to the collaborative research structure we’ve developed between the affiliate institutions,” said Pal. “Through these collaborations we can implement both a bench-to-bedside and bedside-to-bench research model that will lead to better patient care at City of Hope through access to clinical trials and precision medicine approaches.”</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The paper, titled “<a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.europeanurology.com/article/S0302-2838%2820%2930543-1/fulltext" target="_blank">Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors</a>,” features additional City of Hope and TGen authors, along with a researcher from the Centro de Oncologia do Paraná in Curitiba, Brazil. Portions of the work were supported by a grant from Bristol-Myers Squibb.</p>​<br><br></div></div><p><br></p> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/77/dr-sarah-highlander.jpg2020-08-19T07:00:00ZTGen
Medical Students Explore Efficacy of Potential COVID-19 TherapeuticMedical Students Explore Efficacy of Potential COVID-19 Therapeutic<div class="ExternalClassEC9C84727A7247D0919F22C1470F7407"><html> <p style="text-align:center;">​​<span style="font-size:12px;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";background-color:window;">Medical Students Ryan Farhat, Mohammad Mousa and Eshaan Daas</span></p> <div style="box-sizing:border-box;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;font-size:1.25rem;margin-bottom:1rem !important;color:rgb(33, 33, 33) !important;" class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item">Perspective Analyzes the Clinical and Historical Information Available on Convalescent Plasma Transfusion</div> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:17px;line-height:23px;margin-bottom:3rem;padding-bottom:1rem;border-bottom:1px solid rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Three medical students at the University of Arizona College of Medicine – Phoenix are trying to improve clinical decisions for <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/covid-19" target="_blank">COVID-19</a> by consolidating the clinical and historical information available on a treatment known as Convalescent Plasma (CP) Transfusion.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">This study was led by fourth-year medical students Ryan Farhat, Mohammad Mousa and Eshaan Daas, along with their mentor <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/about/news/inaugural-division-chief-pulmonary-medicine-critical-care-and-sleep-medicine-named" target="_blank">Marilyn Glassberg, MD</a>, chief of the Division of Pulmonary Critical Care and Sleep Medicine. Findings were published on July 28, 2020, in <em><a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://www.frontiersin.org/articles/10.3389/fmed.2020.00435/full" target="_blank">Frontiers in Medicine</a></em>.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p> <figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:0px;height:auto;background-color:rgb(232, 237, 243) !important;"> <div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"> <img style="box-sizing:border-box;border-width:0px;vertical-align:middle;max-width:100%;margin:5px;width:0px;" title="Marilyn Glassberg, MD" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/glassberg-story.jpg" data-entity-uuid="ac0e786d-522b-4a93-aafa-f6982ba9719d" data-entity-type="file" class="img-fluid" alt="Marilyn Glassberg, MD" /> </div> <figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;font-size:14px;line-height:20px;margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;"> <em style="box-sizing:border-box;">Marilyn Glassberg, MD</em> </figcaption> </figure>There are more than 10 million cases and 500,000 deaths reported worldwide caused by COVID-19, with no effective treatment regimen. Historically, CP has been utilized in the treatment of viral respiratory pathogens. This study explored the efficacy of CP to facilitate an informed decision regarding the use of CP for COVID-19.<p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“With the rising mortality of COVID-19 and the lack of successful therapy, every possible treatment must be properly explored,” said Mousa. “CP is plasma with COVID antibodies from patients who have recovered from the virus. It has been used historically in previous virus outbreaks and a few early case reports have demonstrated that it may be beneficial for patients with active infections. CP is already being used in many hospitals around the world for those who are failing current treatment regimens. The need for a large randomized control trial is extremely necessary to determine if CP is effective.”</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">This project started during the initial phase of the current pandemic when the early studies in China were published. Mousa said that they were fortunate to work with Dr. Glassberg, who provided excellent mentorship and strong support during this project.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“There were a few potential therapies for COVID-19 when we started this project,” said Farhat. “We heard about hydroxychloroquine, remdesivir, azithromyocin and dexamethasone being effective in treating symptomatic patients. Convalescent plasma has been historically used to treat SARS and MERS, making us curious about its effectiveness in treating our current pandemic. We hope that the completed clinical trials can lead to an improvement in the morbidity and mortality worldwide.”</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The perspective looked at the advantages of CP against COVID-19 by analyzing studies using CP during SARS, influenza pandemic and MERS, which demonstrate potential for clinical efficacy during the COVID-19 pandemic. The perspective also highlighted the limitations of CP implementation — such as transfusion of blood products, specifically plasma, being associated with a few rare adverse effects.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">"Perspectives help direct future studies by identifying data that is needed to provide efficacy," Dr. Glassberg said. “Ryan, Mohammad and Eshaan had a specific question: 'Would CP be efficacious?' Our perspective suggested that more studies needed to be done, with the most recent trial suggesting that the timing and titer of neutralizing antibodies make a difference in outcome."</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">After evaluating the advantages and limitations of CP, the study said that there is promise in this treatment option for patients with COVID-19. They added that there are currently multiple randomized trials in progress evaluating the effectiveness of CP.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“We hope our work contributes to the advancement of our understanding of this virus and results in positive health care outcomes,” Daas said. “Lastly, while novel treatment options are explored by researchers around the world, it is still a collective duty to keep our community healthy with measures such as social distancing, wearing a mask and hand washing.”<br></p></div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/76/covid-therapy-header.jpg2020-08-18T07:00:00ZUA
NewsletterNewsletter<div class="ExternalClass8A30601637B24C1084B22ACF69642572"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <table style="border-collapse:collapse;table-layout:fixed;background-color:rgb(86, 166, 173);" bgcolor="#56a6ad" cellspacing="0" cellpadding="0" border="0" align="center" width="100%"> <tbody> <tr> <td style="background-color:rgb(255, 255, 255);padding:0px;" bgcolor="#ffffff" valign="top" align="center" class="layout-container"> <div class=""> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:22px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:22px;font-weight:bold;"> </span> <span style="font-size:22px;font-weight:bold;color:rgb(235, 169, 66);">TODAY </span></div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-style:italic;font-weight:bold;">An Update on the People, Places, and Possibilities of the Phoenix Biomedical Campus in Downtown Phoenix • Oversight provided by Arizona State University (Michael Crow, President), Northern Arizona University (Rita Cheng, President), University of Arizona (Robert Robbins, President), Arizona Board of Regents (John Arnold, Executive Director), and City of Phoenix led by Mayor Kate Gallego • August 12, 2020</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">I’m excited to launch this newsletter in my new capacity as the first executive director of the Phoenix Biomedical Campus. I’d like to thank my new leadership for choosing me for this position and the tremendous opportunity to lead the PBC – Arizona Board of Regents Executive Director John Arnold, Arizona State University President Michael Crow, Northern Arizona University President Rita Cheng, and University of Arizona President Robert Robbins. Together, I am tasked with spearheading efforts to develop and meet the PBC’s strategic goals and partner with the City of Phoenix to attract commercial enterprises that align with the work of the universities.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">My previous gig working with an amazing group of people at Downtown Phoenix Inc. (DPI) gives me a great jumping off point to focus my energies (during a global pandemic and thereafter) to promote an incredibly important and exciting component of our Downtown and region. With this periodic newsletter, I’ll share news and highlights of the people, places, and possibilities that make the PBC special.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">If you haven’t been to the PBC lately, let’s recap. The PBC is a 30-acre urban campus planned for more than six-million square feet of biomedical-related research, academic, clinical and business facilities. It contains among the highest concentrations of research scientists and complementary research professionals in the region, providing firms with excellent opportunities for growth and collaborative efforts with industry leaders. From start-ups to multinationals, the PBC suits both established enterprises and those looking to expand and develop. Hundreds of future health care professionals in over a dozen disciplines are trained by educators from ASU, NAU, UArizona, and Maricopa Community Colleges. Surrounding the PBC is Downtown Phoenix, the Evans Churchill neighborhood, and Roosevelt Row Arts District, offering one of Arizona’s most walkable, interesting and vibrant communities.</span> </div> <div align="left"> <br> </div> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);">Every day I learn something new about the PBC. What follows is an overview of recent news stories about some of the amazing work being accomplished by highly trained professionals in an environment where collaboration thrives. I’ll be sharing more in the future and in the meantime, I welcome your questions, comments, ideas, and feedback.</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PEOPLE </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Noteworthy individuals making a difference</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://healthsciences.arizona.edu/connect/features/pediatrics-pandemic-qa-dr-gary-kirkilas">Dr. Gary Kirkilas, UArizona College of Medicine-Phoenix pediatrician, shares his observations about the impact of COVID-19, encourages parents to use facts for health decisions</a> (UArizona, 07-15-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.phoenix.gov/newsroom/housing/1375">Melanie Delgado Santacruz, Project Soar participant, on her way to Princeton U.</a> (City of Phoenix, 07-02-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.wnycstudios.org/podcasts/takeaway/segments/phoenix-arizona-covid19-doctor-front-lines">Dr. Frank LoVecchio on the front lines of COVID-19</a> (WNYC, 06-30-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.phoenixnewtimes.com/music/tempe-mural-memorializes-local-musicians-chester-bennington-doug-hopkins-11473992">In spare time, UArizona employee Tommy Gwinn launches website and mural project to recognize past Valley musicians</a> (Phoenix New Times, 06-08-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=http-3A__news.nau.edu_in-2Dthe-2Dspotlight-2Dmay-2D1-2D2020_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=Fsr2KcgZ6LNlOEGnhfNFEO4qF2TU-RcM1yVjTEqMnN8&s=Q3qm6Ak4BgLcdrUtp9Qxe08TZ76k4RJFhRo1b6a1z7c&e=">Kurtis Manley, NAU PA, receives American Academy of Physician Assistants's Preceptor of the Year Award two years in a row</a> (NAU, 05-01-20) </li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://azbigmedia.com/business/former-gov-jane-hull-and-husband-die-of-natural-causes/">Jane Hull, former Arizona Governor and PBC “champion,” passes away</a> (AZ Big Media, 04-19-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PLACES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Properties and new developments where good things happen</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.lifescienceleader.com/doc/thriving-life-sciences-sector-demands-strategic-real-estate-0001">Thriving life sciences sector demands strategic real estate, such as Wexford Science + Technology Phase 1 at PBC</a> (Life Science Leader, 07-27-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.phoenixnewtimes.com/arts/fresh-artist-opportunities-in-metro-phoenix-11466137">Wexford Science + Technology adding three art installations to its PBC building</a> (Phoenix New Times, 04-20-20)</li> </ul> <div align="left"> <span style="font-size:12px;color:rgb(0, 0, 0);"></span> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.connect.media/sundt-dpr-underway-on-20m-phoenix-biomed-campus-redev/">Sundt, DPR underway on $20M PBC redevelopment</a> (Connect Phoenix, 04-17-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="left" width="100%" class="spacer editor-col OneColumnMobile"> <div class="gl-contains-spacer"> <table style="border-collapse:collapse;table-layout:fixed;" border="0" cellspacing="0" cellpadding="0" width="100%" class="editor-spacer"> <tbody> <tr> <td valign="top" align="center" class="spacer-container"> <table style="border-collapse:collapse;table-layout:fixed;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="padding-bottom:10px;height:1px;line-height:1px;" valign="top" align="center" width="100%" class="spacer-base"> <img class="" style="display:block;width:5px;margin:5px;" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" vspace="0" hspace="0" border="0" alt="" /> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">POSSIBILITIES </span> <span style="font-size:12px;font-weight:bold;color:rgb(83, 102, 127);">- Significant research & educational opportunities going on</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.eurekalert.org/pub_releases/2020-07/uoah-uat072720.php">UArizona aims to provide rapid tests for those exposed to biothreats, such as COVID-19</a> (EurekaAlert, 07-27-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="/news-events/59">TGen’s Ashion Analytics and HonorHealth show how “organoids” can help pinpoint right therapies for cancer patients</a> (TGen, 07-22-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/news/2020/july/10/tgen-drug-could-enable-immune-attack-on-ovarian-cancer/">TGen identified immune effects of a drug in aggressive ovarian cancer that strikes young women</a> (TGen 07-10-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.eurekalert.org/pub_releases/2020-07/ttgr-tsi070820.php">TGen-led study identifies unique cells that may drive lung fibrosis</a> (TGen, 07-08-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/news/2020/july/02/poba-medical-assembles-10-000-tgen-test-kits-per-month/">TGen teams with POBA Medical to produce 10K COVID-19 test kits per month</a> (TGen, 07-02-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://uahs.arizona.edu/tomorrow/classic-chicken-or-egg-question-comes-cancer">Classic “chicken or egg” question comes to cancer </a>(UArizona, 06-15-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://kjzz.org/content/1591189/reinventing-medical-residencies-during-covid-19">Reinventing medical residencies during COVID-19</a> (KJZZ, 06-15-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.tgen.org/news/2020/june/11/tgen-s-ashion-certified-for-nci-match/">TGen’s Ashion Analytics certified for NCI’s Match Center clinical trials</a> (TGen, 06-11-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://wexfordscitech.com/university-city-science-center-announces-ignite-innovation-campaign-lead-support-from-university-of-pennsylvania-and-wexford-science-technology/">Leaders share insights about rising bioindustry in nation’s 5th largest city</a> (Wexford Science + Technology, 06-05-20)</li> </ul> <div> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=http-3A__news.nau.edu_spotlight-2Djune-2D5-2D2020_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=Fsr2KcgZ6LNlOEGnhfNFEO4qF2TU-RcM1yVjTEqMnN8&s=jpSBWQs96tkgyXD4p6VAb7_Swd-AgwuS1Vh_BVicXuA&e=">NAU's Doctor of Physical Therapy programs receive full 10-year accreditation from Commission on Accreditation in PT Education</a> (NAU, 06-05-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://businessfacilities.com/2020/04/biotech-and-life-sciences-finding-the-dna-for-success/">Biotech is shining bright in the Valley of the Sun</a> (Business Facilities, 04-03-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.usnews.com_best-2Dgraduate-2Dschools_top-2Dhealth-2Dschools_northern-2Darizona-2Duniversity-2D105330&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=Fsr2KcgZ6LNlOEGnhfNFEO4qF2TU-RcM1yVjTEqMnN8&s=ov3lFvYh4cHlf3tpTZ4WyDJAR-SKiYKcT46MRtVTL0w&e=">NAU PA program ranked #37 out of 260</a> (US News & World Report, 2019-20)</li> </ul> <div align="left"> <br> </div> <ul style="padding:0px;margin:0px 0px 0px 40px;"> <li style="padding:0px;margin:0px;line-height:1.2;font-size:12px;color:rgb(0, 0, 0);text-align:left;"> <a style="text-decoration-line:underline;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.usnews.com_best-2Dgraduate-2Dschools_top-2Dhealth-2Dschools_northern-2Darizona-2Duniversity-2D105330&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=Fsr2KcgZ6LNlOEGnhfNFEO4qF2TU-RcM1yVjTEqMnN8&s=ov3lFvYh4cHlf3tpTZ4WyDJAR-SKiYKcT46MRtVTL0w&e=">NAU OT program is Arizona's top ranked at #93</a> (US News & World Report, 2019-20)</li> </ul> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="text-align:center;" valign="top" align="left" width="100%" class="center-text content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text center-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <div align="left"> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">PBC</span> <span style="font-size:12px;font-weight:bold;"> </span> <span style="font-size:12px;font-weight:bold;color:rgb(235, 169, 66);">PARTICULARS</span> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="" width="100%" class=" editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text editor-text "> <div></div> <div class="text-container galileo-ap-content-editor"> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Contact:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(0, 0, 0);">David Krietor, Executive Director, 602-741-5580, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:david.krietor@asu.edu">david.krietor@asu.edu</a> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Website:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=">bio</a> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__biomedicalphoenix.com_&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ZkOduS1eiLUbvWLZ-8ug9vL9jHDR32Y_z26zPsk2vak&m=-wKoE3rm1i95DXGiQyqWJla6ia5YA9fsFMAO4vC9trM&s=XmoGrKj6ux3_Hjm5HLDxe1wzR5CGHEalThzpBkYVG90&e=">medicalphoenix.com</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whitehead@phoenix.gov">Claudia Whitehead</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="mailto:claudia.whithead@phoenix.gov">claudia.whithead@phoenix.gov</a> <span style="font-size:12px;color:rgb(0, 0, 0);"> </span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Events Calendar:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(0, 0, 0);">Coming soon!</span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Directory:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <span style="font-size:12px;color:rgb(33, 41, 51);">Coming soon!</span> </div> <div> <br> </div> <div> <span style="font-size:12px;color:rgb(83, 102, 127);font-weight:bold;">Getting Around:</span> <span style="font-size:12px;color:rgb(83, 102, 127);"> </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://phoenixmed.arizona.edu/campus">Campus Map</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://www.valleymetro.org/maps-schedules">Public Transit</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="http://gridbikes.com/">Bike Share</a> <span style="font-size:12px;color:rgb(0, 0, 0);">, </span> <a style="text-decoration-line:underline;font-size:12px;color:rgb(0, 0, 0);" target="_blank" rel="noopener noreferrer" href="https://parking.arizona.edu/parking/biomedical-campus/index.php?referral=compurchase">Parking</a> </div> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="left" width="100%" class="divider-container editor-col OneColumnMobile"> <div class="gl-contains-divider"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%" class="editor-divider"> <tbody> <tr> <td valign="top" align="center" class="divider-container"> <table style="border-collapse:collapse;table-layout:fixed;cursor:default;min-width:100%;" class="galileo-ap-content-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="padding:9px 0px;" valign="top" align="center" width="100%" class="divider-base divider-solid"> <table style="border-collapse:collapse;table-layout:fixed;width:680px;min-width:100%;height:1px;" align="center" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="background-color:rgb(214, 214, 214);border-bottom-style:none;height:1px;line-height:1px;padding-bottom:0px;" bgcolor="D6D6D6" align="center" height="1"> <img class="" style="display:block;width:5px;margin:5px;" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" vspace="0" hspace="0" border="0" alt="" /> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="left" width="100%" class="content editor-col OneColumnMobile"> <div class="gl-contains-text"> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="font-family:verdana, geneva, sans-serif;font-size:14px;color:rgb(46, 47, 47);display:block;line-height:1.2;padding:10px 40px;" valign="top" align="left" class="editor-text content-text"> <div></div> <div class="text-container galileo-ap-content-editor"> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">PBC </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">| </span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">David Krietor, Executive Director</span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> 602</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;">-741-5880 </span> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;">|</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> </span> <a style="text-decoration-line:underline;font-size:10px;color:rgb(83, 102, 127);font-weight:bold;" target="_blank" rel="noopener noreferrer" href="mailto:david.krietor@asu.edu">david.krietor@asu.edu</a> <span style="font-size:10px;color:rgb(235, 169, 66);font-weight:bold;"> |</span> <span style="font-size:10px;color:rgb(83, 102, 127);font-weight:bold;"> biomedicalphoenix.com</span> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <table style="border-collapse:collapse;table-layout:fixed;min-width:100%;" class="galileo-ap-layout-editor" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="top" align="left" width="100%" class="spacer editor-col OneColumnMobile"> <div class="gl-contains-spacer"> <table style="border-collapse:collapse;table-layout:fixed;" border="0" cellspacing="0" cellpadding="0" width="100%" class="editor-spacer"> <tbody> <tr> <td valign="top" align="center" class="spacer-container"> <table style="border-collapse:collapse;table-layout:fixed;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td style="padding-bottom:10px;height:1px;line-height:1px;" valign="top" align="center" width="100%" class="spacer-base"> <img class="" style="display:block;width:5px;margin:5px;" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif" vspace="0" hspace="0" border="0" alt="" />​<br></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/97/PBC photo 2.jpg2020-08-12T07:00:00ZPhoenix Bio News
New Jersey couple welcomes quadruplets at Banner hospital in PhoenixNew Jersey couple welcomes quadruplets at Banner hospital in Phoenix<div class="ExternalClassECA73AE07D5A477FBD7CB9A22B2ED5D8"><html> <p>​</p><span id="ms-rterangepaste-start"></span><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">PHOENIX (August 12, 2020) – First-time parents from New Jersey, Jennifer and Nicholas Stepenosky, welcomed four new babies into the world on June 16 at Banner – University Medical Center Phoenix, in spite of a global pandemic and other major health challenges.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">The Stepenoskys welcomed three baby girls and a baby boy – Caitlin, Addison, Emilia, and Elliott – at 27 weeks and 3 days.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">"After finding out we were going to have a high-order multiple pregnancy in early January, we knew this wasn't a normal pregnancy," said Jennifer. "It's high risk, and there is a lot more at stake since we would need more care to make sure the babies and myself were safe."</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Jennifer was first admitted to a hospital in Pennsylvania at just 16 weeks gestation after losing one of the five babies due to an incompetent cervix. This prompted the couple to start looking for alternative options for enhanced prenatal care.</p><h4 style="box-sizing:border-box;font-family:kyrialsanspro;line-height:1.1;color:rgb(34, 39, 72);margin-top:10px;margin-bottom:1em;font-size:18px;"><span style="box-sizing:border-box;font-weight:700;">Video: </span><a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="http://bannerhealth.mediaroom.com/nj_quadruplets_broll" target="_blank">Interviews and B-Roll of the Stepenoskys</a></h4><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">"Most doctors would say, 'You need to set up an appointment with Dr. Elliott,' [but] I was able to get his cell phone number from my support group and just called him directly," said Jennifer. "He was on the phone with me for 45 minutes without even knowing who I was or what my pregnancy looked like. He went through all the details of what we needed to do… I knew that we needed to come out here [to Phoenix] for treatment."</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">The Stepenoskys faced a very complicated pregnancy, but Dr. John Elliott, a perinatologist at <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.bannerhealth.com/locations/phoenix/banner-university-medical-center-phoenix" target="_blank">Banner – University Medical Center Phoenix</a> and Valley Perinatal Services – who assumed care of Jennifer and the babies while in utero – saw this as an opportunity to help the New Jersey couple to make their lifelong dreams of starting a family finally come true.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Jennifer made her first trip to Phoenix in March, shortly after she was discharged from a nearby hospital back home. During her first visit to Banner – University Medical Center Phoenix, Dr. Elliott performed a cerclage, also known as a cervical stitch. This is a treatment for cervical weakness, when the cervix starts to shorten and open too early during pregnancy, usually causing either a late miscarriage or preterm birth.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Jennifer was able to go home to New Jersey for several weeks following the cerclage. She returned to Phoenix at 23 weeks in her pregnancy and remained hospitalized at Banner – University Medical Center Phoenix until the birth of the quadruplets.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Dr. Elliott has extensive knowledge and experience in managing and delivering high-order multiplies. He first delivered a set of quadruplets in 1984 and has since delivered 110 quadruplets and 25 quintuplets. To Dr. Elliott’s knowledge, this was also the first case of a delayed internal delivery for a set of quintuplets in the world.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">After spending nearly three months in Phoenix, the Stepenoskys will be returning home today back to the East Coast. The four babies will be medically transported to a children’s hospital in Delaware. All four babies have made quick and successful progress with their development where each one has now doubled in size.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">“We are really looking forward to being back home with our family and friends,” said Jennifer. “It’s been a long yet rewarding journey and we can’t wait for them to meet the four new little additions to our family.”</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">The Stepenosky family will continue to post updates on the progress of each baby on their <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.facebook.com/FiveStepsForUs/" target="_blank">Facebook</a> and <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.instagram.com/fivestepsforus/" target="_blank">Instagram</a> accounts (@FiveStepsForUs) for those interested in following their story as a family of high-order multiples.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Banner – University Medical Center Phoenix is a large teaching hospital that has provided medical care to Arizona and the Southwest since 1911. It is part of Banner – University Medicine, a premier academic medical network. The institution, which has trained thousands of doctors over decades as a teaching hospital, is the academic medical center for The University of Arizona College of Medicine – Phoenix. The hospital, recognized by U.S. News and World Report as one of the nation’s best hospitals, specializes in heart care, cancer care, high-risk obstetrics, neurosciences, organ transplants, medical toxicology and emergency care, including a Level I trauma center. Banner – University Medical Center Phoenix is part of Banner Health, a nonprofit health care system with 28 hospitals in six states. For more information, visit <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.bannerhealth.com/universityphoenix" target="_blank">bannerhealth.com/universityphoenix</a>.​<br></p><span id="ms-rterangepaste-end"></span><p><br></p></html></div>https://biomedicalphoenix.com/Lists/News/Attachments/65/Stepenosky_Quadruplets_2-medium.jpg2020-08-12T07:00:00ZUA
COMBAT STUDY PRELIMINARY RESULTS SHOW RESPONSE OF 32% IN TREATMENT OF PANCREATIC TUMORSCOMBAT STUDY PRELIMINARY RESULTS SHOW RESPONSE OF 32% IN TREATMENT OF PANCREATIC TUMORS<div class="ExternalClassADEF8C8F38B9487D8D35A7066FBE35C1"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Tuesday August 11, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="COMBAT study preliminary results show response of 32% in treatment of pancreatic tumors " href="https://www.tgen.org/news/2020/august/11/tgen-honorhealth-combat-fights-pancreatic-cancer/" target="_blank">COMBAT STUDY PRELIMINARY RESULTS SHOW RESPONSE OF 32% IN TREATMENT OF PANCREATIC TUMORS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen and HonorHealth investigators are encouraged with results and hope to show patient benefit in larger studies</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">SCOTTSDALE, Ariz. — Aug 11, 2020 —</span> Working with an international team of researchers, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth Research Institute</a> and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, <em style="box-sizing:border-box;border-radius:0px;">Nature Medicine</em>. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The “COMBAT trial” (NCT02826486) is a prospective, open label, phase IIa clinical trial for patients with metastatic pancreatic cancer, meaning their cancer had spread to other parts of the body. Patients were given pembrolizumab, an immune therapy drug, in combination with BL-8040, an agent that makes the tumor microenvironment more receptive to immune therapy. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study was conducted in Arizona at the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth Research Institute</a> and at 30 other locations in the U.S. and across the globe, including Spain, Israel and South Korea. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The two-part clinical trial began in September 2016: </p> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;"> <li style="box-sizing:border-box;border-radius:0px;">Cohort 1, a group of 37 patients whose cancer had already progressed on other therapies, were treated with pembrolizumab and BL-8040. Importantly, it appeared this combination therapy made pancreatic cancer more “hot,” meaning it could work in tandem with the body’s own immune system. Previous studies have shown pancreatic tumors to be “cold,” meaning immune therapies like pembrolizumab were not able to act on the cancer.</li> </ul> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;"> <li style="box-sizing:border-box;border-radius:0px;">Preliminary results of Cohort 2 were reported in the manuscript on a group of 22 patients (out of approximately 40 patients in total expected in the cohort), who had previously received one line of chemotherapy. These patients received pembrolizumab and BL-8040, as well as chemotherapy drugs 5-fluorouracil and nano-liposomal irinotecan.</li> </ul> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The percentage of meaningful tumor shrinkage was 32% in Cohort 2, which is double what is available for individuals with pancreatic cancer with traditional chemotherapy. While the study is small, these preliminary results are encouraging and there is hope that we will be able to do larger trials to see if the response to therapy is high and if it is better in comparison to traditional treatment,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/physicians/erkut-borazanci" target="_blank">Erkut Borazanci</a>, M.D., M.S., a medical oncologist and physician-investigator at HonorHealth Research Institute, a clinical associate professor at TGen, and one of the paper’s authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This clinical trial is currently in a follow-up phase of the study. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Pancreatic cancer is an aggressive disease that carries a high mortality rate. It is the third-leading cause of cancer death in the U.S., following lung and colorectal cancers. In 2020, the five-year survival rate for pancreatic cancer is 10%, which has increased from 6% in 2014.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Next steps for this research would be to compare this COMBAT combination therapy in future studies to other treatment options, such 5-fluorouracil, leucovorin and nano-liposomal irinotecan.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">COMBAT derives its name from letters in one of the study’s descriptions: <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">Com</span></span>bination of <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">B</span></span>L-8040 and Pembrolizum<span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">a</span></span>b in Patients with Metastatic Pancrea<span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">t</span></span>ic Cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The COMBAT treatment continues at the HonorHealth Research Institute. For more information, please go to <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/company/research-institute" target="_blank">HonorHealth.com/research</a>, call 480-323-1339 or email <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:clinicaltrials@honorhealth.com" target="_blank">clinicaltrials@honorhealth.com</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This research is supported by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.biolinerx.com/about" target="_blank">BioLineRx Ltd</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study – <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.nature.com/articles/s41591-020-0880-x" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial</em></a> – was published May 25, 2020, in <em style="box-sizing:border-box;border-radius:0px;">Nature Medicine</em>. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # # </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/74/dr_daniel_von_hoff.jpg2020-08-11T07:00:00ZTGen
25-YEAR DOLPHIN STUDY REVEALS FACTORS CONTRIBUTING TO AGING RATES IN LONG-LIVED MAMMALS25-YEAR DOLPHIN STUDY REVEALS FACTORS CONTRIBUTING TO AGING RATES IN LONG-LIVED MAMMALS<div class="ExternalClass2D3FBC4144364893A8D0DA3367F87064"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Monday August 10, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="25-year dolphin study reveals factors contributing to aging rates in long-lived mammals" href="https://www.tgen.org/news/2020/august/10/tgen-finds-dolphin-data-could-extend-human-longevity/" target="_blank">25-YEAR DOLPHIN STUDY REVEALS FACTORS CONTRIBUTING TO AGING RATES IN LONG-LIVED MAMMALS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen-Epitracker analysis of U.S. Navy data uncovers groundbreaking science that may help delay aging in dolphins and humans</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. and SAN DIEGO, Calif. — Aug. 10, 2020 — </span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.epitracker.com/" target="_blank">Epitracker Inc.</a> and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, today announced the results from a groundbreaking, 25-year study of bottlenose dolphins that identified factors differentiating individuals with slow and accelerated aging rates.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study results, which will be published this week in the <em style="box-sizing:border-box;border-radius:0px;">Proceedings of the National Academy of Sciences</em>, highlights how biological differences between dolphins, living in the same natural ocean environment and receiving routine medical examinations under the care of the U.S. Navy, may inform new approaches to slow degradative processes associated with aging. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Epitracker, a life sciences company applying metabolomics and other advanced omic technologies to discover therapeutics targeting aging-associated diseases, and TGen, a non-profit biomedical research institute, leveraged archived health data on 144 dolphins receiving meticulous care throughout their lives. These health data included 44 clinically relevant measurements on 5,889 biological routine samples collected throughout the dolphins’ lifetimes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Amazingly, this work all started with the sole intent of continually improving the health and welfare of dolphins,” said Stephanie Venn-Watson, D.V.M., M.P.H., co-founder and CEO of Epitracker Inc. and Seraphina Therapeutics, and the study’s lead author. “The fact that our work is resulting in groundbreaking approaches to delay aging and improve health for both dolphins and humans is a dream come true.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Navy dolphins, which on average live 50 percent longer than wild dolphins, consumed a controlled and well-maintained fish diet and received ongoing health monitoring and medical care. The routine health data and 44 measures collected over time were analyzed to determine aging rates and establish aging rate-related biomarkers that could also be studied in humans.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">TGen and Epitracker discovered four key biomarkers in dolphins associated with an accelerated aging rate. Two of these biomarkers, which already are used in assessing older people, decreased linearly with age: hemoglobin, used to detect anemia; and lymphocytes, used to detect immunosenescence, or weakened immunity. Importantly, while some dolphins had declines in these clinical biomarkers as they aged, including declines leading to clinical anemia and immunosenescence, others had no declines during the same aging timeframe.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While it has long been believed that there are factors influencing why some humans and mammals age faster than others, identifying those factors requires a data set that has been difficult to develop in species closely related to humans — one that is sufficiently large, robust, longitudinal in nature, and collected in a well-controlled population over lifetimes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The nature of the Navy dolphins’ shared environment created a perfect setting to generate unparalleled longitudinal health data using easily measured biomarkers that identified slow and accelerated aging in dolphins,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/nik-schork/" target="_blank">Nicholas Schork</a>, Ph.D., a TGen Distinguished Professor, Scientific Director for the National Institute on Aging’s Longevity Consortium, and the study’s senior author.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The results from the analysis of the dolphin population are directly translatable into human biology and will now empower us to identify how aging rates vary in humans and what we might be able do to slow the rates down for all,” said Dr. Schork, who also is Director of TGen’s Quantitative Medicine & Systems Biology Division.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This study is one of three recently published peer-reviewed scientific articles from Epitracker and its spin-out health and wellness company, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.seraphinatherapeutics.com/" target="_blank">Seraphina Therapeutics</a>, demonstrating the promise of applying advanced technologies to delay aging in dolphins and humans.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In April 2020, Epitracker reported in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230769" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">PLOS ONE</em></a> the discovery of shifted dolphin serum metabolomes and improved health resulting from a wild-type fish diet. Specifically, increased dietary intake of pentadecanoic acid (C15:0), a trace dietary odd-chain saturated fatty acid present in some fish as well as dairy fat, independently predicted raised hemoglobin and alleviated chronic anemia in dolphins. A subsequent series of controlled laboratory studies demonstrated evidence of repeated, broad health benefits of C15:0 related to healthy aging, including attenuated anemia and fibrosis, lowered inflammation and cholesterol, and improved cellular stability and mitochondrial function. The growing body of evidence supporting C15:0 as the first essential fatty acid to be discovered in 90 years, was published by Epitracker and Seraphina in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.nature.com/articles/s41598-020-64960-y" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Scientific Reports</em></a>, a <em style="box-sizing:border-box;border-radius:0px;">Nature</em> publication, in May 2020.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Our discovery of slow and accelerated aging dolphins are now enabling us to compare thousands of small molecules in the archived serum of individuals with and without aging-related conditions and help find which molecules have the greatest promise of protecting the health of aging mammals,” Venn-Watson said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Seraphina Therapeutics is currently advancing C15:0 as a once daily dietary supplement, food fortifier and nutritional intervention to protect against aging-associated breakdown and as a potential treatment of C15:0 deficiency disorders in humans. Seraphina aims to have C15:0 available for purchase as a supplement during Fall 2020 and as a food ingredient in January 2021.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In addition to developing C15:0 supplements for Navy dolphins, Epitracker is working cooperatively with the U.S. Navy to study additional serum metabolites that may help prevent and treat chronic aging-associated conditions present in both dolphins and humans, including pulmonary, hepatic, and neurogenerative diseases, including Alzheimer’s disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">For more information on Epitracker Inc. and the research discoveries made, please read the full published paper — <em style="box-sizing:border-box;border-radius:0px;">25-Year Longitudinal Dolphin Cohort Supports that Long-Lived Individuals in Same Environment Exhibit Variation in Aging Rates</em> — in the <em style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.pnas.org/cgi/doi/10.1073/pnas.1918755117" target="_blank">Proceedings of the National Academy of Sciences</a></em>, or visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.epitracker.com/" target="_blank">www.epitracker.com</a>. To learn more about Seraphina Therapeutics, its science-based approach to advancing global health or the discovery of C15:0, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.seraphinatherapeutics.com/" target="_blank">www.seraphinatherapeutics.com</a>.<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> <br style="box-sizing:border-box;border-radius:0px;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">City of Hope</a>, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">Twitter @TGen</a>.<span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> </span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/73/us-navy-dolphin.jpg2020-08-10T07:00:00ZTGen
Researchers to Develop Device to Accurately and Quickly Detect COVID-19Researchers to Develop Device to Accurately and Quickly Detect COVID-19<div class="ExternalClass32993B30DBF04D19867D1E038F2EC274"><html> <div style="text-align:center;">​TERESA JOSEPH</div> <p> <br> </p> <div class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item" style="box-sizing:border-box;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;font-size:1.25rem;margin-bottom:1rem !important;color:rgb(33, 33, 33) !important;">The Center for Applied NanoBioscience and Medicine Awarded Grant from NASA to Develop Prototype by September 2020</div> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item" style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:17px;line-height:23px;margin-bottom:3rem;padding-bottom:1rem;border-bottom:1px solid rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Amid the <a target="_blank" href="https://phoenixmed.arizona.edu/covid-19" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">coronavirus pandemic</a>, a team of researchers at the University of Arizona College of Medicine – Phoenix are developing a device that will easily and accurately detect COVID-19 in a matter of minutes.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <a target="_blank" href="https://phoenixmed.arizona.edu/anbm" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">The Center for Applied NanoBioscience and Medicine</a>, directed by <a target="_blank" href="https://phoenixmed.arizona.edu/anbm/zenhausern" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">Frederic Zenhausern, PhD</a>, has received a grant to extend the development of its current space-based health monitoring system to build a prototype for COVID-19 testing by September 2020. The grant for $150,000 is from <a target="_blank" href="https://www.bcm.edu/academic-centers/space-medicine/translational-research-institute" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">the Translational Research Institute (TRISH)</a> through NASA Cooperative Agreement NNX16AO69A. Dr. Zenhausern’s lab is working on the project with Dr. Pierre Cosson at the University of Geneva in Switzerland, and Dr. David Aucoin at the University of Nevada in Reno.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“As cases of the virus continue to increase across the globe, specifically in Arizona, the need for a rapid diagnostic test for the COVID-19 virus is crucial,” Dr. Zenhausern said.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“TRISH is pleased to see progress on the technology Dr. Zenhausern and his team are making for fast and accurate COVID-19 detection,” Kristin Fabre, PhD, chief scientist at TRISH. “This demonstrates how tools developed for deep space missions, designed specifically to address unknown medical needs, are being applied to address the COVID pandemic.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Currently, the test on market takes several days to get results, due to the requirement for being processed with large automated instrument at centralized laboratories, like Sonora Quest or LabCorp.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Zenhausern’s lab is developing a Vertical Flow Assay diagnostic system that can combine genes and antibodies directed to specific viral components of the SARS-Cov-2 onto a paper membrane through which biological fluids can flow and antigen interactions can be detected by the light scattering from gold nanoparticles whose imaging is directly interfaced with a smartphone. A user will self-collect a small finger-prick of blood or a spit of saliva, and then the liquid will be pushed through the paper membrane. Essentially, the device will take a picture of the array of spots from multiplex molecules onto the paper, which then can be analyzed by an algorithm on a cloud server prior to being sent back to the users in less than 15 minutes, telling them if they’ve been exposed to the virus.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Our goal is to get a more accurate, comprehensive and faster test out there,” Dr. Zenhausern said. “Testing is extremely important. If we had this kind of device, we would have the capability to test for SARS-COV-2 infection sooner and faster, and we could provide more information moving forward in guiding medical countermeasures for reducing fatalities, better managing health care resources, while bringing people back to safer work environments.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">At present, polymerase chain reaction (PCR) and antibody testing are the two major ways that health care systems are testing for COVID-19, and a majority of tests use the gold standard PCR — which detects genetic information of the virus (the RNA) at high sensitivity with less than 200 copies of the virus in a sample; but PCR can only detect if someone is actively infected with the virus, and cannot detect post exposure to the infection. PCR testing for the virus typically includes a nasal swab, which involves a soft brush going up the nose for a few seconds to collect cells and fluids along the passageway.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Unlike PCR, antibody tests can detect proteins if someone has been previously infected, but recovered from the virus. However, the sensitivity and specificity are limited. The team is using recombinant antigen production technology, which provides a synthetic alternative to the long inoculation of animal models over several months to generate antibodies against the virus. Dr. Zenhausern’s team, comprised of Jerome Lacombe, PhD, and Jian Gu, PhD, partnered with researchers in Geneva who are working to design and validate a pipeline of antibodies against the various proteins of the viral components.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">For example, the spike proteins (S) on the surface of the SARS-COV-2, its membrane protein (M), the nucleo-capsid (N) and the envelope (E) proteins. The team also designed smaller antibody fragments or “nanobodies,” which can be very stable and specific. These reagents have been made available as open source for research and the team has already reported in the literature over a dozen antibodies against COVID N, S, E or M proteins. These biomarkers from the different domains of the virus are typically printed into arrays of spots onto the vertical flow assay membrane, so the biological fluid can be flown through the thickness of the paper and provide enhanced limit of detection by more than 100 times over standard lateral flow immunoassay, such as the common tests commercially available for other health conditions.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Through our device, we are combining the benefit of both platforms by increasing capabilities of looking at a much broader panel of disease signatures while significantly increasing the test sensitivity by orders of magnitude,” Dr. Zenhausern said.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">A vertical flow assay test is when the biofluids go toward and through the thickness of the paper, not by capillarity along the length of the test strip. This changes the mechanisms of fluidics and physics, which allows testing to look at multiple biomarkers for a wider range of pathogens, instead of just looking at one target biomarker. “It’s much faster and more sensitive,” Dr. Zenhausern said, “while the volume of the samples can be tuned from a small droplet of blood to a large volume of saliva or urine allowing us to detect low abundance target pathogens without the need for pre-concentrating the specimen prior to run a test.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Already in Arizona and other parts of the world, scientists have discovered a mutated strain of the coronavirus. Mutations can impact diagnostics, but a unique aspect of this platform is the ability to add or modify biomarkers to the test with a high-quality control and fast turn-around-time for production. As more antibodies against coronavirus are detected and as scientists continue to find mutated strains of the virus, researchers can add these markers to the platform and turn it into a large-scale production in the matter of a few weeks.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">According to Dr. Zenhausern, due to the current health crisis, we will need to have rapid testing everywhere that is less invasive and readily deployable at home for more personalized diagnostics.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Through this technology, we could deliver point of care diagnostics in a parking lot, hospital emergency room, in an outpatient clinic and at a pharmacy, or even at home, that could run the test in several minutes while delivering secure results,” Dr. Zenhausern said.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Zenhausern hopes that this platform improves diagnostics not only for COVID-19, but for other viruses and conditions. His team is using a similar technology platform to detect pathogens and Tier 1 biothreats in the Armed Forces, and has worked with NASA TRISH to improve diagnostics for radiation exposure in deep space mission to Mars. Any kind of biological signature, this device could potentially detect. Besides diagnostics, there is also significant potential for building viral nanoparticles as future therapeutic treatment and vaccines.<br></p> </div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/75/zenhausern-photo.jpg2020-08-05T07:00:00ZUA
UARIZONA-TGEN LED TEAM IDENTIFIES NEW BIOMARKERS TO DIAGNOSE AND MONITOR BRAIN INJURIESUARIZONA-TGEN LED TEAM IDENTIFIES NEW BIOMARKERS TO DIAGNOSE AND MONITOR BRAIN INJURIES<div class="ExternalClass969950D0EE1C4C8BBCCA6CDE205A78F4"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Friday July 31, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="UArizona-TGen led team identifies new biomarkers to diagnose and monitor brain injuries" href="https://www.tgen.org/news/2020/july/31/proteomic-analysis-reveals-new-brain-injury-biomarkers/" target="_blank">UARIZONA-TGEN LED TEAM IDENTIFIES NEW BIOMARKERS TO DIAGNOSE AND MONITOR BRAIN INJURIES</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">Integrated protein and metabolite analysis open the door to more precise ways of guiding treatment for the nearly 70 million people worldwide who annually suffer traumatic brain injuries</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 31, 2020 —</span> A scientific team led by the University of Arizona and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, identified a robust set of biomarkers through proteomics and metabolomic analysis that could help guide treatment for tens of millions of patients who each year sustain brain injuries, potentially preventing severe long-term disabilities.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The team’s findings were reported in a study published today in the <em style="box-sizing:border-box;border-radius:0px;">Nature</em> journal: <em style="box-sizing:border-box;border-radius:0px;">Scientific Reports</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">An estimated 69 million people worldwide annually sustain traumatic brain injury (TBI). That includes at least 3 million in the U.S., resulting in nearly 288,000 hospitalizations, 56,800 deaths and more than 90,000 with permanent disabilities.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">One of the practical applications of the study was to show the effectiveness of a treatment for brain injuries known as RIC (Remote Ischemic Conditioning). RIC involves, for example, using a tourniquet to restrict, then release, the flow of blood in one of the head-injury patient’s arms or legs. Scientists still don’t know why, but circulating molecules in the bloodstream are produced that could help the brain minimize or repair the injury through this seemingly unrelated technique of on-again, off-again flow of oxygen and nutrients to a patient’s limb.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The molecules released by alternately restricting and releasing the blood flow seem to have a neuro-protective effect,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/patrick-pirrotte/" target="_blank">Dr. Patrick Pirrotte</a>, Director of TGen’s Collaborative Center for Translational Mass Spectrometry and one of the study’s senior authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Using mice models and TGen’s state-of-the-art mass spectrometry facility to analyze proteins and metabolites, Dr. Pirrotte’s team identified biomarkers that showed the effectiveness of RIC, and additional biomarkers that could be used to measure the presence of the injury.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Premature return to normal or strenuous activities can worsen the (TBI) condition and induce chronic health-related issues, the study says, further exacerbating the onset of neurodegenerative diseases.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The biomarkers we identified allow us to measure the extent of the injury, and monitor RIC-aided recovery from brain injury,” said Dr. Khyati Pathak, a member of Dr. Pirrotte’s team and one of the study’s authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The newly-identified biomarkers can provide a more exacting, molecular-level diagnosis of TBI.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Traumatic brain injury, particularly in its less severe form, may not seemingly require hospitalization or an emergency room visit,” said Dr. Jonathan Lifshitz, Director of the UArizona’s Translational Neurotrauma Research Program: a joint venture between the UArizona College of Medicine-Phoenix; a branch of Barrow Neurological Institute at Phoenix Children’s Hospital; and the Phoenix VA Health Care System.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“For millions of individuals, there often is no health care access immediately after TBI events, whether it be organized sports, recreational activities, occupational hazards, military service, or domestic violence,” said Dr. Lifshitz, one of the study’s senior authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The use of RIC — the alternating restriction and release of blood flow to an arm or leg — has been shown in clinical studies to be effective in other emergency medical situations, including cardiac arrest, organ transplantation, and lung injury.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“RIC is an easy to teach, practical intervention for a brain injury outside of the hospital setting. It allows for immediate care to the patient with the intent to reduce brain injury pathology,” said Dr. Maha Saber, who is affiliated with Barrow and UArizona and is the study’s lead author.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This research study — <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.nature.com/articles/s41598-020-69865-4" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Proteomic analysis identifies plasma correlates of remote ischemic conditioning in the context of experimental traumatic brain injury</em></a> — was funded by grants from the National Institutes of Health (NIH-R21-NS096515, F31-NS090921, and T32-AG044402).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/72/patrick-pirrotte.jpg2020-07-31T07:00:00ZTGen
UArizona Aims to Provide Rapid Tests for Individuals Exposed to Biothreats and Pathogens, Such as COVID-19UArizona Aims to Provide Rapid Tests for Individuals Exposed to Biothreats and Pathogens, Such as COVID-19<div class="ExternalClassB8A82FB060624E5FA321BCE44452036E"><html> <p style="text-align:center;">​<span style="color:rgb(155, 155, 155);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;text-transform:uppercase;background-color:window;">TERESA JOSEPH</span></p> <div> <div> <span style="box-sizing:border-box;" class="field field--name-title field--type-string field--label-hidden"> <br> </span> </div> <a style="box-sizing:border-box;color:rgb(1, 28, 72);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:16px;" href="https://twitter.com/uazmedphx/" target="_blank" class="field_media_contact_twitter_url"></a> <br> </div> <p> <span style="color:rgb(33, 33, 33);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:1.25rem;font-weight:700;background-color:window;">​Thanks to a U.S. Department of Defense Contract for as Much as $9.5 Million, College of Medicine – Phoenix and Partners Aim to Develop a Portable Device to Easily and Accurately Detect Biological Threats</span> </p> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:15px;line-height:20px;margin-bottom:3rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">To better protect individuals serving on battlefields or dealing with an event, such as the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/covid-19" target="_blank">COVID-19 global pandemic</a>, as well as potential future pandemics, scientists at the University of Arizona College of Medicine – Phoenix are leading an effort to develop a device for easy, quick and accurate detection of pathogens and biological threats.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/anbm" target="_blank">The Center for Applied Nanobioscience and Medicine</a> (ANBM) at the UArizona College of Medicine – Phoenix is heading the effort, under an Other Transaction Agreement (OTA) with the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://www.dtra.mil/" target="_blank">Defense Threat Reduction Agency</a> (DTRA), an agency within the U.S. Department of Defense. The agreement is a $9.5 million ceiling contract for three years, to provide about 3,000 devices.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/anbm/zenhausern" target="_blank">Frederic Zenhausern, PhD</a>, ANBM director and interim co-chair of the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/bms" target="_blank">Department of Basic Medical Sciences</a>, and his team members, including associate professor Jian Gu, PhD, are creating the device, in collaboration with scientists from the University of Nevada, Arizona State University, Duke University and Whitespace Enterprise — an Arizona-based startup founded by Dr. Zenhausern. The group is responsible for mass production of the technology.<img style="box-sizing:border-box;border-width:0px;vertical-align:middle;float:right;max-width:100%;margin:5px;width:0px;" title="" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/zenhausern-story_0.jpg" data-entity-uuid="8296785b-4bb8-4af1-859d-35b8cd92735a" data-entity-type="file" class="img-fluid align-right" alt="Frederic Zenhausern, PhD" /></p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“An individual in a combat zone or a first responder in the field could know within minutes if they have — or were exposed to — a serious pathogen or biothreat,” Dr. Zenhausern said. “We want the brave individuals serving on the front lines to be safe, and this device potentially could prevent a next pandemic by providing rapid diagnostic testing for a broad range of threats, including coronaviruses.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The team is developing a vertical flow immunoassay (VFI) diagnostic test that interfaces with a smartphone, as the only system component requiring battery power. Users would take a small finger prick of blood, or a syringe of urine, and then push the liquid onto a test strip. Essentially the device would take a picture of that paper membrane, which would be analyzed and sent back to the users, telling them if they have been exposed to pathogens, such as anthrax or Y. pestis, which can cause the plague or possibly other bacteria and viruses.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Two major platforms for microbial diagnostics are available, including polymerase chain reaction (PCR) tests, which look at the nucleic acid molecules of the organism, and antibody or immunoassay testing. The immunoassay test typically is color-coded, like a pregnancy test, and uses a lateral flow immunoassay method that involves a piece of paper upon which biofluid, such as blood or urine, is placed.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The biofluid would migrate along the paper and meet different antibodies to determine if an individual’s body has produced an immune response to the virus, or if antigens could be detected. Then an interaction occurs, signaling the individual has been exposed to the biothreat, like a line appearing through the paper.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Lateral flow immunoassay tests are limited to only a few antibodies and are not very sensitive or fast, but they are inexpensive and safe, which has made it a popular option in the past,” Dr. Zenhausern said. “Through our device, we are combining the benefit of both platforms by increasing capabilities of looking at a much broader panel of disease signatures while significantly increasing the test sensitivity by orders of magnitude.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">A vertical flow immunoassay test is when biofluids go toward and through the paper, not by capillarity, along surface of the test strip. This changes the mechanisms of fluidics and physics, which allows testing to look at multiple biomarkers for a wider range of pathogens, instead of just looking at one target biomarker.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“It’s much faster and more sensitive,” Dr. Zenhausern explained, adding this device would have more capabilities than technology currently available and could be applied to illnesses, such as influenza, Ebola or the COVID-19 threat — or any other biological signature.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Dr. Zenhausern’s team at the University of Arizona Health Sciences and additional collaborators have worked tirelessly to take this idea from concept to production, and I am grateful for their dedication,” said University of Arizona President <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://president.arizona.edu/dr-robert-c-robbins-biography" target="_blank">Robert C. Robbins, MD</a>. “This research is an incredible example of how university research directly serves the community. By protecting first responders and others who have an increased likelihood of pathogen exposure, including those serving in combat zones, we can improve public health and prevent future outbreaks. I am immensely proud of our faculty who are spearheading this vital work, and I am eager to see its impact.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Zenhausern said, due to the pandemic, a change in the health care delivery system will occur. “We will need to have rapid testing that is less invasive and more personalized.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">A previously DTRA-sponsored program successfully established design rules of the proposed VFI platform technology, which will be scaled up for this product-development project. This increase would encompass the U.S. Food and Drug Administration regulatory filing and delivery of thousands of devices. The OTA contract also includes a subsequent production option for future commercialization and possible stockpiling through the Department of Defense.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The OTA program is a partnership among several investigators and their teams, which have been collaborating for many years. These teams are led by world-renowned scientists such as David Aucoin, PhD (University of Nevada Reno); Tuan Vo-Dinh, PhD (Duke University); and Doug Montgomery, PhD (Arizona State University); as well as many industry partners.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The collaboration among most of these institutions began in 2016 after receiving about $2 million in a DTRA contract to study this technology and determine how it could be applied for the detection of Tier-1 bioagents in defense operations.<br></p> </div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/64/zenhauern-dod.jpg2020-07-23T07:00:00ZUA
TGEN CENTER FOR RARE CHILDHOOD DISORDERS PATIENT IS HEADED TO MARSTGEN CENTER FOR RARE CHILDHOOD DISORDERS PATIENT IS HEADED TO MARS<div class="ExternalClass90032E1993CB473C8C426119C64CC951"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Thursday July 23, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="TGen Center for Rare Childhood Disorders patient is headed to Mars" href="https://www.tgen.org/news/2020/july/23/tgen-c4rcd-patient-is-headed-to-mars/" target="_blank">TGEN CENTER FOR RARE CHILDHOOD DISORDERS PATIENT IS HEADED TO MARS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">Alex Yiu, whose rare neurological disorder was diagnosed by TGen, will celebrate a combination birthday and ‘Perseverance’ pre-launch party and fundraiser on July 25</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 23, 2020 —</span> Alex Yiu, whose once-mysterious and debilitating disease was eventually diagnosed by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, turns 15 years old this week.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">And to celebrate his birthday, NASA is sending Alex to Mars.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex, who has been a space enthusiast since he was a young child, couldn’t be happier about it.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">His name is etched on a microchip embedded on the newest and most sophisticated Mars rover called <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://mars.nasa.gov/mars2020/" target="_blank">Perseverance</a>. It is set to launch from Florida sometime between July 30 and Aug. 15, and land on Mars in February inside the 30-mile-wide Jezero Crater, which scientists — including those at ASU and UofA — think was once a large water-filled lake. The Perseverance rover will collect rock and soil samples, seeking signs of ancient life. Aboard the rover will be the Mars Helicopter, the first drone ever deployed on the Red Planet.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex’s mother, Caroline Cheung-Yiu, says her teenage son is looking forward to the launch. To celebrate, his family is hosting a virtual combination birthday and prelaunch party as a fundraiser for TGen’s Center for Rare Childhood Disorders.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex has always been fascinated about space. He helped build a model of the solar system in middle school, loves Star Wars movies, and even dressed as Darth Vader for Halloween.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“When he was younger and we took him to science centers, he was always interested in space,” Caroline said. Alex still loves watching the NASA channel on TV. As a gift from one of his special education teachers, Alex's name is one of 10.9 million names etched on the microchips on board Perseverance.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Once healthy child now has debilitating condition</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Born healthy with no complications, Alex was an active, social and happy boy. Today, he is entirely dependent on his family for his care and activities of daily living. He is fed via a tube, cannot walk, cannot talk and relies on a non-invasive ventilator to breathe. He communicates by blinking his eyes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">At age 3, Alex walked with an unusual gait. His motor skills and coordination became awkward. Gradually he became increasingly clumsy on his feet, requiring increasing support to walk safely. He could no longer walk by age 6. Progressively, his speech slowed and slurred and by age 7 his family could no longer understand him. Eating and drinking became challenging.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Family life for Alex revolved around a multitude of doctor consults for health issues, traveling for appointments with neurologists at leading institutions, a slew of tests and applications to programs dedicated to undiagnosed patients. His initial visits to TGen nearly a decade ago yielded no significant findings.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We held onto the hope that once we found the cause, we could find treatments,” Caroline said. “We reached out to researchers, specialists, and other parents already lighting the way.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Accidental discovery of diagnosis by TGen</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In the fall of 2018, by what his mother called a “miraculous intervention,” Alex was a cold case revisited at TGen’s Center for Rare Childhood Disorders. A mutation in a gene called IRF2BPL  had just been discovered earlier that year.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Keri Ramsey, a nurse and Clinical Co-Director of TGen’s Center, was searching for another patient when she accidentally came across Alex’s file. Using a new computer diagnostic tool, and having recently seen two new scientific studies about IRF2BPL, Ramsey found that Alex had this same mutation.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Immediately, I saw this mutation in this gene,” Ramsey said. “It was perfect timing.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">After 12 years of relentlessly searching for answers to Alex’s progressive neurodegenerative condition, Alex’s family finally had a diagnosis: NEDAMSS (Neurodevelopmental disorder with regression, abnormal movements, loss of speech and seizures).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Unfortunately, there are as yet no treatments for NEDAMSS. Still, while Alex’s family waits for a breakthrough, they are raising funds so that other TGen patients and their families can receive a diagnosis.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“What’s amazing about Alex’s mom is that she continues to fight for other families who still don’t have a diagnosis. To her, it’s still so important, and that’s why she continues to reach out to us because she knows the value of having that diagnosis and because for so many years they didn’t have it,” Ramsey said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Our hearts ache knowing that there are other families struggling and feeling alone with no diagnosis,” Caroline said. “We shall never give up, we forever hold onto hope, and just like the Mars Rover Perseverance, our perseverance continues.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To contribute to a fund in Alex’s name to TGen’s Center for Rare Childhood Disorders, please go to: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/alex" target="_blank">https://www.tgen.org/alex</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex’s combined birthday and pre-launch party starts at 1 p.m. Arizona and California time this coming Saturday, July 25, and will feature a country love song written by Alex. To join the party, please <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://docs.google.com/forms/d/e/1FAIpQLSe_ihS1WitY1pC4J70C0WWKba4tAX-YvpC5QzYpJYR4FuMRxA/viewform" target="_blank">RSVP here</a> to get your Zoom boarding pass.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To see a story about Alex produced by National Public Radio, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.npr.org/sections/health-shots/2019/10/16/769462793/a-boys-mysterious-illness-leads-his-family-on-a-diagnostic-odyssey" target="_blank">click here</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To see Alex’s Countdown to Mars on Vimeo, go to: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://vimeo.com/439803390" target="_blank">https://vimeo.com/439803390</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/71/alex-yiu.jpg2020-07-23T07:00:00ZTGen
TGEN’S ASHION ANALYTICS® AND HONORHEALTH SHOW HOW ‘ORGANOIDS’ CAN HELP PINPOINT THE RIGHT THERAPIES FOR CANCER PATIENTSTGEN’S ASHION ANALYTICS® AND HONORHEALTH SHOW HOW ‘ORGANOIDS’ CAN HELP PINPOINT THE RIGHT THERAPIES FOR CANCER PATIENTS<div class="ExternalClass71754A0ACB574D3BAF61A3A87600FB30"><html> <p style="text-align:center;"> <span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span> <span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span> <span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a> </span> </p> <p style="text-align:left;"></p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:667.5px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">New PATRIOT analysis unveiled at this week’s AACR meeting; builds on Ashion’s GEM-ExTra program, providing unprecedented accuracy in prescribing anti-cancer treatments</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:667.5px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — June 22, 2020 —</span> Precision medicine, using the power of the human genome to diagnose and treat patients, is about to get even more precise.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">A new program called PATRIOT, developed by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, is using organoids — laboratory cultures derived from samples of patient tumors — to provide a whole new level of accuracy in prescribing anti-cancer treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">PATRIOT builds on other precision medicine programs devised by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics</a>, a TGen clinical laboratory, which uses its <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank">GEM ExTra</a><span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">® </span>proprietary test to match each patient’s unique cancer to the best available cancer treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">PATRIOT, which stands for <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.abstractsonline.com/pp8/#%21/9045/presentation/3954" target="_blank"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PAT</span>hway based <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">R</span>NA and DNA <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">I</span>ntegration with tumor <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">O</span>rganoid <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">T</span>esting for clinical therapeutics</a>, will be showcased in a study presentation June 22-24 at the second 2020 virtual annual meeting of the American Association for Cancer Research (AACR).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Cancer tumors are complicated,” said Dr. Sunil Sharma, Deputy Director of TGen Clinical Sciences and Chief of Translational Oncology and Drug Development at the HonorHealth Research Institute. “PATRIOT is a very powerful platform that will make GEM ExTra even more powerful. This will expand the use of RNA analysis in a way that has never been used before.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In this system, organoids — which can mimic the reactions of solid tumors in patients’ bodies —are grown in a laboratory and then used to test different anti-cancer therapies.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“It’s a way of conducting clinical trials on a laboratory plate,” said Dr. Sharma, who also is a Professor and Director of TGen’s Applied Cancer Research and Drug Discovery Division.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The study being presented at AACR shows how Dr. Sharma’s TGen lab, using melanoma tumor samples provided by HonorHealth, used the new PATRIOT system to identify potential therapeutic targets by focusing on molecular pathways within tumor cells, a level of analysis that goes beyond searching for mutations in DNA, and even builds on top of the intricate analysis of RNA-expression provided by Ashion’s GEM ExTra.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“These druggable targets were validated on the tumor organoids,” said Dr. Sharma, who hails the system as a whole new way to provide therapeutic benefit to patients. “This allows for a holistic assessment of a patient’s tumor for improving therapy recommendations and expanding personalized therapy options.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition, he said, PATRIOT analysis of organoids gives investigators the ability to test immunotherapy options in the laboratory.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion’s GEM ExTra platform already has expanded the therapeutic potential of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Fact-Sheet" target="_blank">genomic sequencing</a> by using RNA sequencing to identify novel fusions and alternate transcripts, providing additional tumor profiling data in addition to that identified by DNA sequencing.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Unlike many other genomic sequencing tests, which use panels of dozens or even hundreds of known cancer-causing genomic variants, Ashion’s GEM ExTra screens cancer patients for <em style="box-sizing:border-box;border-radius:0px;">all</em> of the nearly 3 billion nucleotides, or letters, in human DNA, which includes more than 19,000 genes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The next step, Dr. Sharma said, is to test the predictions from PATRIOT and GEM ExTra analysis of patient organoids in the laboratory to see if they might work in a larger clinical trial.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This study was supported by funding from Flinn Foundation grant #2193.<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics<br style="box-sizing:border-box;border-radius:0px;"></span>At Ashion, our goal is to accelerate the adoption of genomic analysis for clinical decision support to improve the treatment of patients with refractory, rare or aggressive disease. We are experts at Next-Generation Sequencing-based clinical laboratory services, deriving our pedigree from the pioneering precision medicine work at the Translational Genomics Research Institute (TGen) in Phoenix. Ashion Analytics’ mission is to develop and deliver the premier personalized medicine diagnostic, data analytic, and clinical coordination services, which assist healthcare providers in offering their patients individualized treatment options, and which improve outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About HonorHealth <br style="box-sizing:border-box;border-radius:0px;"></span>HonorHealth is a non-profit, local community healthcare system serving an area of 1.6 million people in the greater Phoenix area. The network encompasses five acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer care network, clinical research, medical education, a foundation and community services with approximately 12,300 employees, 3,700 affiliated physicians and 3,100 volunteers. HonorHealth was formed by a merger between Scottsdale Healthcare and John C. Lincoln Health Network. HonorHealth’s mission is to improve the health and well-being of those we serve. Learn more at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://honorhealth.com/" target="_blank">HonorHealth.com</a></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About HonorHealth Research Institute<br style="box-sizing:border-box;border-radius:0px;"></span>HonorHealth Research Institute is helping shape the future of medicine. We're finding cures and improving treatments in areas like gene therapy, early drug/device development, early detection and prevention of disease. Through our clinical trials and applied research, we’ve given hope and improved the lives of patients from all 50 states and 28 different countries around the globe. Our advanced technologies and cutting-edge treatment options are introducing tomorrow’s cures, today. For more information on oncology clinical trials for cancer contact HonorHealth Research Institute Nurse Navigators (480) 323-1364 or email <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:clinicaltrials@honorhealth.com" target="_blank">clinicaltrials@honorhealth.com</a> or learn more at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth.com/research</a>.  Follow HonorHealth Research Institute on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/HonorHealthcares" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/honorhealth" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/HRInstitute_AZ" target="_blank">Twitter @HRInstitute_AZ. </a> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_tag_container"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;" class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50"></ul> </div> <div style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_label_container"> <div style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_labels_container"></div> </div> </aside>​<br></div> </div> <span id="ms-rterangepaste-end"></span> <p style="text-align:left;"> <br> </p> <p style="text-align:center;"> <br> </p> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="text-align:center;"> <br> <br> <br> </div> </li> </ul> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/59/dr_sunil_sharma.jpg2020-07-22T07:00:00ZAshion Analytics
TGEN, CITY OF HOPE LOOKING TO CREATE PERSONALIZED ROADMAPS FOR THE TREATMENT OF KIDNEY CANCERTGEN, CITY OF HOPE LOOKING TO CREATE PERSONALIZED ROADMAPS FOR THE TREATMENT OF KIDNEY CANCER<div class="ExternalClass8B5C1DB374104E0C8252D76950F8F08D"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Wednesday July 22, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="TGen, City of Hope looking to create personalized roadmaps for the treatment of kidney cancer" href="https://www.tgen.org/news/2020/july/22/tgen-city-of-hope-roadmaps-to-treat-kidney-cancer/" target="_blank">TGEN, CITY OF HOPE LOOKING TO CREATE PERSONALIZED ROADMAPS FOR THE TREATMENT OF KIDNEY CANCER</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">Physician-scientists are using one of the world’s most comprehensive genomic analysis tools to determine whether targeted therapy or immunotherapy has the best chance of working for each individual patient</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz., and DUARTE, Calif. — July 22, 2020 —</span> Experts at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/" target="_blank">City of Hope</a> and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a> are using one of the world’s most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While the physician-scientists are at the beginning of this long journey, they believe they’re on the right path. They recently published a study in the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://jitc.bmj.com/content/8/2/e000953" target="_blank">Journal of Immunotherapy of Cancer</a> that suggests mutations in the TERT gene predicts that a patient may not be receptive to immune checkpoint inhibitors such as nivolumab or pembrolizumab.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The hope is to one day identify patients who will benefit from immunotherapy and those who will not. Eventually we may be able to distinguish which patient is better suited for other treatments, like targeted therapy,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/people/pal-sumanta" target="_blank">Sumanta Pal</a>, M.D., one of the study’s senior authors and co-director of the Kidney Cancer Program at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. Examples of targeted therapy include vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors like cabozantinib.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Nearly 74,000 new cases of kidney cancer will be diagnosed this year, and about 14,800 people will die from the disease, according to the American Cancer Society. Ironically, experts know patients who have certain genetic mutations are more susceptible to specific drugs, but most doctors are not genetically sequencing each kidney cancer patient’s tumors, Pal said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“It’s a paradox: We don’t use targeted therapy in a targeted fashion,” he added. “At City of Hope, we have begun to provide comprehensive genome and exome sequencing for all patients with Stage 4 cancer, regardless of their cancer site.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">City of Hope is on pace to be the only major cancer center in the United States to genetically profile the tumors of every single patient, regardless of cancer type. The goal is to enable patients to receive effective targeted therapies or to enroll people in innovative clinical trials as early as possible so that they can fight their disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In the study, Pal and his colleagues sent samples of 91 patients’ tumors to TGen’s clinical laboratory, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics</a>, so that the specimens could be sequenced by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank">GEM ExTra</a> a leading-edge tool that features tumor-normal whole exome sequencing and tumor whole transcriptome sequencing. These are molecular-level analyses of each patient’s entire protein-coding DNA and RNA.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The goal was to identify genomic alterations that correlated with therapy response,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/sara-byron/" target="_blank">Sara Byron</a>, Ph.D., assistant professor in TGen’s Integrated Cancer Genomics Division and co-senior author of the study. “We wanted to use this ‘real-world evidence’ to explore potential molecular and genomic features associated with response.” (<a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/" target="_blank">Ashion Analytics recently announced</a> that Medicare has approved coverage of GEM ExTra, potentially providing 44 million more patients access to this test, which aims to match patients with the best available treatments for their disease.)</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Kidney cancer treatment regimens involving either targeted therapy or immunotherapy have burgeoned since 2015. Because new treatments sprouted so rapidly, scientists have not yet discovered the ideal strategy to sequence regimens for optimal outcomes. Moreover, the current way treatment risk is assessed tends to be subjective with ingrained bias, the study reported. City of Hope and TGen are working to develop objective laboratory-based biomarkers for kidney cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Only patients whose genomic profiling was performed prior to systemic treatment were included in the study. Patients received either targeted therapy known as VEGF tyrosine kinase inhibitors (sunitinib, cabozantib, lenvatinib/everolimus) or immunotherapy (nivolumab, ipilimumab, pembrolizumab). They were divided into those who received no clinical benefit, meaning their disease progressed, or those who received clinical benefit, meaning the disease shrunk or stabilized for more than six months. Some 19,396 genes and nucleic sequences were analyzed to tease out a therapeutic treatment plan that would have best suited each patient based on their specific tumor mutations. More research in larger sample sizes are needed, but the scientists are off to a good start.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Stage 4 cancer is often considered incurable, but that doesn’t always have to be the case,” Pal said. “By sequencing all protein-coding DNA, that is by sequencing the whole exome, we may be able to identify new therapeutic targets, and that’s a very exciting prospect.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/tests-and-treatments/bone-marrow-and-blood-stem-cell-transplants" target="_blank">bone marrow transplantation</a> and immunotherapy such as <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/research/car-t-cell-therapy" target="_blank">CAR T cell therapy</a>. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.cityofhope.org/research/beckman-research-institute/about-beckman-research-institute/beckman-research-institute-milestones" target="_blank">numerous breakthrough cancer drugs</a> are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Report’s Best Hospitals: Specialty Ranking. Its main campus is located near Los Angeles, with <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/about-city-of-hope/locations" target="_blank">additional locations</a> throughout Southern California. For more information about City of Hope, follow us on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/cityofhope/" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/cityofhope" target="_blank">Twitter</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.youtube.com/user/cityofhopeonline" target="_blank">YouTube</a> or <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.instagram.com/cityofhope/" target="_blank">Instagram</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact<br style="box-sizing:border-box;border-radius:0px;"></span>Zen Vuong<br style="box-sizing:border-box;border-radius:0px;">City of Hope<br style="box-sizing:border-box;border-radius:0px;">626-409-9367<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:zvuong@coh.org" target="_blank">zvuong@coh.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/69/sara-byron.jpg2020-07-22T07:00:00ZTGen
ASHION ANALYTICS ANNOUNCES INNOVATIVE CANCER TREATMENT PARTNERSHIP WITH ELEVATION ONCOLOGYASHION ANALYTICS ANNOUNCES INNOVATIVE CANCER TREATMENT PARTNERSHIP WITH ELEVATION ONCOLOGY<div class="ExternalClassCE5BA87BAD024C64B7290E33B0785836"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Wednesday July 22, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Ashion Analytics announces innovative cancer treatment partnership with Elevation Oncology" href="https://www.tgen.org/news/2020/july/22/ashion-analytics-teams-with-elevation-oncology/" target="_blank">ASHION ANALYTICS ANNOUNCES INNOVATIVE CANCER TREATMENT PARTNERSHIP WITH ELEVATION ONCOLOGY</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Ashison Analytics GEMExTra test detects rare NRG1 gene fusions in patients whose cancer is driven by this genomic alteration for potential matching to a clinical trial</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 22, 2020 —</span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics LLC</a> today announced a partnership with <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.elevationoncology.com/" target="_blank">Elevation Oncology</a>, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion’s proprietary GEM ExTra® test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">NRG1 gene fusions are a rare genomic alteration implicated as a driver of tumorigenesis and growth across many types of solid tumors, including lung, breast, pancreatic, ovarian, and colorectal cancers. <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://nrg1fusion.com/" target="_blank">CRESTONE</a> — or <span style="text-decoration:underline;">C</span>linical study of <span style="text-decoration:underline;">RE</span>sponse to <span style="text-decoration:underline;">S</span>eribantumab in <span style="text-decoration:underline;">T</span>um<span style="text-decoration:underline;">O</span>rs with <span style="text-decoration:underline;">NE</span>uregulin 1 (NRG1) fusions — provides an investigational treatment opportunity for patients with any advanced solid tumor who have not responded or are no longer responding to standard cancer treatment, and whose tumor has tested positive for an <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://nrg1fusion.com/wp-content/uploads/2020/07/EO0003-001-000_NRG1-fusion-1-pager.pdf" target="_blank">NRG1</a> fusion.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This partnership creates a new dynamic in the way cancer patients can be matched to precision medicine therapeutics. By first identifying a genetic driver that has an available targeted therapy option, in this case an NRG1 fusion and the investigational therapy seribantumab, the diagnostic technology, data insights, and network reach at Ashion Analytics can be leveraged to efficiently identify and directly match eligible patients to the CRESTONE trial using test results that are already available today, while also maximizing the value of every additional test.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“The comprehensive nature of the GEM ExTra test means that its value grows directly with each new genomic driver that is identified and each new precision therapy under development,” said Laurie Goodman, Ph.D., Ashion Analytics Director of Business Development and Medical Affairs. “Partnerships like this enable us to continuously facilitate the ability for our patients to receive the most up-to-date information about the emerging treatment opportunities available to them today.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/" target="_blank">Ashion Analytics recently announced</a> that Medicare has approved coverage of its proprietary cancer profiling test, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank">GEM ExTra</a>®, one of the nation’s most comprehensive genomic cancer analysis tests. Medicare coverage enables potentially 44 million more patients to afford this test, which aims to match patients with best available treatments for their disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2020/june/11/tgen-s-ashion-certified-for-nci-match/" target="_blank">GEM ExTra</a> detects tumor-specific mutations in both DNA and RNA, allowing physicians to make the best-available treatment recommendations for patients with advanced solid tumors. An Ashion study poster presented at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=80cc45bf65&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOToaeHqm$" target="_blank">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</a><span style="box-sizing:border-box;border-radius:0px;">.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This leading-edge test provides treating physicians with vital interpreted information needed to understand changes to a patient’s genomic profile. It outlines a therapeutic treatment plan best suited for each patient. Conditions that may benefit from this approach include treatment of refractory, rare or aggressive cancers.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We are partnering with Ashion Analytics because we recognize the sensitivity and continuing potential of their GEM ExTra cancer profiling test,” said Shawn Leland, PharmD, RPh, Founder and Chief Business Officer of Elevation Oncology. “Elevation Oncology is committed to expanding the benefit of precision medicine to all patients with cancer by developing therapies that make results from tests like GEM ExTra clinically actionable, no matter how rare the finding. Close collaboration between diagnostic and therapeutic developers is critical to re-thinking our approach to clinical trial enrollment as an industry and finding more efficient ways to bring the right treatment opportunities to the patients that need them.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">For more information about seribantumab and the CRESTONE study, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.nrg1fusion.com/" target="_blank">www.NRG1fusion.com</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion Analytics is a clinical laboratory of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics LLC<br style="box-sizing:border-box;border-radius:0px;"></span>Ashion Analytics LLC is a CLIA-certified and CAP-accredited clinical laboratory that uses advanced genomic technologies to offer a wide range of testing capabilities to assist physicians, health systems, research and commercial partners to provide precision cancer treatments. Ashion was developed and launched by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute</a> (TGen), an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/impact?gclsrc=aw.ds&&gclid=EAIaIQobChMIyu7l0Jit6gIVHz2tBh02oA0BEAAYASAAEgIbkPD_BwE" target="_blank">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About GEM ExTra<br style="box-sizing:border-box;border-radius:0px;"></span>To achieve complete analytic coverage of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=792e518cba&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOelLUM2E$" target="_blank">human genome</a>, Ashion uses a proprietary test called <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=7881a18cf6&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOZeMLcKW$" target="_blank">GEM ExTra</a>, which covers all protein coding regions of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=ca7762bff4&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOXhojeuo$" target="_blank">exome</a>), <em style="box-sizing:border-box;border-radius:0px;">and</em> an analysis of all RNA, the messengers of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=05dc9ef049&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOfQbE1cu$" target="_blank">transcriptome</a>). <em style="box-sizing:border-box;border-radius:0px;">GEM</em> stands for <span style="text-decoration:underline;">G</span>enomic <span style="text-decoration:underline;">E</span>nabled <span style="text-decoration:underline;">M</span>edicine, and <em style="box-sizing:border-box;border-radius:0px;">ExTra</em> stands for <span style="text-decoration:underline;">Ex</span>ome and <span style="text-decoration:underline;">Tra</span>nscriptome. Ashion’s GEM ExTra sequences both the individual patient’s normal genome and the patient’s cancer genome. Then the two sets of genomic data are compared to find gene changes, known as mutations, that are specific to the tumor and that may be potentially driving the patient’s cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. <span style="box-sizing:border-box;border-radius:0px;">Follow TGen on </span><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a><span style="box-sizing:border-box;border-radius:0px;">, </span><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a><span style="box-sizing:border-box;border-radius:0px;"> and </span><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a><span style="box-sizing:border-box;border-radius:0px;">.</span><br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Ashion Analytics Contact<br style="box-sizing:border-box;border-radius:0px;"></span>Laurie Goodman, Ph.D.<br style="box-sizing:border-box;border-radius:0px;">Director, Business Development and Medical Affairs<br style="box-sizing:border-box;border-radius:0px;">Ashion Analytics LLC<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:lgoodman@ashion.com" target="_blank">lgoodman@ashion.com<br style="box-sizing:border-box;border-radius:0px;"></a>650-245-8410<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.ashion.com/" target="_blank">www.Ashion.com</a></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">TGen Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_tag_container"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;" class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50"></ul> </div> <div style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_label_container"> <div style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_labels_container"></div> </div> </aside>​<br></div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/70/laurie-goodman.jpg2020-07-22T07:00:00ZAshion Analytics
ASHION ANALYTICS RECEIVES MEDICARE COVERAGE FOR GEM EXTRA® ASSAY FOR PATIENTS WITH ADVANCED SOLID TUMORSASHION ANALYTICS RECEIVES MEDICARE COVERAGE FOR GEM EXTRA® ASSAY FOR PATIENTS WITH ADVANCED SOLID TUMORS<div class="ExternalClass8B2D62744E3942B6913FFD39BD36A32B"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;"> <ul class="list-inline posted-info" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span class="uBlogsy_author_name" style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" title="Steve Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Tuesday July 14, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a target="_blank" href="https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/" title="Ashion Analytics receives Medicare coverage for GEM ExTra® assay for patients with advanced solid tumors " style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">ASHION ANALYTICS RECEIVES MEDICARE COVERAGE FOR GEM EXTRA® ASSAY FOR PATIENTS WITH ADVANCED SOLID TUMORS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;"></em> </p> </div> </div> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 14, 2020 —</span> <a target="_blank" href="http://ashion.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Ashion Analytics LLC</a> announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostic Services Program (MolDX), has awarded coverage to its proprietary cancer profiling test, <a target="_blank" href="http://ashion.com/physicians-2/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">GEM ExTra</a>®, one of the nation’s most comprehensive genomic cancer analysis tests.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a target="_blank" href="https://www.tgen.org/news/2020/june/11/tgen-s-ashion-certified-for-nci-match/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">GEM ExTra</a>, Ashion’s flagship clinical assay, detects tumor-specific mutations, allowing physicians to make the best-available treatment recommendations for patients with advanced solid tumors. The leading-edge test provides treating physicians with vital interpreted information that they need to understand changes to a patient’s genomic profile. It outlines a therapeutic treatment plan best suited for each patient. Conditions that may benefit from this approach include treatment of refractory, rare or aggressive cancers.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“GEM ExTra was designed to be fast and accurate, and now with Medicare coverage, it is also more affordable for a larger set of patients,” said Ashion Medical Director Janine LoBello, D.O. “GEM ExTra differs from other genomic tests on the market due to its versatility, breadth and depth, including the power to sensitively detect mutations with low tumor purity.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">GEM ExTra features whole <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=ca7762bff4&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOXhojeuo$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">exome</a> sequencing, a molecular-level analysis of each patient’s entire protein-coding DNA. The proprietary test identifies point mutations, amplifications, deletions, translocations and transcriptome sequencing. It flags the expression of both rare and common fusion genes and alternatively spliced transcripts (ARv7, EGFRvIII and others). Positive findings in this data may guide patient treatment, leading to more targeted, effective therapies. As an example, the test includes reporting on immuno-oncology markers, providing clinicians with important information on the potential utility of powerful immune checkpoint treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">GEM ExTra is available for use with a variety of biological sample types, including formalin-fixed paraffin-embedded (<span style="box-sizing:border-box;border-radius:0px;">FFPE) tissue specimens and </span>fresh-frozen tissue for solid tumors<span style="box-sizing:border-box;border-radius:0px;">. Results are reported back to physicians within 14 calendar days.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Medicare coverage of GEM ExTra allows Ashion to offer a test to the broader market that is optimized for detection of common and rare mutations and is able to identify more actionable cancer mutations than most other commercially available tests,” said Audrey Ozols, Ashion’s head of market access. “The company is well positioned for growth with payers and physicians alike by offering 44 million more patients access to a best-in-class comprehensive genomic cancer test.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion Analytics was founded by the <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Translational Genomics Research Institute</a> (TGen), an affiliate of <a target="_blank" href="https://www.cityofhope.org/impact?gclsrc=aw.ds&&gclid=EAIaIQobChMIyu7l0Jit6gIVHz2tBh02oA0BEAAYASAAEgIbkPD_BwE" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“City of Hope patients have had access to GEM ExTra’s comprehensive exome sequencing for more than two years,” said Michael Caligiuri, M.D., president of City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. “This sequencing tool often enables clinical teams to offer precision medicine so that patients are given the care most likely to put them into long-term cancer remission and improve their quality of life.”<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"># # #</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About GEM ExTra<br style="box-sizing:border-box;border-radius:0px;"></span>To achieve complete analytic coverage of the <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=792e518cba&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOelLUM2E$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">human genome</a>, Ashion uses a proprietary test called <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=7881a18cf6&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOZeMLcKW$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">GEM ExTra</a>, which covers all protein coding regions of DNA (known as the <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=ca7762bff4&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOXhojeuo$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">exome</a>), <em style="box-sizing:border-box;border-radius:0px;">and</em> an analysis of all RNA, the messengers of DNA (known as the <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=05dc9ef049&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOfQbE1cu$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">transcriptome</a>). <em style="box-sizing:border-box;border-radius:0px;">GEM</em> stands for <span style="text-decoration:underline;">G</span>enomic <span style="text-decoration:underline;">E</span>nabled <span style="text-decoration:underline;">M</span>edicine, and <em style="box-sizing:border-box;border-radius:0px;">ExTra</em> stands for <span style="text-decoration:underline;">Ex</span>ome and <span style="text-decoration:underline;">Tra</span>nscriptome. Ashion’s <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em> sequences both the individual patient’s normal genome and the patient’s cancer genome. Then the two sets of genomic data are compared to find gene changes, known as mutations, that are specific to the tumor and that may be potentially driving the patient’s cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Study highlighting RNA role presented at recent ASCO meeting<br style="box-sizing:border-box;border-radius:0px;"></span>An Ashion study poster presented at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=80cc45bf65&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOToaeHqm$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</a><span style="box-sizing:border-box;border-radius:0px;">.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics, LLC<br style="box-sizing:border-box;border-radius:0px;"></span>Ashion Analytics, LLC, is a CLIA-certified and CAP-accredited clinical laboratory that uses advanced genomic technologies to offer a wide range of testing capabilities to assist physicians, health systems, research and commercial partners to provide precision cancer treatments. Ashion was developed and launched by the <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Translational Genomics Research Institute</a> (TGen), an affiliate of <a target="_blank" href="https://www.cityofhope.org/impact?gclsrc=aw.ds&&gclid=EAIaIQobChMIyu7l0Jit6gIVHz2tBh02oA0BEAAYASAAEgIbkPD_BwE" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Contact<br style="box-sizing:border-box;border-radius:0px;"></span>Laurie Goodman, Ph.D.<br style="box-sizing:border-box;border-radius:0px;">Director, Business Development and Medical Affairs<br style="box-sizing:border-box;border-radius:0px;">Ashion Analytics, LLC<br style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="mailto:lgoodman@ashion.com" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">lgoodman@ashion.com<br style="box-sizing:border-box;border-radius:0px;"></a>650-245-8410<br style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="http://www.ashion.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">www.Ashion.com</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div class="uBlogsy_tag_container" style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <ul class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;"></ul> </div> <div class="uBlogsy_label_container" style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <div class="uBlogsy_labels_container" style="box-sizing:border-box;border-radius:0px;"></div> </div> </aside>​<br></div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-07-14T07:00:00ZAshion Analytics
TGEN’S ASHION ANALYTICS CERTIFIED FOR NCI’S MATCH CANCER CLINICAL TRIALSTGEN’S ASHION ANALYTICS CERTIFIED FOR NCI’S MATCH CANCER CLINICAL TRIALS<div class="ExternalClass5F8DAADB97B14A0092D5EC15B5354F62"><html> <p style="text-align:center;">​<span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></p> <p style="text-align:left;"></p> <span id="ms-rterangepaste-start"></span> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — June 11, 2020 —</span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics</a>, a clinical laboratory of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, is now part of the National Cancer Institute’s MATCH program, which provides patients who have rare or difficult-to-treat cancers with access to unique clinical trials nationwide that might give them the best therapeutic treatments and outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion is one of the nation’s few dozen institutes participating in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match" target="_blank">MATCH</a>, which stands for <span style="text-decoration:underline;">M</span>olecular <span style="text-decoration:underline;">A</span>nalysis for <span style="text-decoration:underline;">T</span>herapy <span style="text-decoration:underline;">CH</span>oice.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Unlike other MATCH participants, which screen patients with panels consisting of a few hundred known gene variants associated with various cancers, Ashion screens cancer patients for <em style="box-sizing:border-box;border-radius:0px;">all</em> of the nearly 3 billion nucleotides, or letters, in human DNA, which includes more than 19,000 genes. Ashion accomplishes this by performing <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Fact-Sheet" target="_blank">genomic sequencing</a> — a molecular-level analysis of each patient’s entire genome. Ashion scientists then <em style="box-sizing:border-box;border-radius:0px;">match</em> each patient’s unique cancer to the best available cancer treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Our genomic cancer analysis is one of the nation’s most comprehensive tests, not only for the MATCH program, but for any cancer patient whose treating physician, or medical team, requires our precision-medicine guidance,” said Dr. Janine LoBello, Ashion’s Medical Director.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">One of the biggest perks for patients who become eligible to enroll in MATCH clinical trials is that the federal government covers the cost of their drugs, which can be substantial, often reaching six figures. MATCH patients, or their medical insurance providers, usually pick up other clinical costs.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em> </span> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> analyzes complete patient genome</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">To achieve this complete analytic coverage of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets" target="_blank">human genome</a>, Ashion uses a proprietary test called <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em></a>, which covers all protein coding regions of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.broadinstitute.org/blog/what-exome-sequencing" target="_blank">Exome</a>), <em style="box-sizing:border-box;border-radius:0px;">and</em> an analysis of all RNA, the messengers of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets/Transcriptome-Fact-Sheet" target="_blank">Transcriptome</a>). <em style="box-sizing:border-box;border-radius:0px;">GEM</em> stands for <span style="text-decoration:underline;">G</span>enomic <span style="text-decoration:underline;">E</span>nabled <span style="text-decoration:underline;">M</span>edicine, and <em style="box-sizing:border-box;border-radius:0px;">ExTra</em> stands for <span style="text-decoration:underline;">Ex</span>ome and <span style="text-decoration:underline;">Tra</span>nscriptome.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em>, Ashion sequences both the individual patient’s normal genome and the patient’s cancer genome. Then the two sets of genomic data are compared to find the gene changes, known as mutations, that are specific to the tumor and may be potentially driving that patient’s cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Study highlighting RNA role presented at recent ASCO meeting</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">An Ashion study poster presented May 29-31 at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3628" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</em></a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“As you can imagine, this requires billions of precise data points to understand each patient’s molecular makeup; to understand which genes are the likely culprits involved in the patient’s cancer, and what therapeutic drug, or drugs, may be best to counter the patient’s disease,” Dr. LoBello explained.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This could include new therapeutics, as well as existing drugs already approved by the U.S. Food and Drug Administration (FDA) for a particular cancer. These FDA-approved drugs could be repurposed to fight a different cancer through any of the more than 1,100 sites nationwide that are conducting NCI-MATCH clinical trials. Clinical trials are most often the first tests of drugs in human patients, after the drugs have undergone substantial computer and laboratory testing to ensure they are safe and effective.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We are excited to be selected by the National Cancer Institute to participate in the NCI’s MATCH program, and we hope that more patients will benefit from this program as a result of our <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em> testing,” said Thomas Royce, Executive Director of Ashion.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">For more information, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">ashion.com</a> or call 844-539-3309.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics<br style="box-sizing:border-box;border-radius:0px;"></span>At Ashion, our goal is to accelerate the adoption of genomic analysis for clinical decision support to improve the treatment of patients with refractory, rare or aggressive disease. We are experts at Next-Generation Sequencing-based clinical laboratory services, deriving our pedigree from the pioneering precision medicine work at the Translational Genomics Research Institute (TGen) in Phoenix. Ashion Analytics’ mission is to develop and deliver the premier personalized medicine diagnostic, data analytic, and clinical coordination services, which assist healthcare providers in offering their patients individualized treatment options, and which improve outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_tag_container"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;" class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50"></ul> </div> <div style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_label_container"> <div style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_labels_container"></div> </div> </aside>​<span id="ms-rterangepaste-end"></span><p style="text-align:left;"><br></p><ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="list-inline posted-info"><li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"><div><br><br></div></li></ul><p><br></p></html></div>https://biomedicalphoenix.com/Lists/News/Attachments/60/janine-lobello.jpg2020-07-11T07:00:00ZAshion Analytics

© City of Phoenix Community and Economic Development